Guide to German Biotech Companies 2025

26th

In cooperation with:

BPI German Pharmaceutical Industry Association

DECHEMA Society for Chemical Engineering and Biotechnology

European Biotechnology Network

VDGH German Diagnostics Industry Association

ISBN 978-3-928383-93-6

26th Guide to German Biotech Companies 2025

© BIOCOM Interrelations GmbH, Berlin 2024

26 th Guide to German Biotech Companies

Published by: BIOCOM Interrelations GmbH, Jacobsenweg 61, 13509 Berlin, Germany Tel. +49-30-264921-0, Fax +49-30-264921-11, service@biocom.de, www.biocom.de

Publisher: Andreas Mietzsch

Executive Producer: Andreas Macht

Production: Martina Willnow

Graphic Design: Michaela Reblin

Printed at: Druckhaus Sportflieger GmbH, Berlin

This book is protected by copyright. All rights including those regarding translation, reprinting and reproduction reserved. No part of this book covered by the copyright hereon may be processed, reproduced, and proliferated in any form or by any means (graphic, electronic, or mechanical, including photocopying, recording, taping, or via information storage and retrieval systems, and the Internet).

ISBN: 978-3-928383-93-6

Editorial

Let’s do it, folks!

Welcome, dear readers, to the international business card of the German biotech industry. This 26th edition again features many interesting, but not all existing companies in the sector. Those who take part here want to make their company internationally visible. As you can read in the following statistics chapter, according to OECD criteria, the total number of dedicated biotech companies in Germany rose from 776 in 2022 to 798 in 2023. This sounds modest, but it is growth against the trend, as the German economy as a whole is currently stagnating. For example, we are pleased to report almost 4,000 new jobs – now 38,120 people work in the sector. So is everything all right?

At company level, this is often the case – for example, financing has recently increased again and expenditure on research and development has also risen to a new all-time high. However, we can by no means be satisfied with what we have achieved. My main concern is that neither politicians, nor capital markets nor the media currently see, understand or communicate the great opportunities that biotechnology offers. In particular, the great advantages offered by industrial biotechnology in the fight against global warming are simply not being recognised at the moment. Germany is still a world leader in research, but far too little is being done to translate the results into successful products. What has long been common practice in the pharma industry is no longer even mentioned as a goal in the rest of the economy: the biologisation of industry.

For decades, we were told that biological alternatives were simply too expensive in view of the low oil prices. Now we have a completely different argument in favour of new technologies: the reduction in CO2 emissions. However, instead of finally allowing CO2 pricing to take effect in large steps via certificate trading, weak governments don’t have the courage to demand something from people – they immediately counter their own regulations with subsidies. This way, we will never achieve a change in the behaviour of responsible citizens and consumers. It would be so simple: we just need clear targets, openness to technology and the polluter pays principle. The economy and consumers will do the rest. If, for example, minced meat from organic fermenters was just as good but cheaper than meat from cruel factory farming, consumers would quickly start to think and change their behaviour.

Biotechnologists are working on alternatives because they know it’s the right thing to do. Fatalism is a bad counsellor. Entrepreneurs and scientists have to be optimists, otherwise they would have missed their calling. That is why I will end this brief editorial not with lamentation, but with the firm conviction that we must succeed in harmonising our economic activities and lives with the natural cycles of our planet. Let’s do it!

Andreas Mietzsch Publisher

The German Biotechnology Sector 2024

On the one hand, on the other. Is good good enough? These are the thoughts that come to mind when looking at the latest OECD data on the development of the German biotechnology sector. On the one hand, the German economy was in a phase of stagnation last year - even a technology of the future finds it difficult to compete against the leaden mood of late. Significant growth therefore appears to be a particular success. On the other hand, the biotechnology sector is developing solutions to two of today’s megaproblems: climate change and the ageing of societies in industrialised countries. Anyone who jumps on this bandwagon has the chance of exponential growth - something that has not happened again in 2023.

After the growth spurt in the early 2020s due to the novel mRNA vaccines against the coronavirus pandemic, industry figures normalised in 2023 - only revenues continued to fall significantly due to the lack of vaccine sales. By contrast, expenditure on research and development rose to a new record high. Companies invested a total of €3.74 billion, with almost €3.4 billion going into the research of new compounds, technologies and products or the further development of existing healthcare projects.

And the role of biotechnology is also becoming increasingly clear in other areas, such as feeding a growing world population: CRISPR/Cas and precision fermentation are the current growth drivers. In the field of sustainable materials, biotechnology applications offer innovative and climate-friendly solutions, as do new recycling technologies for the circular economy.

Not only has investment in research and development increased significantly, but a large number of new employees have also been hired, despite the prevailing shortage of skilled labour. It is also pleasing to note that a number of new companies have been set up despite the poor general economic climate. All of this testifies to the industry’s strong self-confidence and enthusiasm for innovation.

These assessments are confirmed by the results of BIOCOM’s Biotechnology Company Survey 2024, which analysed the key figures for 2023 in the spring. BIOCOM has been analysing the development of the biotechnology sector in Europe for 38 years. Since 2005, the annual survey of German biotechnology companies has been internationally comparable according to the criteria of the Organisation for Eco -

Key figures of the biotech sector in Germany

nomic Co-operation and Development (OECD). Data collection was only discontinued in 2020 due to COVID-19. The figures and graphs below refer to those companies defined by the OECD as ‘dedicated’ biotech companies.

Decline in sales as a late consequence of coronavirus

The biotechnology sector in Germany has shown impressive steady growth in recent years. As expected, however, revenues in 2023 fell, as in the previous year, due to lower demand for BioNTech’s COVID-19 vaccines. Compared to 2022, the turnover of the now 798 dedicated biotech companies roughly halved to €12.6 billion in 2023.

It is interesting to see how the biotech sector would have developed in 2023 without this distortion. Exclud-

ing the BioNTech share, the sector’s turnover would rise from €8.1bn in 2022 to €8.75bn in 2023. This represents growth of almost 8% and shows that many German biotech companies have now reached a high level of maturity. Although the biotech healthcare sector experienced a decline due to the aforementioned coronavirus effect, it still made the largest contribution to the sector’s total turnover at €9.4bn. The non-specific biotech services sector (€ 2.55 bn; +12.3%) continued to grow. Companies specialising in industrial biotechnology (€ 502 million, +16%) also achieved an impressive increase in turnover. Turnover in the agricultural sector increased by 4.7% to € 39.7 million.

New all-time high in expenditure for research and development

In 2023, expenditure on research and development (R&D) in biotechnology in Germany continued to rise,

Fig. 1: Turnover and R&D expenditure of dedicated biotech companies in EUR million

exceeding the previous year’s record by 12.2% to €3.74 billion.

The R&D expenditure of the ‘red’ biotechnology companies accounted for over 90% of the industry’s total research expenditure; within the sector, it increased by 12.3% from € 3.02 billion in 2022 to just under 3.4 billion euros in 2023. However, Mainz-based vaccine specialist BioNTech continued to account for around half of the sector’s research spending. BioNTech invested €1.78 billion in R&D in 2023, with the focus of the company’s activities shifting back to its original focus: oncology. A cancer vaccine is seen as the ‘next big thing’. The company is using its considerable financial reserves from the coronavirus era.

R&D spending increased in almost all other biotechnology segments despite the difficult economic environ -

ment. In the industrial biotechnology segment, R&D expenditure increased by 23.7% to €100.8 million. Biotechnology service providers and bioinformatics companies increased by 8.5% and 10.4% respectively (€210.5 million and €19.1 million). Only agro-biotechnology companies saw their R&D spending decline by 8.4% to €14.2 million – an indictment of Germany as a business location in light of the global triumph of CRISPR/Cas & Co.

Employment growth remains strong

The number of people employed in dedicated biotech companies increased by 10.8% to 38,120 in 2023. There were increases in all sectors. The largest increase of 19.2% was in industrial biotechnology companies, which employed 3,040 people in 2023. The number of service providers increased by 13.2% to 12,680. Companies in the bioinformatics sector

increased their workforce by almost 13% (790 employees), followed by 8.5% in the healthcare sector (21,200 employees). The number of employees in the agrobiotechnology sector also increased by 2.5% to 410.

Strong in medical biotechnology

The development of drugs is the focus of most biotech companies - and not only in Germany. Here, too, there is no danger of political or social backlash. 397 companies (49.7%) belong to the medical or “red” biotechnology sector. They focus on the development of drugs, vaccines, new diagnostic methods and personalised medicine. More than 21,200 people were employed in medical biotechnology in 2023. Turnover totalled €9.4 billion (-58.4%). Expenditure on research and development totalled €3.39 billion (+12.3%).

Fig. 2: Sources of financing for dedicated biotech companies

Therapeutics development –highly risky, lengthy and expensive

In 2023, a total of 75 companies in Germany already had one or more products in clinical phase I in their pipeline. This number is growing slowly but steadily, which is not surprising given that drug development is risky, lengthy and expensive and therefore difficult for small and medium-sized biotech companies to manage. How much potential a technology or research approach has, and how mature a medical biotechnology company is, is generally reflected in the number of drug candidates and their stage of clinical development. Each step and each phase has its own particular hurdles, and each stage of development often involves greater investment and higher risk. Whether in Germany or elsewhere, experts estimate that the development of a new drug now costs one to three billion euros and takes ten to fifteen years. Yet

only one in 10,000 compounds ever makes it from discovery to market.

Against this backdrop, a look at the current pipeline of German biotech companies always says something about the maturity and innovative strength of the industry. A total of 143 biologically active substances were in one of the clinical phases, 107 of which were biologicals (+16) and 36 small molecules (+1).

The vast majority of medically oriented biotechnology companies (219 companies) are either still in the preclinical stage of therapeutic research or offer a technology platform as a service to the healthcare sector. The number of these companies has grown steadily in recent years, highlighting the growing importance of broadly applicable technology platforms in drug development, either in terms of drug classes or indications.

As reported in Q1 of the following year

Diagnostics – a decisive factor in the fight against diseases

Experts believe that stratified and personalised medicine will play an even greater role in diagnostics in the future. Tailoring medical diagnoses and therapies to the individual characteristics and needs of patients opens up the possibility of more precise and personalised treatment, which can also minimise adverse drug reactions. Overall, this can lead to better treatment outcomes and reduced costs for healthcare systems.

Just over a quarter (26%, 103 companies) from the medical sector were involved in the development of diagnostics in 2023.

Biotechnological service providers –a growth engine

With 221 companies and 12,680 employees, the area of non-specific biotechnological services is the second largest pillar of the German biotech sector. This seg -

ment includes all companies that offer devices and reagents or services that are primarily based on biotechnological principles. However, this also includes contract researchers and biomanufacturing experts.

In 2023, these companies were once again able to significantly increase their turnover. More than two and a half billion euros in turnover were generated in this segment, which corresponds to an increase of around 12% compared to 2022. R&D expenditure has also risen again compared to 2022, namely by 8.5% - a clear indication of the positive assessment of business prospects. Approximately a third of all employees in the German biotech sector work in this segment. The number of employees rose by 13.2% in 2023. This segment has shown continuous growth within the German biotech sector for years.

Industrial biotechnology –the underestimated alternative Industrial applications for various sectors are now being developed by 110 biotech companies in Germany (2022: 96). This segment has seen the largest increase in new companies in 2023. In times of climate change, it is not surprising that industrial biotechnology has enormous potential for change. For example, it can replace or optimise conventional production processes. By using microorganisms, enzymes or bioengineered materials, more environmentally friendly and sustainable processes can be developed - biotechnological reactions take place at normal temperatures and pressures, and residues are biodegradable.

Biotechnology makes it possible to use bio-based raw materials instead of fossil fuels and non-renewable resources. Microorganisms can be used to degrade pollutants, purify biological wastewater and remediate contaminated soil or water. Biotechnological processes also enable more efficient waste treatment and disposal. Industrial biotechnology can also help increase food production and improve food security. Precision fermentation, for example, offers innovative solutions to food challenges and sustainability issues. In the field of sustainable packaging and materials, biotechnology

Fig. 3: Number of annual new biotech start-ups over time

applications offer innovative and climate-friendly solutions, as do sustainable textiles and waste-to-value approaches in a circular economy.

Not only did the number of companies in industrial biotechnology in Germany increase by almost 15% in 2023, but the other key figures are also pointing upwards. But this is growth at a low level. If politicians and capital markets recognised the dormant potential here, a disruptive development would be quite realistic.

Agrobiotechnology –still facing headwinds

The use of biotechnology in plant breeding and agriculture has declined in Europe over the years due to strict regulations and general scepticism, especially towards green genetic engineering. It has stabilised at a low level since 2015. In 2023, 19 companies were active in this segment in Germany, one more than in the previous year. There was a trend reversal in the number of employees and turnover, both of which were positive. Only R&D investment continued to decline. As long as new genomic technologies (NGT) are hampered rather than promoted by the legislature, a real upturn is yet to come.

Bioinformatics –huge boost from AI

A small but steadily growing number of companies (2023: 51, +2) are mainly involved in bioinformatics: a multidisciplinary field of research that combines methods from computer science, statistics and biology. Modern high-throughput methods require the systematic collection and analysis of ever-increasing amounts of medically relevant data. Computer science provides the leverage to harness the potential of this data for prognostic, diagnostic and therapeutic applications. But also in other areas, such as phenotyping or precision breeding, the latest methods require increasingly comprehensive data evaluation.

Last but not least, artificial intelligence (AI) is giving the field a huge boost. The global market is focused on integrating AI technologies with bioinformatics, which uses advanced algorithms and computer models to

analyse biological data. This synergy aims to improve the efficiency and accuracy of processing the huge data sets generated by genomics, proteomics and other areas of life sciences. AI applications in bioinformatics include predictive modelling, data interpretation and pattern recognition, providing insights into complex biological phenomena.

Continued strong momentum in newly formed companies

A stagnant economy, high interest rates and pessimism about the future have apparently not affected biotechnology start-ups. Last year saw a high level of start-up activity. At the end of the first quarter, 20 new start-ups were already known for 2023. As experience shows that many start-ups are announced later in the year for the previous year, the actual number of startups is expected to be significantly higher again. As in previous years, start-ups predominantley emerged in the medical sector (14 companies). There were three new companies in the service sector, two in industrial biotechnology and one in bioinformatics.

Fig. 4: Main areas of activity of dedicated biotech firms

First-class investment level reflects good business prospects

After a post-corona slump in the previous year, the willingness to invest increased again in the year under review. German biotech companies were able to raise a total of almost EUR 1.2 billion - an impressive 25% increase from the previous year. Listed companies

raised a total of EUR 723 million in 13 capital increase rounds. In contrast, private venture capitalists raised only €475 million, which were invested in 23 different companies. This preponderance of stock market funding over venture capital is likely to reflect the increasing maturity of the German biotechnology sector.

Methodology and background

The data and facts used here are taken from the biotechnology company survey carried out annually by BIOCOM AG. It is based on the guidelines of the Organisation for Economic Cooperation and Development (OCED). In December 2004 the OECD harmonised the large number of existing definitions for biotechnology. Since then, all OECD countries have been called upon to base their biotechnology surveys on the so-called “Framework for Biotechnology Statistics” (www.oecd.org).

The OECD differentiates between two different categories of companies within the biotech sector: “Dedicated biotechnology companies” on the one hand and “other biotechnologically active companies” on the other. According to the OECD definition, the former are biotechnologically active companies whose main corporate objectives are the use of biotechnological processes for the manufacturing of products or the provision of services or the implementation of biotechnological research and development. In contrast to this type of dedicated biotech companies, the main corporate objective of “other biotechnologically active companies” is not exclusively the application of biotechnological processes. The OECD describes those companies as the ones using biotechnology only as part of their business and field of activity, such as

pharmaceutical and chemical companies or seed manufacturers.

For the purposes of biotech statistics, BIOCOM has drawn up a questionnaire based on the OECD definitions explained above. A total of 998 companies were contacted between February and April 2024. The selection of the companies contacted for the survey took into account the OECD definition in comparison with the company database of BIOCOM AG. 413 of the companies surveyed answered either by questionnaire or after a telephone call. The response rate or verification rate is 41%.

In accordance with the OECD guidelines, when selecting companies, care was taken to include all companies that deal with biotechnology in Germany and are based in Germany. For this reason, companies that are majority owned by a non-German parent company but have R&D activities in Germany were also taken into account. When recording jobs, business figures and business areas, the survey was only carried out for the German locations of a company. If a company has more than one location in Germany, it is counted once with the corresponding cumulative values.

The cut-off date for the survey was 31.12.2023, for start-ups 31.3.2024.

Prefaces of Biotech Associations

Prefaces

BPI expands the BioPharm business area

Dr. Kai Joachimsen, General Manager BPI e.V.

According to recent surveys, there are around 670 pharmaceutical companies in Germany. These are both location-orientated and owner-managed companies as well as German branches of multinational corporations. It is still the case that almost 92% of pharmaceutical manufacturing companies in Germany employ fewer than 500 people. The pharmaceutical industry is therefore a reflection of the German economic structure and is of great importance for growth, employment and innovation effects.

BPI represents the full Spectrum of the Pharmaceutical Industry

The German Pharmaceutical Industry Association (BPI) represents the entire spectrum of the pharmaceutical industry - nationally and internationally - with around 260 members employing around 78,000 people. Traditionally location-orientated companies as well as internationally operating groups have joined forces in the BPI. Members include research-based pharmaceutical companies and generics firms, companies from the fields of biotechnology, herbal medicines, homeopathy/anthroposophy, veterinary medicines, manufacturers with a mixed portfolio and pharmaceutical service providers. With over 70 years of experience in the topics of pharmaceutical research, development, authorisation, manufacture and marketing, the BPI offers integrated solutions for the entire pharmaceutical market and supports the whole life cycle and value chain of a medicinal product; at a national level, regionally in six state associations and with its own team in Brussels.

What makes the BPI unique in the association landscape is its unrivalled expertise in all topics relating not only to the entire value chain of a medicinal product or therapy, but also across all pharmaceutical sectors. In order to continuously improve the framework conditions for pharmaceutical companies, we actively help to shape them, orientate ourselves towards patient needs and make a significant contribution to healthcare. Close networking with our members is of central importance.

Pharmaceutical companies assume responsibility for supplying society with medicinal products and medical devices. They develop new active ingredients as well as medicines based on proven active ingredients to improve people’s lives. We are service providers and lobbyists for our members and are passionate about supporting them in their important task. Therefore, we work closely with partner associations and healthcare industry organisations at state, national and European level. Thanks

to our close links with the VCI, our members enjoy the same rights as direct VCI members. The BPI represents the interests of its members in the BDI as well as in the European organisation EUCOPE.

We ensure that an excellent selection of medicines is available at all times and we are constantly working to improve and optimise the German healthcare system. This system is still well positioned in both European and international comparison. Healthcare expenditure corresponds to 12.8% of GDP and expenditure of over €5,900 per person. In 2022, Germany cared for 16.8 million patients. This is made possible by developments in the biotech sector, among other things. According to data published this year for the biotech sector, Germany had almost 800 biotech companies last year, an increase of 3% compared to the previous year.

Strengthening the biotech location in Germany

The German biotech sector is therefore one of the most important biotech locations worldwide. The medical biotech sector, which is characterised not only by diagnostic products but above all by therapeutic developments and production, stands out in particular. The gene and cell-based therapies sector is particularly noteworthy here. These are currently on the upswing, even politically: at the beginning of summer this year, the Federal Ministry of Research accepted a document on the development of a national strategy for gene and cell-based therapies, which was drawn up with the strong involvement of the BPI in a multi-stakeholder dialogue. The implementation of the strategy is intended to improve access to gene- and cell-based therapies for patients and strengthen Germany’s position as a centre of research and innovation in international competition. The strategy emphasises the enormous potential of the future field of GCT for patient care. However, this requires measures to be taken that can accelerate the translation of results from Germany’s strong basic research into clinical practice and at the same time make gene and cell-based therapies safe, efficient, affordable and widely accessible. This is necessary in order not to fall behind internationally. Germany still occupies a leading position in the availability of gene and cell therapies (in regulatory terms, they belong to the so-called Advanced Therapy Medicinal Products - ATMPs) in the EU (of 20 centrally approved ATMPs in Europe, 17 are available here. In the USA, on the other hand, 26 are already available for healthcare).

Expanding BioPharm: BPI’s Focus on Life Sciences

Overall, it is very important to support the German life science industry with great vigour. This is why the BPI is expanding the BioPharm business area and establishing further business areas such as oncology and immunology. In this way, the BPI specifically promotes biotech companies in these areas and ensures the expansion and strengthening of the investment-worthy life science sector in Germany.

Bundesverband der Pharmazeutischen Industrie e.V. (BPI) Friedrichstraße 148

10117 Berlin

Tel.: +49 (0) 30 2 79 09 0

E-Mail: info@bpi.de

www.bpi.de

Prefaces

A fermenter for innovation

Dr Kathrin Rübberdt, Head of Division Science & Industry at DECHEMA e.V.

Food from the bioreactor, ATMP and personalised medicine, the production of chemicals – there is hardly any field where biotechnology does not open up new opportunities. The challenge today is more than ever to translate research findings into commercially successful applications. Investing large sums into new technologies requires trust and courage at the best of times; in times of transformation and uncertainty when whole industries are in decline, it seems nearly impossible. On the other hand, biotechnology can be a major tool in mastering exactly this transformation, in turning around the decline and in securing a sustainable and prosperous future.

DECHEMA aims to support this process. True to our motto, we not only enable the dialogue between science and industry; in addition, we are the voice of applied research for biotechnology and bioprocessing in politics, economy, and society. More than 5,500 members from large companies and SMEs as well as university and research institutions form the core of our network provide their ideas and expertise. Organised by topics, expert sections and working groups are the backbone of DECHEMA’s work. This is where people meet regularly in a trusting setting to identify challenges and discuss possible solutions. The ideas that are born from these discussions are then shaped into concrete activities.

Tangible results

Our activities address all topics of biotechnology from the identification and optimization of natural APIs, the processing of renewable resources into industrial products, to pharmaceutical production and the integrated application of chemical and biotechnological catalysis. With our interdisciplinary approach, we offer the opportunity for scientists and engineers to jointly develop technological solutions that pave the way to the commercialization of biotechnological processes and products.

Besides events and cooperations, DECHEMA’s publications are tangible results of this process. In 2024, experts from very different fields united in the development of a Status Paper Circular Economy that points out the concrete contributions of chemical engineering and biotechnology to the closing of cycles.

In a study on the “Potential of Precision Fermentation for Lower Saxony”, DECHEMA’s experts analysed the prerequisites and requirements to build a precision fermentation industry in Lower Saxony – starting from the biotechnological aspects such as productivity and development of new production organisms via an outline for the establishment of demo plants to the question of market and market uptake.

In addition to papers with a strategic focus, DECHEMA also regularly publishes working aids, such as recommendations for the characterisation of single-use reactors or the most recent paper on “Cost Engineering for Modular Plants”.

Expanding networks

Hardly any current topic can be successfully tackled by one discipline or organisation alone. Thus, networking beyond one’s inner circle is more important than ever. A wide variety of events organised by DECHEMA enables young researchers as well as established experts to renew and expand their personal network – be it at conferences such as the German Conference on Synthetic Biology, the 3D Cell Culture conference, the “Himmelfahrtstagung” on bioprocessing, or any of the many other focused scientific events.

An additional perspective is covered by the Network of Female Managers in the Life Sciences (powered by DECHEMA). It serves as a catalyst that provides impulses for women in the life science industry. Varying topics that range from supply chain to oncology and pharmaceutical production to leadership regularly attract up to 40 participants to meetings hosted by members on their company sites or at DECHEMA.

Making an impact

Besides bioeconomy, biotechnology and pharma, DECHEMA addresses the chemical industry, energy & climate, water management and resources. It is therefore uniquely positioned to combine various perspectives and stimulate cooperations between different industries. ACHEMA is the platform where this becomes most visible. As the leading global trade show for the process industries, the exhibition and congress cover the whole value chain and are a meeting point for stakeholders from all over the world.

ACHEMA also serves as a showcase that broadcasts the capabilities of the process industry far beyond the inner community towards economy and politics. DECHEMA is also continuously in touch with decision makers in politics and funding organisations, pointing out funding needs and key challenges that should be addressed from a R&D point of view. In the field of biotechnology, this includes the active engagement in the Dialogue Platform Industrial Bioeconomy of the Federal Ministry for Economy and Climate Action and the exchange on the National Strategy on Gene and Cell Therapies where we both serve as speakers and brokers for our community.

Being an active part

A non-profit organisation like DECHEMA owes everything to its active members; in turn, it can serve the larger community and be a part of the thriving biotech landscape featured in this guide. If you want to learn more about DECHEMA, are looking for cooperations, or want to submit your ideas, get in touch – we are looking forward to shaping the future of biotechnology together!

DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e.V. Theodor-Heuss-Allee 25 60486 Frankfurt am Main Germany

Tel. +49 69 7564 -0 info@dechema.de

Prefaces

VDGH: Shaping the future

We are delighted that the 26th edition of the “Guide to German Biotech Companies” is once again an indispensable reference work for the German biotechnology and life sciences sector. Over the years, this publication has developed into a valuable platform that brings together not only national but also international players in the sector. It offers a comprehensive overview and is an important tool for promoting the visibility of German biotech companies.

Biotechnology in Germany has developed into one of the most dynamic and forwardlooking sectors. It is a key driver of innovation in the healthcare sector, but also in many other areas of science. In this context, the German Diagnostics Industry Association (Verband der Diagnostica-Industrie – VDGH) is proud to represent not only the interests of in-vitro diagnostics (IVD) manufacturers, but also those of life science research (LSR) companies. Together with our member companies, we are actively shaping the future of Germany as a centre of research and support innovations that go far beyond biotechnology.

The close links between the biotechnology, diagnostics and life science research sectors are now more important than ever. Over time, many biotech start-ups are developing into important players in diagnostics, thereby expanding the range of innovative products for healthcare. The IVD industry provides valuable tools from routine diagnostics to personalised medicine with its test systems, while the LSR industry enables indispensable research results that catalyse progress in biotechnology. In the emerging age of cell and gene therapy, the biotech industry is becoming increasingly important as a producer of innovative therapeutic approaches. The LSR industry provides the basic components for the manufacturing process of cell and gene therapies.

The VDGH has set itself the task of pooling the interests of these two key sectors and representing them with a strong voice in politics and society. We play a decisive role as a mediator in the German association landscape. In no other country in Europe are the associations so deeply involved in the political decision-making process as in Germany. The VDGH is regularly consulted by ministries, authorities and the German Bundestag, where it represents the interests of its members. Whether it is a question of legal framework conditions or self-administration in the healthcare sector - we ensure that the interests of our industries are heard. In the Life Science Research department in particular, we promote the visibility of this industry as a driver of innovation in research and development. Here, companies benefit from exclusive services such as access to the FundFinder database, which pools all relevant research funding from Germany

Dr Martin Walger VDGH – Association of the Diagnostics Industry

and four other European countries. This not only facilitates orientation in the often confusing funding jungle, but also opens up targeted opportunities for members to find funding data from all sources bundled together and in an otherwise unrivalled breadth and depth in one place. In addition, we offer our members comprehensive market insights, e.g. through our annual market and product surveys, which provide insights into German market developments and industry trends. No other commercial report offers such detailed data on developments in the life science sector. This exclusive information helps companies to make strategic decisions and optimise market opportunities.

Another important aspect of our work is communication and public relations. We ensure that the innovations and successes of our members are publicised in the media and at industry events. With events such as the LSR Spotlight Forum at analytica trade fair in Munich or our LSR blog, we help to ensure that the public recognises the important contributions our industry makes to research and healthcare. The VDGH plays an equally central role for IVD companies. Our successful lobbying work, for example on pandemic legislation, and our significant involvement in shaping the European IVD Regulation are just two examples of how we represent the interests of our members. In doing so, we rely not only on national but also European networks such as MedTech Europe.

However, VDGH membership offers companies far more than just political representation. It opens up access to a broad network of experts and decision-makers, exclusive market analyses and studies as well as valuable training opportunities. Our members benefit from regular seminars and workshops on topics such as regulatory affairs or sustainability in the industry, which help them to successfully assert themselves in a constantly changing regulatory environment.

For companies in the field of life science research and diagnostics, membership of the VDGH offers invaluable added value. Together, we join forces to represent the interests of our industry, promote innovative projects and further strengthen Germany as a business location. The VDGH provides access to a unique network that creates synergies and realises potential that goes far beyond the individual performance of individual companies.

At the heart of the association’s work are the committees, i.e. the specialised departments, committees and working groups. A total of more than 30 committees provide targeted advice on the entire range of topics relevant to the industry. Every member has free access to all working structures. The exchange of knowledge and the joint development of industry positions take centre stage. We invite all companies to take advantage of the comprehensive benefits of VDGH membership and actively shape the future of our industry. Together, we can further advance Germany as a centre of research and healthcare and create pioneering innovations. What can we do for you? Please feel free to contact us!

VDGH – Verband der Diagnostica-Industrie e.V.

Neustädtische Kirchstr. 8 10117 Berlin

Tel. 030-2005 99-40 Germany

www.vdgh.de

Profiles of German Biotech Companies

Name ›

4base lab AG advanced molecular analysis

Address/P.O. Box › Postal Code/City › State ›

Contact Person › Telephone › Email

Website ›

Founded (year) › Type of Laboratory ›

Areas of Activity ›

Aspenhaustr. 25

72770 Reutlingen

Baden-Wuerttemberg

Dr Johannes Ries

+49-7121-317878-0 pharma@4base-lab.com

https://en.4base-lab.com/pharma/ 1995

GMP, S1/L2

| Identity/quality assessment of mRNA/ DNA vaccines

| Contamination analysis of residual DNA/RNA

| Vaccine quality analysis by Nanopore direct RNA-sequencing

| DNA/cDNA-sequencing by Sanger

| Determination of mRNA poly(A) tail length

| Sequencing the CDS in mRNA

| Direct colony full-length sequencing

| Contract research/outsourcing

| Viral- and microbial detection

The Experts

For almost three decades, 4base lab has been at the forefront of molecular analysis, maintaining GMP-compliant laboratories that consistently meet the highest industry standards. As a reliable partner of mRNA/DNA vaccine manufacturers including leading pharmaceutical companies, 4base lab offers safety at every stage of the manufacturing process.

Excellence through collaboration is our guiding principle. Our team of experienced scientists and qualified technicians partners closely with you to comprehend your unique objectives. We leverage this understanding to develop customized assays and validation methods that are tailored to your specific requirements and ensure optimal results.

Customized advice and flexible adaptation of our test systems are our strengths.

The services

DNA sequencing: The confirmation of sequence identity is an essential part of the production of therapeutic nucleic acids. 4base lab offers reliable non-GMP and GMP sequencing services according to Sanger, covering all steps necessary for the determination of complete DNA sequences. Even samples with ultra-low DNA concentrations, limited volume or colonies can be sequenced in full-length using validated Rolling Circle Amplification (RCA) methods.

RNA sequencing: The assessment of therapeutic mRNA vaccines directly, without reliance on intermediate molecules, is increasingly in focus of regulatory quality control requirements regarding the sequence coding identity, modifications, and structural motifs. 4base lab offers a qualified analysis pipeline to address these issues directly on the RNA.

Determination of poly(A) tail length: for determination of poly(A) length of mRNA vaccines, qualified sequencing strategies utilizing Sanger adapter sequencing as well as Oxford Nanopore Technologies (ONT) direct RNA sequencing are available.

Residual nucleic acid analysis: Detection of residual DNA contamination. Safety at every step of your manufacturing process of mRNA vaccines. Various validated qPCR/RT-PCR protocols are established for the detection of residual E. coli genomic DNA, RNA and plasmid DNA contaminant in mRNA vaccines.

Development and Validation: New detection systems can be developed at any time according to customer requirements and validated in accordance with ICH Q2.

Viral and microbial detection: Please inquire for available systems.

Quality assurance

4base lab has been maintaining GMP compliant laboratories for molecular analysis for almost three decades. Furthermore, 4base lab is certified according to DIN EN ISO 9001, DIN EN ISO 14001 and accredited according to DIN EN ISO 17025.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

AGC Biologics

Czernyring 22 69115 Heidelberg

Baden-Wuerttemberg

Ben Clauberg

+49-1515-7528832

bclauberg@agcbio.com www.agcbio.com F I 

2,500+ 2018

Technology Transfer, Process Development, Analytical Development, cGMP Manufacturing, Quality Control and Quality Assurance, and Process Validation

Areas of Activity ›

Mammalian and Microbial-based Therapeutic Proteins, Recombinant DNA, Plasmid DNA (pDNA), Messenger RNA (mRNA), Viral Vectors, and Genetically Engineered Cells.

Request for › Further Collaborations

We are currently seeking additional collaborations and have capacity available at all of our sites in Europe.

AGC Biologics is a global CDMO (Contract Development and Manufacturing Organisation) providing pharmaceutical development and manufacturing services for protein-based biologics and cell and gene therapies. With seven facilities and teams of scientists across three continents, we have the resources and available capacity you need to bring your next project to life. From development to clinical trials to full-scale commercialisation, we can help you reach your goals at any stage in your drug product’s journey.

We specialise in the following modalities and substances: mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.

Our sites offer services you need at any stage of product development and manufacturing, including Technology Transfer, Process Development, Analytical Development, cGMP Manufacturing, Formulation Development, Quality Control and Quality Assurance, and Process Validation.

We have several sites near Germany that can service small, medium, and large biotech companies, global pharmaceutical organisations, and emerging advanced therapies organisations working on cell and gene therapies.

European Facilities

Heidelberg, Germany

The Heidelberg facility serves as a hub for microbial systems and services for our global customers. The site has scientists with several decades of protein expression experience, which has enabled AGC Biologics to establish a centre for custom pDNA and mRNA service lines at this site. We have just completed an expansion in 2023, adding a new line to offer more pDNA and mRNA projects, at a faster pace.

The facility’s segregated line design allows for capacity and technological flexibility while ensuring compliance with the current global guidelines required for cGMP compliance.

Copenhagen, Denmark

The Copenhagen site is one of the most active biologics facilities in the AGC Biologics network.

Onsite, we operate multiple mammalian and microbial cGMP manufacturing lines at a variety of scales, and the facility also offers a great depth of technological flexibility.

The core teams of scientists have been working together to develop and manufacture biologics for two decades. This expertise and experience mean that your product is managed by some of the best in the business.

The Copenhagen site added a new manufacturing building in 2024 that more than doubled its single-use bioreactor mammalian cell-culture capacity.

Milan, Italy

AGC Biologics Milan specialises in cell therapy and viral vector development and manufacturing. The site works with any cell type and lentiviral, retroviral, and adeno-associated viral vectors. This site expanded in 2023 to offer more more vector manufacturing capacity for clinical and commercial projects.

The facility was the first cell and gene therapy site approved in Europe for GMP manufacturing of clinical and commercial supplies. The core scientific team has 30 years of expertise in the field and unique knowledge you will not find anywhere else.

The Milan team has developed 3 commercial products including, before joining the AGC network, bringing its own product to market (Zalmoxis ®). This experience means they understand the processes, procedures, and painstaking work involved in developing and bringing these treatments to market.

Sites in Japan and U.S.A.

With one site in Japan and three in the U.S., one of the unique things about AGC Biologics is we can produce products on three continents. If you need something done outside of Europe, we have the network and global supply chain to meet your needs.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email

Website

Social Media › Number of Employees › Founded (year) ›

Areas of Activity ›

anwerina Deutschland GmbH

Reichskanzler-Müller-Str.21 68165 Mannheim

Baden-Wuerttemberg

Dr Christoph Karl, CEO +49 621 46079340 +49 621 46079341 information@anwerina.com www.anwerina.com I 10+ 2012

Medical device implants for the treatment of osteoarthritis. Pharmaceuticals in the field of bone health, including: | osteoporosis and | bone metastases.

Your Expert in Bone Health

anwerina AG’s German subsidiary, anwerina Deutschland GmbH has a long history.

› 1960 Röhm Pharma GmbH in Weiterstadt was founded as a joint venture between Smith Kline Diagnostics and Norwich Eaton, later Procter & Gamble.

› 1993 Röhm Pharma merged into Procter & Gamble Pharmaceuticals Germany GmbH.

› 2009 the pharmaceutical division of Procter & Gamble Pharmaceuticals was integrated into Warner Chilcott.

› 2012 anwerina Deutschland GmbH as a daughter of anwerina AG, Switzerland, founded in 2009, continues the successful tradition in bone health, as a small but highly specialised company located in Mannheim.

The continuous search for innovative solutions in conjunction with a creative and motivated team are the success factors that have distinguished anwerina and its parent companies over the last 50 years and has left a lasting impression on the market.

Patents › Request for › Further Collaborations

anwerina is holding >80 patents for new pharmaceuticals and medical device implants

anwerina collaborates with pharmaceutical and medtech companies, CMOs, research institutes and VC investors with the purpose of improving patients’ outcomes

Bisphosphonates with Calcium and Vitamin D3

anwerina specialises in bisphosphonates for the treatment of osteoporosis and bone metastases. By inhibiting the so-called ‘osteoclasts’, bisphosphonates reduce bone loss. What makes the products special, is the addition of calcium and vitamin D3 compounds, which improve compliance, safety and efficacy. There is compelling clinical evidence that adequate calcium and vitamin D supplementation is crucial in prevention of progressive bone loss and recommended along all antiresorptive and osteo-anabolic pharmaceutical treatment. An evidence-based assessment of the need for an adequate supply of calcium and vitamin D specifically for patients with reduced bone mass can be found in the country-specific guidelines for the diagnosis and treatment of osteoporosis and the management of bone metastases.

R&D

Apart from the continuous research and development in improving pharmacological treatments related to the bone metabolism, anwerina has from 2012 on specialised in research and development in osteoarthritis. ARTHROSTYLE™ presents a disruptive technology for cartilage regeneration, CLR (Cellular Lift Regeneration™). This minimally invasive, single-procedure solution has the potential to revolutionise the treatment of osteoarthritis and improve patient outcomes. CLR offers a first-in-class, worldwide patented method for regenerating cartilage in various joints, potentially providing a cure for osteoarthritis via autologous mesenchymal stem cells. Positive safety and efficacy prototype testing, and in-vitro proof-of-concept have been achieved. anwerina is currently looking for partners helping to finalise ARTHROSTYLE™’s development for worldwide commercialisation.

Improving patients’ life quality

anwerina is in intensive contact with leading experts in our indication areas, helping us that new developments for the benefit of patients can be implemented quickly. We improve quality of life of patients with diseases or trauma to the musculoskeletal system, both in the development and marketing of unique drugs and medical devices.

Vision

Our guiding principle is to be among the best. 12 years of success on behalf of bone health are providing an excellent base for further development. For anwerina, “strong together” is not only a symbol of the corporate culture, but also an engine for facing new challenges. anwerina is convinced that their passion for improved quality of life and high-quality medical care are the basis for our commitment and our work. “passion for patients” is our driving force behind facing new challenges and mastering them.

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Persons › Telephone › Fax › Email › Website ›

Number of Employees › Founded (year) › Areas of Activity › External › Collaborations

AvenCell Europe GmbH

Tatzberg 47 01307 Dresden

Saxony Jana Fiebiger

+49-351-44664500 +49-351-446645099

jana.fiebiger@avencell.com www.avencell.com 56 2011 | Immunotherapy | Oncology

| Intellia Therapeutics | Cellex Cell Professionals | Blackstone Life Sciences

Company overview

AvenCell Europe GmbH located in Dresden is a clinical-stage biopharmaceutical company developing next-generation immunotherapies to treat cancer and autoimmune disease patients with high unmet medical needs.

AvenCell’s mission is to overcome the limitations of current-generation chimeric antigen receptor (CAR) T cell therapies with an improved therapeutic window and substantially expand the types of cancer treatable with adoptive cell therapy, including solid tumours.

AvenCell’s deep pipeline of immunotherapies includes two in clinical trials for haematological malignancies and several preclinical candidates.

AvenCell’s Universal Switchable CAR platform combines the best of two worlds – the powerful anti-tumour response of CAR-T and flexible soluble adaptors termed targeting modules (TM) allowing flexible targeting of multiple antigens to overcome tumour escape and deepen responses. AvenCell’s Allogeneic platform is engineered to overcome graft-versus-host disease as well as graft rejection by host T and NK cells and aims to provide highly effective “off-the-shelf” cell therapies at significantly reduced costs.

Technology

The Universal Switchable CAR-T platform consists of two components and can be rapidly switched on and off. It comprises genetically modified T cells with a chimeric antigen receptor and targeting modules (TM). TMs act as soluble adaptors that mediate a reversible, specific binding to the universal CAR and additionally realize directed targeting of cancer cells via a highly flexible antigen-binding moiety. TMs efficiently penetrate and accumulate in bone marrow and solid tumour tissue. Their simultaneous binding to the universal CAR and the target antigen acts as a switch leading to activation and expansion of universal CAR-bearing effector T cells and subsequent cancer cell lysis. Crucially, the switch-off mechanism (removal of TM) avoids acute and long-term toxicity and T effector cell exhaustion seen in conventional CAR-T cell strategies.

The Allogeneic platform allows AvenCell’s pipeline candidates to benefit from world-leading CRISPR cell engineering, enabling large-scale batch manufacturing of allogeneic products from healthy donors and compelling cost reductions.

Through the combination of both differentiated platforms, AvenCell now aims for CAR-T cell therapies with an improved therapeutic window and to provide persistent, safe, and versatile ‘off-the-shelf’ cell products that enter new dimensions in cellular immunotherapy.

Clinical progress

AVC-101, AvenCell’s lead clinical autologous cell therapy program, is directed against the CD123 antigen and designed for the treatment of patients with haematologic and lymphatic malignancies positive for CD123. The phase I study using a Universal Switchable CAR with a CD123-directed TM is currently in completion and has provided platform validation.

AvenCell’s lead allogeneic cell therapy program AVC201, combining the Universal Switchable CAR technology with the Allogeneic platform to provide an “off-theshelf” product for the treatment of relapsed/refractory AML is currently investigated in a phase I clinical trial including up to 35 patients at multiple sites in Germany and the Netherlands.

Name ›

Address/P.O. Box ›

Postal Code/City

State

Contact Person

Telephone

Fax

Email

Website

Number of Employees

Founded (year)

Type of Laboratory

Areas of Activity

Axolabs GmbH

Fritz-Hornschuch-Str. 9

95326 Kulmbach

Bavaria

Dr Ingo Röhl

+49-9221-82762-0

+49-9221-82762-99 info@axolabs.com www.axolabs.com

~230

2000 (as Ribopharma; acquired by LGC in 2017) S1, S2

Research solutions for preclinical and clinical development with a focus on nucleic acid therapeutics (NAT), including bioinformatics-guided sequence selection, high quality oligonucleotide manufacturing, analytics (GMP), bioanalytics (GLP, GCP), lead molecule identification, and in vitro and in vivo pharmacology

Intellectual Property

Collaborations

Proprietary bioanalytical assay for the detection and quantification of oligonucleotides in blood and tissue; proprietary lipid platform for LNPmediated cellular delivery of nucleic acids

Axolabs collaborates with research groups around the world in the field of oligonucleotide therapeutics, including > 15 Big Pharma enterprises, > 200 biotech companies, and > 30 academic research institutes

Axolabs is the leading custom research organisation focused on the discovery, development and manufacture of oligonucleotide and nucleic acid therapeutics. Founded firmly on our world-leading know-how and more than 20 years of experience, we provide high-end preclinical and clinical development solutions tailored to our clients’ needs.

At our branches in Petaluma, California, and Berlin we have manufacturing and purification capabilities for oligonucleotide drug substance under the standards of GMP.

Services and Products

Manufacturing

› High-quality non-GMP oligonucleotide synthesis in quantities of up to several 100 g

› GMP production of oligonucleotides (in Berlin and Petaluma)

› Custom-tailored process optimisation

› Chemical synthesis of long RNA/DNA sequences

› Wide range of chemically modified oligonucleotides and conjugates

› Potency and stability improvement

› Process-related impurity marker synthesis and reference standards

› Lipid synthesis

Analytics

› Broad capabilities for CMC analytical method development

› Physicochemical and thermodynamic characterisation

› Stability determination in biological matrices

› Identification of impurities and metabolites by LC/MS

GMP-compliant analysis of oligonucleotide APIs

› Release testing for Drug Substances and Drug Products

› ICH-compliant stability studies

Analyses specific to mRNA therapeutics

› Cap structure by uHPLC with ESI-MS

› Poly-A tail by uHPLC with ESI-MS

› Purity by uHPLC with UV

› Release testing of mRNA-LNP Drug Products

PK and biodistribution

› GLP-and GCP-certified test site

› Proprietary assay system for sensitive detection of oligonucleotides

› Quantification of mRNA

Oligonucleotide lead identification

› Bioinformatics assessment for sequence pre-selection

› Oligonucleotide design and synthesis

› High-throughput in vitro screening

› Lead characterisation and optimisation

› Efficacy and early safety assessment

Biological and pharmacological tests and analyses

› Safety and toxicology

› Cell-based assays for cell function, proliferation and toxicity

› Ligand-receptor interaction and uptake studies/ histology

› Flow cytometry

Platform for functional cell type-specific delivery of oligonucleotides and mRNAs

› In vitro functional analysis and in vivo models

› Rational oligonucleotide designs tailored for specific delivery systems

› Proprietary lipid nanoparticle formulations

Gene-editing therapeutics

› Unprecedented purity of therapeutic sgRNAs for CRISPR Cas and prime editing applications

› Superior biological editing efficiency

Name ›

B4 PharmaTech GmbH

Office:

B4 PharmaTech GmbH

Address/P.O. Box › Postal Code/City › State

Altensteinstraße 40 14195 Berlin Berlin

Laboratories and Shipping Address:

B4 PharmaTech GmbH

Address/P.O. Box › Postal Code/City › State

Contact Person

Telephone

Email

Website

Number of Employees › Founded (year)

Areas of Activity ›

Arnimallee 22 14195 Berlin Berlin

Dr habil. Stefan Kubick

+49-172-1600-001 info@b4pt.de www.b4pt.de 10 2023

Cell-free Protein Synthesis, Protein Production Service, Antibody-Drug-Conjugates, Linkers and Conjugation Strategies, Tailor-made Enzymes, Membrane Proteins and Bioconjugates, Assay Development, Quality Control of RNA-based Vaccines

Cell-free protein synthesis expands the possibilities of protein production. B4 PharmaTech focuses on customised protein synthesis, the commercialisation of systems for cell-free protein synthesis and the synthesis and analysis of antibody-drug conjugates.

Cell-free systems enable fast, automatable, scalable and multi-parallel protein synthesis. Fluorescencelabelled proteins, tailor-made enzymes, complex membrane proteins, cytotoxic proteins and immunotoxins as well as proteins with chemical linkers are produced in cell-free systems.

Difficult-to-express proteins are synthesised under defined conditions. In a step-by-step process, B4 PharmaTech offers a user-friendly production of the desired protein in the best possible cell-free system.

B4 PharmaTech’s expertise covers the following areas:

› Parallel evaluation of the synthesis of your protein of choice in different cell-free systems (Feasibility study, Proof of concept)

› Design and generation of optimal templates for prokaryotic and eukaryotic cell-free systems

› Protein production in prokaryotic and eukaryotic cell-free systems (e.g. translationally active lysates derived from cultured E.coli, yeast, insect, CHO and human cell lines)

› Tailor-made cell-free systems for customer-specific applications

› Production of posttranslationally modified proteins

› Optimisation of reaction conditions (e.g. balancing the redox conditions, solubility and stability screens, increasing functionality by adjustment of the reaction environment, supplementing the reaction mixture with co-factors, chaperones, detergents, rare tRNAs)

› 14C radiolabelling of the protein(s) of interest for detailed quantitative and qualitative analysis (yield, homogeneity of the full-length product, detection of posttranslational modifications, e.g. glycosylations)

› Determination of the overall rate of protein breakdown by radiolabelling (Targeted protein degradation, controlled perturbation of protein activity)

› Labelling of subunits, protein fractions, or purified proteins

› Introduction of mutations for protein engineering

› Protein assembly by design

› AI-based protein design in combination with iterative cell-free protein synthesis methods

› Cell-free Synthesis of different formats of antibodies in the range of small single chains up to full length IgG

› Production of Nanobodies in Cell-free Systems

› Development of Antibody Fluorophore Conjugates

› Customised Antibody-Drug Conjugates

› Quality control of proteins using HPLC and mass spectrometry analysis

› Cell-free GPCR Production

› Synthesis of Ion Channels, Transporters and Poreforming Proteins in Cell-free Systems

› Cell-free Assembly of multimeric Membrane Proteins

› Membrane Protein Stabilisation and Solubility Screening

› Functional analysis: Electrophysiology and Ligand Binding

› Bioactive subcellular Compartments

› Proteomics for Virus Detection

› Cell-free Enzyme Engineering through Artificial Intelligence and Machine Learning

› On-Chip Automation of Cell-free Protein Synthesis

Biaffin GmbH & Co KG

Address/P.O. Box › Postal Code/City › State

Contact Person

Telephone

Fax

Email

Website

Social Media

Number of Employees

Founded (year)

Type of Laboratory

Areas of Activity

AVZ 2, Heinrich-Plett-Str. 40

34132 Kassel

Hesse

Dr Bastian Zimmermann

+49-561-8044668

+49-561-8044665 info@biaffin.com www.biaffin.com www.proteinkinase.biz

F I Q 8 2001

Analytical, ISO 9001:2015 certified

Service provider for biomolecular interaction analysis using SPR Biacore technology; supplier of recombinant proteins and reagents for kinase research and signal transduction

Company overview

Collaborations

Request for › Further Collaborations

Collaborations with academic research groups and industrial partners

Biaffin is looking for strategic partners interested in complementing their analytical portfolio with SPR Biacore technology.

Biaffin GmbH & Co KG is an ISO 9001:2015 certified bioanalytical service provider specialised in the application of biosensors based on surface plasmon resonance (SPR) for biomolecular interaction analysis (BIA). BIA technology is ideally suited for highly accurate kinetic characterisation of any interacting molecules in real time in a label-free state. Biaffin has extensive knowledge and many years of experience in various application areas and supports biopharmaceutical drug development programme of pharma, biotech, and generic drug companies as well as scientific institutions worldwide as a competent partner. Our services are performed by a highly specialised team (PhD level scientists) in a laboratory well equipped with several state-of-the art SPR instruments (5x Biacore T200, 1x Biacore 8K+). Sufficient capacity of SPR instruments allows Biaffin to start interaction studies on short notice, quickly run multiple projects in parallel, and receive results in a timely manner. A qualified Biacore T200 instrument is available for SPR assay validation and GMP-like SPR analysis. The company’s expertise is documented by many peerreviewed publications in renowned scientific journals.

Analytical services for biopharmaceutical development

For the development of therapeutic antibodies, biopharmaceuticals, and biosimilars, Biaffin offers reliable SPR services for a highly accurate, quantitative kinetic characterisation, semi-quantitative kinetic ranking, or rapid qualitative screening of drug candidates. SPR assays have already been established for many target proteins and can be developed quickly by application of established protocols for reversible and site-directed coupling of biomolecules using specific capture surfaces. These assays can be applied for comparability and stability studies and batch-to-batch comparison during process optimisation. Available assay formats include dual-potency assays, pair-wise epitope mapping, and determination of active concentration based on binding activity (calibration-free methods). Assays can be validated and conducted under GMP-like conditions on a qualified Biacore instrument.

ADCC SPR assays

ADCC SPR assays are established for interaction analysis of antibodies with Fc gamma receptors (CD16, CD32, CD64) including receptor variants and different species, neonatal Fc receptor (FcRn), and complement C1q binding.

Small molecule drug development

Biaffin’s services in small molecule drug development comprise customised SPR assay development for defined target proteins, fragment screening, hit validation, secondary screening, kinetic profiling, competition analy sis, and lead optimisation of compounds to improve specificity, selectivity, and potency. Early ADME studies (serum protein binding) and studies on mode of action, cofactor requirements, and thermodynamic binding analysis further support the drug development process.

Catalogue products

Apart from analytical services, Biaffin offers a range of products serving customers’ needs in kinase research and exploring cellular signal transduction pathways. Biaffin’s product portfolio, available from the online shop www.Proteinkinase.biz, comprises recombinant proteins (kinases, cytokines, receptors, CD antigens), peptide substrates, specific inhibitors, and a biochemical ATP determination assay for customers’ in-house research.

Quality statement

Biaffin has successfully implemented and maintains a Quality Management System certified according to the ISO 9001:2015 international standard, enhancing our ability to supply high-quality products and provide reliable, innovative services according to the highest quality standards, which consistently meet the needs and expectations of our clients.

Address/P.O. Box

Postal Code/City

State

Contact Person

Telephone

Fax

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

Bio-Techne GmbH

Borsigstraße 7a 65205 Wiesbaden-Nordenstadt Hesse

Wahid Ahmadjhan

+49-6122-90980 +49-6122-909819 info.de@bio-techne.com https://www.bio-techne.com F I I  ~3,100 1981

Bio-Techne empowers scientists and clinicians by providing high-quality reagents, analytical instruments, and precision diagnostics.

>$1.1B (FY23) 8% of Revenue

Member of

Bio-Techne is a global developer, manufacturer and supplier of high-quality reagents, analytical instruments, and precision diagnostics.

Bio-Techne has an extensive catalogue of over 500,000 products. Incorporated in 1981 as R&D Systems™, Novus Biologicals, ACD, Tocris BioScience, ExosomeDx and ProteinSimple, the company changed its name to Bio-Techne in 2014. Our growth has been accelerated through acquisitions, organic investments, diversification of our customer base and expansion into new markets. In fiscal year 2023, Bio-Techne delivered net sales of over $1.1 billion. Bio-Techne includes the following brands: ACD, Asuragen®, ExosomeDx, Lunaphore, Novus Biologicals, ProteinSimple, R&D Systems and Tocris Bioscience.

Together, we unlock the possibilities of science

Our products and services cover a wide range of solutions to accelerate basic scientific understanding, translational research, and diagnostics.

› We develop and manufacture high-quality proteins, antibodies, small molecules, and immunoassays, as well as arrays, stem cell products, cell culture reagents, and other cell biology tools. If you are looking to minimise variability in your research, scale up processes, or transition to GMP-grade raw materials, we can assist you on your journey and make a difference in your research workflows.

› Our protein detection and analytic instruments help reveal new insights into the true nature of proteins and simplify your lab life. With our comprehensive portfolio of tools, which includes Simple Western™ and Simple Plex™ systems that quantify protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics.

› In spatial biology, we bring sensitive and specific innovation to researchers, helping them to understanding the spatial basis of gene expression and provide automation solutions that simplify technology adoption for translational research laboratories. Both individually and in partnership our RNAscope™ technol-

ogy and COMET™ systems make multiomic spatial biology solutions, accessible to researchers.

› We support the genetic and oncology diagnostic fields with our kits for research and clinical applications, through molecular diagnostic control and exosome-based liquid biopsy diagnostics. In addition we develop and manufacture controls, calibrators and assays for regulated diagnostics.

› With this experience we are able to make our vast portfolio of sample testing services and product development available as custom services, offering a variety of ways for to streamline and improve your experimental processes. In addition, we offer precision medicine services to pharma partners spanning the continuum from biomarker discovery to post market commercialisation of companion diagnostic (CDx) products.

› Through extensive experience in developing, manufacturing, and commercialising innovative products and services, we welcome partnerships of shared expertise and resources through business development and in-licensing new technologies with a shared goal of positively impacting research and clinical applications.

Whether you’re at the cutting edge of academic research, translating basic discoveries to therapeutic leads, or at a facility that requires the highest level of diagnostic testing, our award-winning tools and solutions empower scientists and clinicians to achieve reproducible and consistent results.

Trusting Bio-Techne means choosing confidence that every solution you use will help move you toward better answers.

Name ›

Address/P.O. Box ›

BioCopy AG

Switzerland Innovation Park Novartis Campus

Building WSJ-210

Lichtstrasse 35

Postal Code/City › Country › Contact Persons › Email › Website › Social media ›

Number of Employees ›

Areas of Activity ›

CH-4056 Basel

Switzerland

Dr. Matthias Wiedenfels, CEO

info@biocopy.com

Biocopy.com I

40

Drug Discovery and Development Immuno-oncology

TCR-like Antibody Engineering

Development of next-generation Cancer Drug Candidates

AI-powered closed-loop Platform pHLA complexes

The BioCopy Group

BioCopy is a German-Swiss biotech company headquartered in Switzerland with one R&D site in the south of Germany. BioCopy is breaking new ground in the development of next generation cancer drugs with its proprietary technologies joined in a unique AI-powered engineering platform.

The BioCopy platform

The BioCopy platform is designed to streamline and optimise the drug discovery and development process. It combines AI-powered workflows with wet-lab data in a closed-loop feedback system.

Streamlining Drug Discovery and Development

One of the most promising strategies in fighting cancer is the development of drugs that target specific markers typically concealed within cancer cells. While this approach holds great potential for therapeutic breakthroughs, it also presents significant challenges in identifying the ideal antibody and developing the optimal drug.

BioCopy focuses on the target class of so-called pHLA complexes. These are intracellular proteins presented as peptide fragments via HLA complexes on cell surfaces. Certain pHLA complexes are only found on cancer cells, making them ideal targets for cancer treatment – however, the difference to healthy cells is very small.

The engineering of therapeutic antibodies that target pHLA (so-called TCR-like antibodies) has been challenging and high-risk due to toxicity issues and the difficulties in the later manufacturing process.

BioCopy unlocks the transformative potential of TCRlike antibodies with a unique solution. We combine expertise in the pHLA space with high-throughput screening technologies, advanced protein engineering, and cutting-edge cell culture. This wet lab framework is integrated with databases and artificial intelligence, enabling accelerated learning through a closed-loop feedback system.

The generated proprietary data is fed into BioCopy AI-powered engineering workflows which identify the most promising antibody candidates for a particular kind of cancer.

The combination of bioinformatic workflows and advanced AI tools broadens the scope of off-target sequences, ensuring comprehensive coverage and precise analysis. This minimises off-target toxicity, which is one of the biggest challenges in the development of such drugs.

Parallel Assessment and Development

The BioCopy approach ensures exceptional efficacy and safety. Our platform allows us to work on multiple tasks and processes in parallel.

This paves the way for a streamlined, efficient and highly effective path from molecular concepts to drug candidates that are not only ready for clinical trials, but have a high probability of success.

At BioCopy, we herald a revolution in the discovery and development of drugs with pHLA targeting, and we are redefining the benchmark for time to market.

Name ›

Boehringer Ingelheim Biopharmaceuticals GmbH

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website ›

Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity › Net Sales › Relevant R&D Budget › Request for › Further Collaborations

Binger Strasse 173

55216 Ingelheim

Rhineland-Palatinate

Dr Barbara Esch

+49-6132-77-0

+49-6132-72-0

bioxcellence@boehringer-ingelheim.com www.bioxcellence.com about 53,000 in 2023 1885 in Ingelheim, Germany S1

Focus on human pharmaceuticals, animal health and biopharmaceutical contract manufacturing

25.6 billion in 2023 5.8 billion in 2023

Boehringer Ingelheim BioXcellence™ is a dedicated partner for biopharma companies, providing comprehensive development and GMP manufacturing services. Renowned for its reliability, the company supports clients throughout the lifecycle of their products, thus transforming biologic innovations into commercial realities.

BioXcellence manufacturing – Tailored capacities. Reliable supply. Your success, our commitment. Boehringer Ingelheim BioXcellence™ is a leading biopharmaceutical contract manufacturer – a reliable partner that accompanies customers throughout the lifecycle of their products. We provide E2E biopharmaceutical manufacturing based on mammalian cell culture and microbial fermentation.

We have extensive experience with a variety of different host cells, producing a broad range of molecules in accordance with cGMP manufacturing guidelines and covering all stages of development, including aseptic filling. Our focus is on creating value for our customers through robust processes, effective preparation for launch, and global clinical and commercial supplies of high-quality biopharmaceuticals.

We are committed to maintaining high-quality standards in all operations, with robust systems designed to meet stringent regulatory requirements, and strong quality control capabilities that ensure product quality at every manufacturing stage. Our team’s extensive regulatory experience and impressive inspection track record demonstrate our ability to navigate complex regulations and integrate in-depth technological knowledge into our operations.

World-class expertise

With over 40 years of biotechnology experience and a team of dedicated and highly trained employees, we have helped our customers bring more than 45 bio pharmaceutical medicines to the market, serving patients all over the world. Our expertise spans across various host cells, enabling us to produce a wide array of molecules. Our commercial portfolio comprises monoclonal antibodies, recombinant proteins, antibody fragments, and recombinant vaccines, and is complemented by intensive experience in bi- and multispecific antibodies, Fc fusion proteins, scaffolds, peptide hormones, and pDNA.

World-class facilities

Our network of manufacturing facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria, and Shanghai in China. With more than 440 kL for mammalian cell culture and 12 kL for microbial fermentation in fully licensed multiproduct facilities we are your right partner for high-quality global supplies of biopharmaceuticals to patients. This is evidenced by our regulatory excellence: our operations are based on fully licensed multi-product facilities for all major markets; one-quality, one-compliance and one-regulatory are the foundation of our global network.

Your world-class production partner

For many of our customers, we are the preferred partner for reliable supplies. Seven of the top 10 pharmaceutical companies already trust us due to our extensive commercialisation experience. At Boehringer Ingelheim, we are deeply invested in the success of your product. Our shared passion is reflected in our commitment to providing the highest quality services and solutions to ensure your product reaches its full potential.

Aside from our extensive experience and technical expertise, which complements yours, there are several other compelling reasons to choose us as your trusted contract manufacturing partner. At Boehringer Ingelheim, we have learned over the generations that the challenging path towards health innovation requires long-term commitment, resilience, and transformative action.

Let’s build a future together based on our history. We have capabilities to complement your expertise and are committed to turning your biologic innovation into commercial reality.

Name ›

Address/P.O. Box ›

Postal Code/City › State › Telephone › Email

Website

Social Media ›

Number of Employees ›

BRAIN Biotech AG

Darmstädter Str. 34–36 64673 Zwingenberg Hesse

+49-6251-9331-0 public@brain-biotech.com www.brain-biotech.com www.brain-biotech-group.com

Creating a #BiobasedFuture

BRAIN Biotech AG is a leading provider of biobased products and solutions designed to support sustainable industrial processes.

As the parent company of the global BRAIN Biotech Group, BRAIN Biotech AG excels in:

Founded (year) › Type of Laboratory › Areas of Activity ›

Around 330 in BRAIN Biotech Group at several sites in USA and Europe; around 120 at R&D research campus in Zwingenberg, Germany 1993

S1, S2, L1, L2

l Enzymes and proteins

l Microbial strain development

l Bioprocess Development

l Biomanufacturing

l Bioactive natural compounds/ Bioinformatics

Request for › Further Collaborations

We’re looking for partners in the food, feed, chemicals and cosmetics and pharma industries to work with us to develop innovative bio-based solutions.

› Crafting innovative custom solutions based on enzyme discovery, enzyme technology, development of microbial producer strains and bioprocess development.

› Producing specialty enzymes and proteins on an industrial scale, with fermentation facilities in the UK (2 x 10 m³) and production sites across Europe and the USA.

In particular, we support companies in the food and beverage industry, the life science sector, as well as companies with environmental issues.

Technology Services

› Enzymes and Proteins: Leveraging function and sequence-driven discovery, rational enzyme engineering, and bioinformatics to design tailored applications. With our metagenomics database MetXtra™ we offer one of the most powerful databases for the discovery of new, patentable enzymes of industrial interest.

› Microbial Strain Development: Specialising in microorganism discovery, genetic and metabolic engineering, and the development of production strains to create powerful protein and enzyme producers.

› Bioprocess Development: Offering process development and optimisation, process transfer and scaleup, and comprehensive analytics designed for production.

R&D Services

Enzyme Optimisation and Discovery

If an enzyme product isn’t available in the BRAIN Biotech Group’s portfolio, our metagenome libraries facilitate sequence- or activity-based searches for new candidates. We also optimise existing enzymes to better meet complex process and application needs.

Genome Editing Tools and Services

Utilising our proprietary CRISPR/Cas platforms named G-dase E and G-dase M with a variety of unique nucleases for custom genome editing services across multiple applications. These tools, developed in-house, stand apart from common nucleases like Cas9 or Cas12a, and are available for licensing.

Process Development and Optimisation

Our expertise covers developing and scaling up bioprocesses from lab-scale to 200L for process validation and sample generation. Our engineers are adept at tech and process transfer to ensure industrial-scale production capabilities.

Applied technologies

› Protein and enzyme engineering

› Natural compound libraries

› Genome editing / independent CRISPR nucleases

› BioArchive with access to nature‘s biodiversity

› Metagenome technologies

› Next generation sequencing

› Precision fermentation & bio-processing

› Applied bioinformatics

› 3D modelling

› Analytics

Name ›

Address/P.O. Box › Postal Code/City › State › Telephone › Fax › Email › Website › Social Media ›

Number of Employees › Founded (year) ›

Areas of Activity ›

CeGaT GmbH

Paul-Ehrlich-Strasse 23

72076 Tübingen

Baden-Wuerttemberg

+49-7071-565-44-55

+49-7071-565-44-56 info@cegat.com www.cegat.com I F  ~ 200 2009

Genetic analysis, next-generation sequencing (NGS)

About CeGaT

CeGaT is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.

Founded in 2009 in Tübingen, Germany, the company combines state-of-the-art sequencing technology with medical expertise – with the aim of identifying the genetic causes of diseases and supporting patient care. For researchers and pharmaceutical companies, CeGaT offers a broad portfolio of sequencing services and tumour analyses. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with its own insights.

The owner-managed company stands for independence, comprehensive personal customer service, and outstanding quality. CeGaT’s laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189, and DIN EN ISO/IEC 17025 and thus meets the highest international standards.

Your true partner for next-generation sequencing (NGS)

Our vision is to make next-generation sequencing available to all life scientists and bring diagnostic knowledge into sequencing service.

We are your true partner for next-generation sequencing. Being pioneers in NGS-based genetic diagnostics, we have a profound understanding of the underlying technology. Based on this, we offer practical applications for research and medicine. Consistently high quality is our maxim: We perform all projects in-house and automate processes whenever possible.

We strongly believe that teamwork is key. Our interdisciplinary team consists of specialists from various disciplines who contribute their specific know-how. A dedicated project manager supports you from beginning to completion and will be your individual contact. Together, we realise smart sequencing solutions to address your research questions.

A comprehensive product portfolio to match your project’s requirements

To support scientists in accomplishing projects of any scope, we offer a broad product portfolio. You can choose from a wide range of sequencing services, such as:

› Whole Genome Sequencing

› Whole Exome Sequencing

› Transcriptome Sequencing

› Ready to Load Sequencing

The portfolio is complemented by analyses suited for microbiome, immunology, translational oncology, and epigenomics studies. We are also your partner of choice for NGS services within clinical studies. All our services can be tailored to your requirements, be it the isolation of nucleic acids, data output format, or further bioinformatic analyses.

High throughput technology meets outstanding scientific expertise

The rapid advancement of technology is constantly increasing the potential of genetic analyses. Therefore, CeGaT continuously invests in the latest equipment. We constantly improve sequencing quality and data analysis by using the most advanced technologies and pipelines available. With the two in-house NovaSeq™ X Plus, five NovaSeq™ 6000, and a PacBio Sequel IIe system, we sequence large quantities of genetic material within a very short time.

For consistently high quality as well as time and cost savings, we rely on the automation of processes. At the same time, human expertise is indispensable to us and an essential pillar of our company. The entire process is supervised by a dedicated project manager who provides advice and support from project design to the final report. We also adopt the strict requirements of genetic diagnostics for research projects.

Name

Address/P.O. Box

Postal Code/City

State

Contact Person

Telephone

Email

Social Media

Number of Employees

Founded (year)

Cellex Cell Professionals GmbH

Melli-Beese-Str. 9-11 50829 Cologne North Rhine-Westphalia Business Development +49-221-25091961 businessdevelopment@cellex.me www.cellex.me

350+

Company founded in 2001

Active in ATMP manufacturing since 2016

Type of Laboratory

2018 opening of the Cellex Cell Manufacturing Plant in Cologne

| 27,000 sq ft GMP-compliant manufacturing area

| Quality control laboratories

| Cryostorage area

Areas of Activity

Collaborations

Full service CDMO partner for Cell and Gene Therapy (CGT) and provider for human starting material FROM BENCH TO BEDSIDE

| Regulatory strategy support and consultancy

| Manufacturing and QP release

| Quality Control System

| Cryostorage

| Coordination and product labeling

| Transports and Logistics

| Specialized in transfer of preclinical development stages to clinical manufacturing and commercialisation

Pharmaceutical companies, large, midsize and small Biotech as well as academia.

Your CDMO partner for cell and gene therapy

Cellex has a high expertise in manufacturing final drug products & intermediate drug products for Cell and Gene Therapy. Benefit from our comprehensive solutions to get your innovative drug products from early preclinical stage. As a reliable and trusted partner of international pharma and biotech companies and with high knowledge in autologous and allogenic development and manufacturing, Cellex is a true full-service CDMO partner.

Manufacturing of CGT products / ATMPs

Our state-of-the-art facility, based in Cologne, offers GMP-compliant contract manufacturing. Together with clients, we design the path from preclinical process development to manufacturing for clinical trials and commercialisation. During the development of robust and efficient manufacturing processes for your CGT product, we will always be in close cooperation with you.

› 10+ manufacturing licenses for autologous and allogenic CGT products

› 4000+ manufactured ATMP batches

› 100% of requested products were manufactured

With a growing team, we cover well-trained and highly qualified operators, project management, and quality control. A consistent leadership ensures continuity and stability.

Why partner with Cellex?

› Expertise in manufacturing cellular intermediates and final drug products

› State-of-the-art facilities with increased production capacity and flexibility

› Laboratories with a broad portfolio of analytical methods to ensure product quality

› Manufacturing process development and optimisation

› End-to-end logistic solutions, individual GDP-compliant transport solutions

› Full service solutions related to CGT products, e.g. Project Management, QP Services, Product Labelling

› High product quality ensured by following all existing laws and guidelines, e.g. EMA regulations, ICH recommendations, GMP guidelines

› Regulatory consultancy and audit capabilities

Human Starting Materials

With a collection site and a highly diverse donor pool, Cellex provides high quality human starting material, e.g. leukopaks, mobilised leukopaks, bone marrow and whole blood for R&D, clinical and commercial use. With >50,000 collections performed, Cellex holds deep expertise in collecting allogenic and autologous cellular blood products. Cell products can be customised to client-specific needs such as donor requirements (e.g. HLA, BMI, gender, age, CMV status) or product requirements (e.g. volume, cell count). We are specialised in providing fresh material tailored to your needs. Donor prescreening and recallable donors are available too. We will find the perfect match.

Why to choose Cellex as a supplier?

› Highly diverse donor database and large network of partners for international donor access

› Healthy & diseased donor material

› Recallable donors available

› Specialised collection centre for rapid access to customised cell products

› Outstanding expertise with regard to allogeneic & autologous starting material

› Autologous patient collections for clinical use

› Located in Cologne with direct access to highways, high speed trains and several airports for fast delivery worldwide

Name › Address/P.O. Box ›

Postal Code/City › State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year) ›

Areas of Activity ›

CG Pharma & Biotech

Business Unit of CG Chemikalien GmbH & Co. KG

Ulmer Straße 1

30880 Laatzen

Lower Saxony

Dr Frank Velte, Head of CG Pharma & Biotech

+49-511-87803-0 info@cg-chemikalien.de www.cg-pharma-biotech.com I

65 dedicated CG Pharma & Biotech 1962

| Manufacturing of customised, sterilefiltered (bio)pharmaceutical process solutions and excipients for upstream and downstream applications

| Standard catalogue products for several pharmaceutical applications

| Scalable from small scale to commercial production

| Ready-to-use sterile filtered solutions in single-use bags

| GMP cleaning solutions for CIP and SIP applications

| Processing of hazardous substances in the cleanrooms (corrosive and flammable)

| In-house production of WfI and AP

CG Pharma & Biotech Your Challenge – Our Solution

As a developer, manufacturer and supplier of critical raw materials, we understand the challenges of our partners and compliance with regulatory requirements. We accompany our partners on the path from the development stage to commercial production. Our services & products are tailored to the needs of our clients and can be selected and combined on a modular basis:

C-Made: Manufacturing of customised formulations for use in upstream, downstream and formulation. PharmProve ®: Multi-compendial production chemicals for use as an ingredient, excipient or API.

Our customers’ most important applications and products include biotechnologically produced active ingredients and drugs, e.g. vaccines, ATMPs, cell culture media and biosimilars, as well as biological drugs

- e.g. plasma-derived medical products, enzymes and heparins.

Tailored Solutions

› Development and production of customised formulations

› In-house R&D department, from laboratory scale to commercial production

› Agile project management, consulting and planning

Professional Analytics

› In-house chemical/physical analytical laboratory

› Testing of starting materials according to pharmacopoeia (e.g. EP, BP, USP, JP, ChP)

› Finished product testing (e.g. appearance, pH,conductivity, density, refractive index, osmolality, assay)

› Microbiological testing (e.g. sterility, endotoxins, RNAse, bioburden)

› Stability testing

Outstanding Quality

› Manufacturing authorisation according to German Drug Law AMG §13

› Quality assurance agreements with customers and suppliers

› Batch release by authorised person

› Risk Base Management | Change control CAPA / OOS System

› Robust Risk management system acc. to ICH Q9

› Product Quality Review: Batch record review, Supplier qualification system, Audit and training system

› Qualification and validation acc. to Annex 15 EU GMP: Process-, cleaning and method validation, Room- and equipment qualification, Software validation

Cleanroom Production

› 800 m2 cleanroom area, divided into areas liquid and solid

› Clean corridor concept

› Production facility free of animal components (AOF)

› Personnel locks

› Weighing of raw materials in cleanroom class C&D

› Compounding and filling in cleanroom class C&D

› 3 filling rooms for liquid media cleanroom class C&D

› 2 filling rooms for solid media cleanroom class C&D

› Automatic transport conveyor system with integrated weighing technology

› SIP/CIP system for sanitisation and cleaning with validated cleaning processes

› In-house quality control including microbiology

› Washroom for cleaning production equipment

› In process use of nitrogen and ultra-pure steam

› Multi-purpose equipment with validated cleaning procedures

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity ›

Coriolis Pharma Research GmbH

Fraunhofer Straße 18b 82152 Martinsried/Munich

Bavaria

Bettina von Klitzing-Stückle

Bettina.klitzing@coriolis-pharma.com www.coriolis-pharma.com I 200+ 2008

Contract research and development

Formulation excellence for biopharmaceuticals, incl.: | Drug Product Development | Analytical Services under R&D and GMP | Manufacturing Services

Coriolis Pharma – Drug Development, Analytical and Manufacturing Services

Coriolis Pharma is a global contract research and development organization (CRDO) and the premier partner for the development of liquid and lyophilized drug products, analytical services, and manufacturing services across a vast array of therapeutic modalities, including biologics, gene and cell therapies and vaccines.

Our expert scientists design and execute platform and custom services to accelerate and derisk your program right from the start and throughout the entire product lifecycle.

Partner with us − Right from the start Accelerate Preclinical Development

We help you establish a robust formulation foundation from the outset, reducing risks and avoiding costly delays later in development. Our collaborative approach and deep scientific expertise ensure that your formulations are optimized for stability and efficacy from day one.

Reliable Early-Phase Support

Transitioning through the mid-phases of drug development involves complex analytical and validation requirements. We provide consistent, reliable support through these critical stages, delivering robust analytical methods that streamline development and ensure compliance.

Efficient Late-Phase Solutions

As your drug approaches commercialization, managing the complexities of process development and regulatory submission becomes paramount. Our development support in this phase provides the necessary insight and expertise to navigate these challenges efficiently.

Commercial Services

We support your drug’s journey to market with proven GMP processes and meticulous attention to detail. We excel at process optimization and release testing alike, providing comprehensive support throughout the final stages of development.

CORIOLIS PHARMA

Expert Guidance Throughout

Navigating biologics development can be daunting, particularly when faced with unique formulation challenges or complex regulatory landscapes. Coriolis acts as a knowledgeable guide, providing specialized insights and collaborative support to address these issues effectively.

Our Services

Drug Product Development

› Developability assessment

› Pre-formulation screening

› Formulation development, optimization and robustness

› Stability studies

› Primary packaging and container closure selection

› Forced degradation studies

› Clinical/commercial in-use and compatibility studies

› Life cycle management and reformulation

Manufacturing Services

› Tox study manufacturing

› Filing of reference material

› Lead lot stability material

› Lyophilization process development, optimisation, transfer and scale-up

› Comparability, pump, headspace & CCIT studies

› Process development

› Manufacturing troubleshooting

Analytical Services under R&D and GMP

› Method development, qualification, and transfer

› Phase-appropriate method validation

› Compendial method verification

› Release testing / Tech transfer support

› Fast track analytics

› Particle characterisation

Coriolis at a Glance

› Established in 2008

› Headquartered in Martinsried, Germany with 6,900+ sqm lab and office space

› R&D and GMP labs under biosafety levels 1 and 2

› Commercial Organization in Michigan, USA

› GMP certified and regularly audited since 2012

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Areas of Activity › External › Collaborations

CureVac

Friedrich-Miescher-Strasse 15

72076 Tuebingen

Baden-Wuerttemberg

Dr Sarah Fakih, Vice President Corporate Communications & Investor Relations

+49-7071-9883-0

+49-7071-9883-1101 communications@curevac.com

https://www.curevac.com/en/

Less than 1,000 2000

Research, development, and manufacturing of transformative medicines based on messenger RNA (mRNA)

Selected CureVac collaborations: | GlaxoSmithKline (GSK) | The University of Texas MD Anderson Cancer Center | myNEO | CRISPR Therapeutics | Harvard Medical School | Genmab

CureVac’s profile

CureVac is a pioneering multinational biotechnology company established in 2000 with the mission to advance the field of messenger RNA (mRNA) technology for applications in human medicine. Over the past two decades, CureVac has focused on the development, optimization, and manufacturing of this versatile biological molecule for medical purposes. The company has introduced and refined underlying technologies essential for the production of mRNA vaccines, including those against COVID-19. CureVac is currently focusing its efforts to apply mRNA technology in the three therapeutic areas of oncology, prophylactic vaccines and molecular therapies, addressing indications with significant unmet medical needs.

Headquartered in Tübingen, Germany, CureVac operates additional sites in the Netherlands, Belgium, Switzerland, and the United States, supporting CureVac’s research, development, and manufacturing activities.

CureVac’s mRNA technology

The CureVac technology builds on more than 20 years of scientific excellence in harnessing mRNA as a universal template for protein synthesis. It is based on a targeted approach to create and optimize mRNA constructs that encode functional proteins that either induce a desired immune response or replace defective or missing proteins. By mimicking human biology, CureVac utilize mRNA to prevent infections and treat diseases through the synthesis of encoded proteins. These new mRNA constructs represent a highly flexible, novel class of medicine that have the potential to address limitations of conventional treatment modalities.

CureVac’s pipeline

CureVac’s proprietary 2nd generation mRNA backbone serves as the foundation of the company’s current clinical and pre-clinical development programs. CureVac’s mission to develop potentially transformative medicines for people and patients focuses on oncology and infectious diseases, where mRNA technology shows immense promise, as well as on other areas with significant unmet medical needs.

In its oncology area, CureVac combines cutting-edge omics and computational tools for antigen discovery to design and develop the next generation of mRNA cancer vaccines. The initial focus is on the development of socalled off-the-shelf cancer vaccines, targeting tumour antigens shared across different patient populations and/or tumour types. In this area, Curevac recently entered a collaboration with the University of Texas MD Anderson Cancer Centre, one of the world’s leading oncology centres. A Phase 1 study assessing the shared antigen approach is currently ongoing in glioblastoma. It is complemented by the development of fully personalized cancer vaccines based on a patient’s individual tumour genomic profile.

In prophylactic vaccines, CureVac joined forces with GSK in 2020. Developments exclusively based on CureVac’s second-generation mRNA backbone yielded promising candidates for seasonal influenza, avian influenza, and COVID-19. These vaccine candidates are currently in Phase 2 clinical trials and show potential to become best-in-class. Under a recent new licensing agreement between CureVac and GSK, GSK has taken control of developing and manufacturing as well as globally commercializing these candidates. This new agreement is a landmark achievement for CureVac, which validates the company’s proprietary mRNA platform. CureVac is poised to make substantial strides in both the prevention and treatment of diseases, reaffirming its role as a leader in mRNA technology.

Dynamic42 GmbH

Address/P.O. Box

Postal Code/City › State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity ›

Winzerlaer Straße 2, Jena 07745 Jena Thuringia

Dr Martin Raasch +49-3641-508101 info@dynamic42.com www.dynamic42.com I  24 2018

Organ-on-Chip, In-Vitro Assays,

3D-Cell Culture, Pre-clinical Testing, Toxicology, Compound Testing, Biochips, Biomedicine, Infection & Disease Modelling

About Dynamic42

Dynamic42 GmbH provides immunocompetent, physiological organ-on-chip models combining ISO-certified, medical-grade standards with ease of use for scientists. As a spin-off from the University Hospital Jena in Germany, the company has developed a strong background in disease and infection modelling. Dynamic42 offers contract research for preclinical drug evaluation in human models of the vasculature, liver, intestine, and lung as well as customized model development. The company further is producer of the DynamicOrgan System the open organ-on-chip platform, provides a variety of medical-grade, low drug adsorption biochips and hands-on training courses within their Dynamic42 Academy.

Contract Research Services

Dynamic42 GmbH develops human, three-dimensional physiological organ models in a biochip. As contract research organization we are testing new drugs as well as novel dosage forms of drugs (i.e. nanoparticles). In addition, we are developing customized biochip-based assays and organ models (disease and infection models) for further studies.

Our services can be used for toxicology screenings, lead identification and optimization as well as in vitro model development. Our unique immune-competent organ models enable scientist to gain deeper understanding of human cellular biology in health and disease. They can help to strengthen pre-clinical data sets, to perform target validation, to investigate molecular mechanisms and to prioritize further developments.

Member of

The DynamicOrgan System

The DynamicOrgan System is the technology behind our organ models and enables scientists to establish organ-on-chip in their own lab. With the system, scientists can build human in vitro disease and infection models to get greater and more meaningful insights into human biology swiftly and without capital spending. The DynamicOrgan System includes pumps, biochips, consumables and, unlike most organ-on-chip devices on the market, the freedom to keep using standard laboratory equipment.

The Dynamic42 Academy

In our Academy scientists can learn the skills to integrate organ-on-chip technology into their research. Our 2-day course offers hands-on trainings in the lab and shorter theoretical sessions by leading experts in the organon-chip field. During the course, attendees will have the opportunity to speak to our lab scientists about the specific models and applications and learn how to best implement them in the lab. Our main goal is it to ensure that all participants can apply the technology in their lab after mastering the course. We do this by strictly limiting the number of participants per course, provision of indepth protocols and leaving room for specific questions and lots of hands-on time with the equipment.

Course content

› Theoretical lecture on organ-on-chip technology by industry experts

› Sterilization & coating of biochips

› Seeding of cells in biochips

› Perfusion set-up with all necessary microfluidic parts

› Medium exchange and sampling of organ model

› Imaging of models via Immunofluorescence with different antibodies

› Seeding of endothelial cells in biochips

› Cleaning of biochip equipment

› Troubleshooting of experiments

› Medium exchange on static biochips

› Permeability assays

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone

Email

Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

EVONIK Operations GmbH

Kirschenallee

64293 Darmstadt Hesse

Dr Ingo Klement

+49-6151-18 3414 ingo.klement@evonik.com www.evonik.com F I I

>1,000 1982

L1/L2/S1/S2,

Strain and process development, analytics, quality control, target validation, piloting and scale-up USP + DSP, commercial routine production

A global precision fermentation leader from strain development to large-scale production

The division Nutrition & Care at Evonik operates a global network of biotechnological production sites at different scales with up to 250 m3 fermentors. This network includes a versatile multi-product site in Slovakia, designed for process scale-up and market launch of new and innovative products, which is available to our industrial partners.

External › Collaborations

CDMO, Joint Development, Supply Agreements, Joint Venture, Venture Capital

Request for › Further Collaborations

Long-term business orientation

Evonik has leveraged its expertise in fermentation and biocatalysis technologies, including strain development, process optimisation, piloting, and large-scale manufacturing to bring a wide range of products to market. These products span various application fields, such as APIs, pharma intermediates, biomaterials, food ingredients, excipients, and cosmetics. With a total CDMO fermentation capacity exceeding 4,000 m³, Evonik’s network of sites in the U.S. and Europe is well positioned to support customer projects and products, regardless of scale or process complexity.

Sustainability as a growth driver for biotechnology services

Industrial biotechnology is a crucial driver for growth and innovation, enabling the development of novel, nature-inspired products that are inaccessible through chemical synthesis, thereby complementing Evonik’s existing technologies and services. Advances in synthetic biology and a shift towards sustainable manufacturing methods are increasing the demand for Contract Development and Manufacturing Organizations (CDMOs) with best-in-class microbial fermentation capabilities. For over four decades, Evonik has been a dependable partner to pharmaceutical companies and other innovators aiming to industrialise disruptive biofabrication technologies.

Member of

Evonik CDMO services – a one-stop shop

In addition to development and production services, Evonik can support customers in techno-economical assessments (TEA) and life cycle assessments (LCA). Leveraging Evonik’s extensive engineering experience, Evonik can also facilitate the realisation of brownfield or greenfield concepts in case the volume demand should exceed current capacities.

As such, Evonik positions itself as a comprehensive, one-stop shop and full-service provider.

The Evonik biotechnology platform

The Evonik Biotech Hub serves as a central hub for various scientific disciplines within the global biotechnological network. With more than 100 scientists at three international sites, the Biotech Hub is the competence centre for industrial biotechnology at Evonik, providing everything from groundbreaking ideas to industrial bioprocesses, facilitating the transformation of business opportunities into commercially feasible processes.

The profound understanding of biological systems, like the interactions in different target systems or the elucidation of the mode of action, as well as the differentiating capability in designing and operating efficient and sustainable manufacturing processes for biomolecules and microbial solutions, enables the Biotech Hub to develop tailored and competitive solutions allowing its customers to assume a leading position in their respective markets.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person

Telephone

Email Address

Internet Website

Social Media

Number of Employees

Founded (year)

Type of Laboratory

EW Biotech GmbH

Am Haupttor - Bau 3668

06237 Leuna

Saxony-Anhalt Isabel Waengler +49-3461-43-8574 info@ew-biotech.com www.ew-biotech.com

2017 (spin-off from the thyssenkrupp biotech devision)

l Chemical

l Microbiological (S1)

l Lab to pilot to demonstration scale

Who we are

EW Biotech GmbH was formed, as an operating unit of EW Nutrition GmbH, in the end of 2016 out of the former biotechnology division of thyssenkrupp AG, which developed biotechnological production processes for polymer-grade succinic as well as lactic acid. The vast experience gained over more than 18 years is offered to customers, providing services in developing and scaling-up bioprocesses with an industrial background as well as production services.

Based at the chemical site of Leuna, near Leipzig, EW Biotech offers all benefits of being part of a chemical park including infrastructure, contract chemical synthesis, and strong partnerships.

Areas of Activity

l Scale-up

l Demonstration campaigns

l Sample production

l Contract manufacturing (CMO)

l Upstream and downstream technologies

Collaborations

Request for › Further Collaborations

Strong partnering network to address even specific customer needs

We join you at any stage of the development cycle and help you to scale-up, demonstrate, and commercialise your process.

Bridging the gap

EW Biotech is specialised in scaling industrial processes from laboratory and pilot scale to demonstration and commercial scale. With our expertise and technical capabilities, we reduce your scale-up risk with new technologies.

We are a one-stop-shop supporting you at any stage of your development.

We operate our fermentation and downstream lines from lab to production scale with aseptic, aerobic 85 m³ fermenter under industrial conditions (24/7).

In addition to scale-up and contract manufacturing services, the facility enables expanded research and development activities in the field of biotech processes.

Mindset and approach

We understand. We have been there

› Successfully developed numerous industrial biotech processes

› Went from lab, pilot, and demo phase to engineering/ commissioning of industrial plants

› Ready to share our experiences

Thinking from the end

› Our approach is guided by the final industrially viable process or plant

› Integrating production experiences and engineering background

› Combining upstream and downstream knowledge

One-stop-shop

› Unique lab-to-market approach

› Strong partnering network

› Hub to access European markets

Dedicated and experienced team

› Track record in industry

› Highly skilled and result driven

› Interdisciplinary approach

Reference projects

› Bio-fertilisers

› Enzymes

› Proteins

› Organic acids

› Polyols

› Probiotics

› Vitamins

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

FGK Clinical Research GmbH

Heimeranstr. 35 80339 Munich Bavaria

Martin Krauss, Dr Edgar Fenzl +49-89-893-119-0 martin.krauss@fgk-cro.com rfp@fgk-cro.com www.fgk-cro.com; I 240 2002

Full service CRO for conduct of clinical studies, offering support in | Regulatory Affairs

| Project Management/Monitoring

| Medical Safety

| Data Management/Biostatistics

| Medical Writing | eSolutions | Quality Assurance all over Europe.

Our daughter companies create special added value for our clients:

| “FGK Representative Service”: EU Representation Services which are legally required for non-European sponsors conducting clinical studies in the EU(EEA).

| “FGK Pharmacovigilance”: Post-Market PV services including QPPV and PMSF.

BVMA - Federal Association of Contract Research Organisations

Request for › Further Collaborations

Small to mid-sized biotech, device or pharmaceutic seeking flexible support in their clinical development

Company overview

FGK Clinical Research is an owner-managed CRO of an ideal size for cooperation with smaller and mid-sized biotech, medical device or pharmaceutical companies. Covering all phases and areas of clinical development in Europe, we have experience in every major medical indication, including oncology, cardiology, neurology, dermatology, and gastroenterology. Broad knowledge in rare diseases, ATMPs and Cell Therapy completes our expertise.

Most staff is located in our headquarters in Munich and our branch office in Berlin, Germany. We have operational subsidiaries in Czech Republic, Hungary, Poland and the UK – where FGK recently acquired the mid-sized CRO Clinicology.

Our approach to a project

The main philosophy for FGK is to prepare and conduct studies in close cooperation with the sponsor. Our operational team works hand-in-hand with all other departments involved. This also applies for the project manager, who is the central contact person delivering all required information to the sponsor.

Timely approvals and efficient troubleshooting are achieved through a combination of centralized project management and local monitoring, as well as local expertise and regulatory submissions within the country of study conduct.

Services

Clinical Operations

› Project management, primary liaison for sponsor communication, status reports, etc.

› Feasibility, site management, monitoring, etc.

Regulatory Affairs

› Consulting on regulatory topics

› Review of study documents (e.g. protocol, informed consent form, labels)

› Clinical Trial Application with submission to EU and non-EU regulatory bodies

› Legal representative – also visit www.fgk-rs.com

Medical Safety/Pharmacovigilance

› Adverse Event Management and assessment/reporting

› Drug safety, medical monitoring and coding of medical terms

› Pharmacovigilance – also visit www.fgk-pv.com

Medical Writing

› Investigator’s brochures, study protocols, ICF and subject information

› Clinical expert reports, clinical publications, IMP and submission dossiers

Data Management

› CRF design and review, clinical trial databases

› Data validation, processing and cleaning, external data handling, CDISC SDTM

Biostatistics and Programming

› Study design, sample size calculations

› Statistical consultancy, analysis plan, programming and reporting

› CDISC ADaM

Quality Assurance

› Audits of investigator site, database and system audits, internal audits

› SOP composition and implementation

eSolutions

› eCRF/ePRO, RTSM, eTMF, CTMS, DCT elements

Name

Address/P.O. Box ›

Postal Code/City

State

Contact Person

Telephone

Email

Number of Employees

Founded (year)

Type of Laboratory

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Division of Pharmaceutical Biotechnology

Inhoffenstr. 7

38124 Braunschweig

Lower Saxony

Christian Heine

+49-531-6181-6000

biopharmaceutical-services@item.

fraunhofer.de

Institute: 478 (2023)

Pharmaceutical Biotechnology: 62 1981

S1, S2, clean rooms of grades D, C, and B

Areas of Activity

Annual Turnover

Request for › Further Collaborations

Biopharmaceutical consultancy, cell line development (CLD), GMP-contract manufacture of cell banks and investigational biopharmaceuticals, bioprocess development, analytical development and bioanalytical service, aseptic fill and finish of investigational medicinal products (IMPs)

€44.8 million (2023)

l Collaborations concerning GMP manufacture of biological active pharmaceutical ingredients for clinical trials and analytical development

l Manufacture of investigational medicinal products (IMPs)

Company overview

As a service to clients, Fraunhofer ITEM develops biopharmaceutical manufacturing processes, performs investigations into cause-and-effect processes, develops methods and concepts for disease diagnosis and therapy, and conducts preclinical and clinical studies. All studies with drug regulatory status are performed in compliance with current GXP regulations: preclinical development is performed in compliance with GLP, clinical studies are conducted in compliance with GCP and biopharmaceutical active ingredients (APIs) and final dosage forms are manufactured in compliance with GMP requirements.

Division of pharmaceutical biotechnology

The service portfolio of the Fraunhofer ITEM Division of Pharmaceutical Biotechnology covers the development of manufacturing processes for biopharmaceutical APIs such as proteins, antibodies and nucleic acids, as well as manufacture of technical batches for preclinical research. Additionally, the division transforms API manufacturing processes into compliance with current Good Manufacturing Practice (GMP) requirements. For its pharmaceutical clients the division performs pilotmanufacture of APIs and sterile investigational medicinal products (IMPs) for use in early-phase clinical trials.

The division has been licensed since 1997. They are equipped with stirred-tank bioreactors of up to 400 litres volume, with process scale chromatography systems and process filtration systems, enabling GMP-compliant manufacture of investigational biopharmaceutical APIs in 0.5–200 gramme quantities. Process equipment is located in grade-D, grade-C, and grade-B clean rooms that have been EU-licensed by the regulatory agencies but meet US regulatory standards (FDA) as well.

The core elements of the GMP cleanroom facilities are Class B (Iso 6) cleanroom suites with laminar flow hoods providing Class Iso 5 (cleanroom class A) working environments for manual aseptic fill and finish operations or as a Restricted Access Barrier System (RABS) equipped with an automated filling line for vials and ampoules with volumes between 1 and 13.3 milliliters and batch sizes up to 9000 units.

Services

› Development of cell lines based on insect cells, CHOcell lines and microorganisms (e.g. E. coli ) for manufacture of biopharmaceutical APIs

› GMP manufacture of master and working cell banks

› N 2 gas-phase storage and shipment of cell banks

› Development of manufacturing processes for biopharmaceutical API such as proteins, glycoproteins/ antibodies, nucleic acids/plasmids, virus-like particles, and bacteriophages

› Validation of cultivation (USP) and purification (DSP) unit operations and complete processes

› Development and validation (ICHQ2) of bioanalytical methods

› ICH stability testing of drug substances and IMPs

› Non-GMP and GMP contract manufacture of biopharmaceutical API

› Aseptic manufacture of final dosage forms as IMPs for clinical trials

› labeling (Annex-13 and EU-Regulation 536/2014 compliant) and release of IMPs for clinical trials

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity ›

GALAB Laboratories GmbH

Am Schleusengraben 7

21029 Hamburg

Hamburg

Dr Jürgen Kuballa

+49-40-36-80-77-0

+49-40-36-80-77-401

info@galab.com www.galab.com/biotechnology/

F I  I

250 1992

Research and contract laboratory for bio-analytics, S1 according to GenTSV, S2 according to BioStoffV

| Synthetic biology | Biocatalysis | Enzyme production | Enzyme immobilisation | Cofactor regeneration | Process development

GALAB Biotechnology – Next level biocatalysis

GALAB Biotechnology is specialised in the biocatalysis of valuable products for a broad range of industrial applications. One of our main focused products are human milk oligo-saccharides (HMOs). Our interdisciplinary experts develop customised bioprocesses with synthetic biology and complex multi enzyme cascades for sustainable and high-yield productions. Moreover, with our GlycoKat ® and NucleoKat ® technologies, we provide innovative, high-quality products and services for our customers.

Synthetic Biology for in vivo production processes

We apply synthetic biology and metabolic engineering for precise modifications of cells to initiate and enhance the production of target compounds. One of our competencies at GALAB Biotechnology is the in vivo synthesis of valuable HMOs with our patented strains. Our engineered Corynebacterium glutamicum and Escherichia coli strains produce high titer of fucosyllactose and sialyllactose. CRISPR/Cas9 is one of our powerful tools for precise genome editing and modifying metabolic pathways. It allows the fast addition of new genes, modification of existing genes or the knockout of specific genes to optimise the synthesis of our target products.

In vitro synthesis – from genes over stable biocatalysts to products

We offer a complete process development service for in vitro synthesis, from genes to products. Our proprietary expression strains are used in high cell density fermentation, which have been developed and optimised over the last 10 years to achieve high enzyme yields. In order

to develop a tailor-made production process for each enzyme, we offer a variety of enzyme purification and preservation methods. Furthermore, our unique enzyme immobilisation technology enables us to produce highly stable enzymes that can be used in different reactor systems. We have developed a technology that simplifies the implementation of multi-enzyme cascades by using our stable immobilised enzymes in packed bed reactors in continuous flow reactor setups.

Modular process design – GlycoKat ®

and NucleoKat ®

Modular process design makes it easy to implement multi-enzyme cascades. Our GlycoKat ® technology enables the continuous synthesis of a wide range of glycosylated oligosaccharides, with simple product changes by replacing individual modules. The addition of our NucleoKat ® technology takes glycosylation to a whole new level. The NucleoKat® technology is a module that enables the regeneration of expensive nucleotide cofactors and can be integrated into other processes for all types of nucleotides.

Services and expertise

› Synthetic Biology to produce HMOs in efficient E. coli and C. glutamicum strains

› CRISPR/Cas9 technology for precise genome editing and modifying metabolic pathways

› Production of pure, active, and stable biocatalysts through formulation- and immobilisation techniques

› Process development in different reactor concepts, e.g. continuous flow operation with packed bed reactors

› Model development of multi-enzyme cascades

› GlycoKat ® and NucleoKat ® modular technology for efficient synthesis and cofactor regeneration

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website › Founded (year) › Type of Laboratory › Areas of Activity ›

glyXera GmbH

Brenneckestraße 20 – ZENIT

39120 Magdeburg

Saxony-Anhalt

Dr Erdmann Rapp (CEO & CSO)

+49-391-6117-251

+49-391-6117-255 info@glyxera.com www.glyxera.com 2011 | Glycomics | Glycoproteomics | Proteomics

High Performance Glycoanalytical & (Glyco)Proteinanalytical Services & Products

glyXera GmbH is a Max Planck Society spin-off, specialised in high performance glycoanalysis. We are utilising separation- and mass-spectrometry-based glycoanalytical tools and have substantial experience in providing glycoanalytical products & services tailored to the specific needs of our customers. Worldwide exclusively glyXera provides the high-performance glycoanalysis system glyXboxTM

Our clients include leading pharmaceutical, biotechnology and food companies throughout the world. We offer you our sophisticated technology platforms and our expertise with respect to glycoanalytical services, tailored to your specific needs. We guide you for better decisions and help you to perform better and faster during discovery phase, R&D, (clinical) trials and approval of your innovative products (biopharmaceuticals (originators & biosimilars), vaccines, food additives, functional food, etc.), and QA/QC in your production stages.

Expertise & pace

glyXera GmbH is specialised in glycoanalysis, utilising state-of-the-art separation- and mass-spectrometrybased glycoanalytical tools and has a strong background in providing glycoanalytical services. We run modern analytical and synthesis labs, equipped with state-of-the-art instrumentation.

glyXera offers high performance glycoanalysis to its clients, providing sophisticated technology platforms and expertise with respect to glycoanalytical services, tailored to the specific needs of the variety of its customers from academia, clinics, pharmaceutical and food industries. We have substantial experience in glycomics, glycoproteomics and proteomics of biotechnological (e.g. recombinant glycoproteins (mAbs, fusion proteins, factors, hormones, etc) or viral membrane glycoproteins) and clinical (blood, milk and other body fluids) samples.

High-performance glycoanalysis

glyXera provides exclusively worldwide fast and reliable glycoanalysis utilising a “real” high-throughput system (method/software/database) with superior performance and capacity compared to other glycoanalysis tools available on the market.

Our patented system glyXboxTM, based on multiplexed capillary gelelectrophoresis with laser induced fluorescence detection (xCGE-LIF) enables generation and comparison of glyco-fingerprints from large sets of samples and structural analysis of glycans within these samples.

High throughput, high resolution, high sensitivity, high reproducibility, high reliability:

› Up to 96 capillaries in parallel enable “real” high throughput

› Up to 3500x more sensitive and 450x faster, compared to LC

› An order of magnitude higher separation power, compared to LC

High-performance glycoanalysis on 3 levels:

› Glycofingerprinting: Glycosylationpattern analysis & comparison

› Standard Glycoprofiling: Identification of glycans in complex mixtures via database matching

› Extended Glycoprofiling: Extended structural analysis of glycans in complex mixtures using exoglycosidase sequencing in combination with repeated glycoprofiling.

Our services

› Glycofingerprinting & Glycoprofiling by xCGE-LIF & HILIC-FLR

› MALDI-MS based Glycoprofiling

› LC-MS based profiling of N- and/or O-glycans

› Monosaccharide (Composition) Analysis

› Site Occupancy Analysis

› Proteomics

› N- & O-Glycopeptide Mapping

› Intact Mass Protein Analysis (Glycoform Determination)

› General (Glyco)-Protein Characterisation by Protein Gel Electrophoresis Pattern Analysis

Our products

› glyXbox CE : High performance glycoanalysis system based on xCGE-LIF (incl. glyXtoolCE software)

› glyXprep: Sample preparation kit for glycoanalysis

› Tailored standards & kits for glycoanalysis

Address/P.O. Box

Postal Code/City

State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Heidelberg Pharma AG

Gregor-Mendel-Str. 22 68526 Ladenburg Baden-Wuerttemberg

Prof. Dr Andreas Pahl, CEO +49-6203-1009-0 investors@hdpharma.com www.heidelberg-pharma.com

100 1997 ADC technology | Takeda | Binghamton University

The leader in next generation ADC payloads

Heidelberg Pharma is a publicly listed clinical stage company working on a new treatment approach in oncology and developing innovative Antibody Drug Conjugates for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.

Unique toolbox with novel ADC technologies

Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumour resistance via numerous pathways and addresses different types of cancer using various antibodies. The goal is to develop targeted and highly effective ADCs for the treatment of a variety of malignant hematologic and solid tumours.

First to use compound Amanitin

Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. Amanitin is cross-linked to different antibodies designed to transport the compound to the cancer cell, where it is absorbed. There, the Amanitin is released and inhibits RNA polymerase II, which results in programmed cell death, or apoptosis. RNA polymerase inhibition is a novel principle in cancer therapy and offers the possibility of breaking through drug resistance and destroying dormant tumour cells, which could lead to significant advances in cancer therapy - even for patients who no longer respond to any other treatment. The Amanitinbased ADC development candidates are called ATACs, which show promising first results in clinical studies.

Leader in Next Generation Payloads

Heidelberg Pharma is pioneering a new treatment approach based on its ADC technologies for the targeted and highly effective treatment of cancer. Our ADC toolbox addresses multiple types of cancer using various antibody-payload combinations and overcomes tumour resistance by targeting dormant tumour cells.

The most advanced product candidate HDP-101 is a BCMA-ATAC, which is currently being tested in a Phase I/IIa clinical study for the treatment of multiple myeloma. Further ATAC candidates are being developed against different targets such as CD37 or PSMA, each in the indications non-Hodgkin’s lymphoma und metastatic castration-resistant prostate cancer.

New compound extends company pipeline

The first candidate that Heidelberg Pharma is developing with a toxin other than Amanitin is HDP-201, an exatecan-based ADC. Exatecan is a topoisomerase I inhibitor that has proven itself in cancer therapy and is used in two already approved ADCs. It differs in its mode of action from that of Amanitin and thus expands the company’s range of compounds. HDP-201, targets guanylyl cyclase-C (GCC), a receptor that is expressed on the surface of intestinal cells and cancer cells in various gastrointestinal tumours.

ADC collaborations

Based on a hybrid business model, the ADC technology platforms are being used to develop proprietary therapeutic candidates, and to create new product candidates in research collaborations with partners. Heidelberg Pharma develops the proprietary ADC candidates into early clinical development phases with the aim of demonstrating their applicability and efficacy in patients. The partners utilise the ADC technologies to combine their own antibodies with Heidelberg Pharma’s payloads. In such cases, preclinical and clinical development is carried out by the partner.

Mission

As a fully integrated biotech company, Heidelberg Pharma is striving to eradicate cancer through a rich pipeline of ADCs driven by innovative payload technologies. Strong partnerships with international pharmaceutical and biotech companies as well as renowned scientific research institutes and medical institutions support this mission and the long-term goal of increasing the company’s success even further.

IBA Lifesciences GmbH

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity › Biological Patents › External › Collaborations

Rudolf-Wissell-Str. 28

37079 Göttingen

Lower Saxony

Dr Mike Rothe

+49-551-50672-0 +49-551-50672-181 info@iba-lifesciences.com www.iba-lifesciences.com

Numerous in- and out-licensing contracts Name ›

l Protein purification and analysis

l Strep-Tactin®XT l Twin-Strep-tag®

Strep-tag ® – the leading affinity tag in recombinant protein production

IBA Lifesciences GmbH is a biotechnology company that develops innovative products for life science research in both academic and industrial settings. Our unique Strep-tag® technology opens up a wide range of application possibilities in the purification and analysis of recombinant proteins.

Strep-tag ® technology

The Strep-tag ® technology exploits one of the strongest non-covalent interactions in nature; the interaction of biotin and streptavidin. Strep-tag ® II and its tandem equivalent Twin-Strep-tag ® are peptide sequences exhibiting intrinsic affinity towards the biotin-binding pocket of two specifically engineered streptavidin variants, Strep-Tactin ® and its high affinity version StrepTactin ®XT. The wide range of affinities as well as the reversibility of the binding interaction make Strep-tag ® the leading affinity chromatography system.

From protein purification...

Strep-Tactin®XT is the high affinity variant for the purification of strep-tagged fusion proteins, providing binding affinities in the picomolar range for Twin-Strep-tag® while still maintaining binding reversibility and mild recovery of immobilized proteins. It is suitable for efficient protein purification independent of protein class and size, including challenging proteins as well as low abundant proteins.

Fused to magnetic beads, MagStrep ® Strep-Tactin®XT, is the ideal tool for complex identification via pull-downs and fast small-scale batch purification in reaction tubes or 96-well plates.

In particular, Strep-Tactin ® XT 4Flow ® high capacity provides superior performance for the purification of strep-tagged proteins from diluted cell extracts and facilitates intensive wash procedures with large volumes of wash buffer. Strep-Tactin ®XT 4Flow ® high capacity resin is stable over a wide range of pH and compatible with various buffer conditions, and can be reused at

least 100 times without losing performance. Due to this frequent reusability, experimental costs can be significantly reduced.

... to analytical applications

The near covalent affinity of Strep-Tactin ®XT to TwinStrep-tag ® expands the range of use towards analytical applications such as high-throughput screening, assay development and protein kinetic studies. You can obtain Strep-Tactin ® XT conjugated to microplates, fluorophores, or chips.

Strep-Tactin®XT coated microplates ensure convenient diagnostic assay and high-throughput screenings with high stability and antibody-free protein immobilization. Moreover, immobilized biomolecules are presented to interaction partners in a uniform manner, which results in reliable and highly reproducible assay formats.

The picomolar affinity is particularly valuable for surface plasmon resonance (SPR) analysis and bio-layer interferometry (BLI) and supports measurements with long dissociation times and slow off-rates. Moreover, Strep-Tactin®XT biosensors can be easily regenerated.

Key features

› Highly selective binding properties leading to unparalleled protein purity (> 95 %)

› Bioactive target proteins due to rapid one-step purification under target specific conditions

› Variability in buffer conditions, e.g. high salts, detergents, metal ions, chelators or reducing agents

› Favorable for protein-protein interaction studies due to mild elution conditions that preserve natural protein structure

› Products covering the entire workflow from cloning, purification to analytical applications (ELISA, FACS, SPR, Microscopy, Western Blot, etc.)

Name ›

Address/P.O. Box ›

Postal Code/City › State

Headquarter

Contact Person

Telephone

Email

Website

Social Media

Number of Employees › Founded (year) ›

Areas of Activity

Immunic Therapeutics

Lochhamer Schlag 21 82166 Gräfelfing Bavaria

New York City, USA

Jessica Breu (VP IR and Communications) +49-89-2080477-09 info@imux.com www.imux.com

F I Q  85 2016 l Immunology

l Chronic inflammatory and autoimmune diseases

External › Collaborations

l Ludwig-Maximilians-University (LMU) Munich, Germany: Department of Pharmacy: Prof. Dr Daniel Merk

l City of Hope Duarte, California, USA: Department of Molecular Imaging & Therapy, Research in Cancer and Immunity, Mechanisms Controlling T-cells: Prof. Zuoming Sun, Ph.D.

l University Hospital Erlangen, Germany: Institute of Clinical and Molecular Virology: Prof. Dr. Manfred Marschall

l University Hospital Frankfurt, Germany: Institute for Infectiology: Prof. Dr. med. Maria J.G.T. Vehreschild

Immunic (Nasdaq: IMUX) is developing oral therapies for chronic inflammatory and autoimmune diseases. With our lead asset vidofludimus calcium (IMU-838), we are aiming to change the paradigms in the treatment of patients with relapsing and progressive forms of multiple sclerosis (MS). Our second clinical-stage program IMU-856 has demonstrated clinical proof-of-concept in celiac disease patients and may represent a completely new treatment approach for patients suffering from various gastrointestinal diseases. IMU-381, currently in preclinical testing, is a next-generation molecule specifically addressing the needs of gastrointestinal diseases.

Vidofludimus calcium: unique dual mode of action targeting relapsing and progressive MS

Immunic’s lead development programme, vidofludimus calcium, is targeted to address multiple drivers of neurodegeneration in MS patients. It is an orally available, next-generation selective immune modulator that acts as a potent, first-in-class nuclear receptor related 1 (Nurr1) activator, in addition to inhibiting dihydroorotate dehydrogenase (DHODH). Nurr1 is a neuroprotective transcription factor and an emerging target in neurodegenerative diseases.

Vidofludimus calcium is currently being investigated in the twin Phase III ENSURE trials in relapsing multiple sclerosis (RMS) and the Phase II CALLIPER trial in progressive multiple sclerosis (PMS). Top-line data of the CALLIPER trial is expected in April 2025; completion of the ENSURE trials in the second quarter and the second half of 2026, respectively.

Immunic believes that vidofludimus calcium has the potential to demonstrate medically important advantages versus currently approved MS treatments, due to its combined neuroprotective, anti-inflammatory and anti-viral effects as well as its favourable safety and tolerability profile, based on exposure to more than 1,800 subjects, to date.

IMMUNIC THERAPEUTICS

The molecule has a targeted effect on hyperactive immune cells without suppressing the normal immune function. It has also shown a robust suppression of MRI lesions and initial signals for a reduction in the rate of confirmed disability worsening in Phase II clinical testing, while also decreasing serum neurofilament light chain (NfL), a biomarker for axonal damage. The broad-spectrum antiviral effect of vidofludimus calcium may support lowering the rate of viral infections and reactivations, including Epstein-Barr virus (EBV) reactivation, potentially resulting in slowing EBV-related neurodegenerative processes.

Vidofludimus calcium in post COVID syndrome: potential read-through to MS

Vidofludimus calcium is also being tested in patients with post-COVID syndrome (PCS). In addition to PCS readouts, the investigator-sponsored Phase II trial aims to evaluate if the drug can reduce fatigue by suppressing the reactivation of EBV. Fatigue is the most common symptom in PCS patients, and also a major issue for MS patients with currently no treatment options available. The results of this trial may provide relevant insights for treating fatigue in both PCS and MS.

IMU-856: restoring a healthy gut by renewal of the gut wall

IMU-856 is an orally available and systemically acting small molecule modulator that targets the protein Sirtuin 6 (SIRT6). The mechanism of action targets the regeneration of bowel wall architecture and restoration of intestinal barrier function, while maintaining full immunocompetency.

Immunic reported positive results from the part C portion of a Phase I clinical trial in patients with celiac disease. IMU-856 was safe and well-tolerated while demonstrating positive results in four key dimensions of the disease’s pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption. Phase II clinical testing is in preparation.

Name ›

Address/P.O. Box ›

Postal Code/City

State

Contact Persons

Telephone

Fax

Email

Website

Social Media

Number of Employees

Founded (year) › Type of Laboratory

Areas of Activity

Indivumed GmbH

Falkenried 88 – Bldg. D 20251 Hamburg Hamburg

Prof. Dr Hartmut Juhl (CEO)

+49-40-4133-83-0

+49-40-4133-83-14 info@indivumed.com www.indivumed-therapeutics.com

I ~100 2002 S2, S1

Drug development partnerships

| Precision oncology R&D

| Pharma and biotech partners

Proprietary cancer database

| Multi-omics data based on high-quality tissue samples

| Extensive clinical data based on longitudinal patient follow-up

Target discovery

| Multi-omic, multivariate analytics

Target validation

| 2D and 3D patient based cellular tumour models

Target characterisation

| Protein class, cellular location

| Biological function, biochemical characteristics

| Cell-based and cell-free screening assays

Request for › Further Collaborations

Indivumed intends to enter into strategic collaborations with industry partners for the joint development of therapeutics.

Moving precision oncology forward with novel, unique drug targets

Indivumed Therapeutics is a biotech company focused on precision oncology. With a data-driven approach we discover novel drug targets and partner with the pharmaceutical industry to develop precision cancer therapeutics. Within our global network of selected partner clinics, we utilise proprietary protocols and procedures to collect tissue of unmatched quality and variety. By systematically characterising the tissue at a molecular level and linking it with longitudinal clinical data, we identify novel targets that would otherwise be undetectable.

Combining biomathematics, bioinformatics and cell biology, we select targets and design proof-of-concept drug screening assays that create higher chances of success in downstream drug discovery and development.

We envision a world where precision therapy offers a cure for every cancer patient.

Highest quality biospecimens make all the difference

The basis of our activity is a strict clinical standard, to which we have been adhering to for the past 20 years. Biospecimen and associated data quality is crucial to making relevant details of a cancer disease transparent. To ensure this quality, our global clinical partners apply numerous proprietary standard operating procedures (SOPs) to the collection and processing of biospecimens, achieving an ischemia time for tissue of 10 - 12 minutes. Also, the collection of extensive longitudinal clinical patient data, covering around 300 individual data points, is performed following defined standards. We have developed and refined all procedures through years of experience working alongside surgeons and pathologists in our network.

Target discovery: using multivariate, multi-omics analyses

The high quality of our biospecimens allows us to use a full multi-omics approach. Using next generation sequencing and mass spectrometry technologies, we extract in-depth molecular information (genomics, transcriptomics, miRNA, proteomics and phosphoproteomics data from both normal and tumour tissue) to feed our comprehensive cancer database. Our data-driven target identification process combines biomathematics and bioinformatics in a multi-omics, multivariate approach to uncover hidden patterns in the vast amount of data and leads to the discovery of novel therapeutic targets.

Target validation: end-to-end comparability with patient based cellular models

Target validation is performed in 2D and 3D cellular models derived from patient material from the same cohorts used for target discovery. These models provide a better representation of the tumour’s physiological processes and display characteristic features of the disease. This approach ensures end-to-end comparability and increases the likelihood of successful therapeutic development further down the pipeline.

Target refinement: preparing the package for R&D partnerships

Indivumed’s IP-protected packages include screeningready targets. Supporting data encompasses: protein class, biological function, mode of action, cellular location and further biochemical characteristics. Proofof-concept drug screening assays are established for cell-free and cell-based compound screening. Set up to be integrated within the R&D pipeline of pharmaceutical partners, our unique target packages serve as a basis for further successful drug development.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity › External › Collaborations Request for › Further Collaborations

innoME GmbH

In der Tütenbeke 36 32339 Espelkamp North Rhine-Westphalia

Pascal Zimmermann (CEO)

Ali Durmaz (Sales Manager) +49-8921-53 77-00 info@innome.de info@zencellowl.com www.innome.de www.zencellowl.com I 5-10 2015

Lab Consumables, Injection-Molding, Coating sensors, Microscope, Lab Devices

| Roche | Hamilton | Technilabo | Quarder

Info@innome.de

innoME is your partner for all cell culture matters

Discover innovative ways with us – from the selfdesigned affordable microscope for the incubator to the OEM business of injecting molding plastics. From high-quality standard consumables for your laboratories to customised solutions, shaped to your requirements. Our passion is lab plastics and developing lab devices.

Our mission is clear: we want to fulfil the diverse needs of scientists, quality assurance officers and manufacturers in the biotech and pharmaceutical industries. Our goal is to accompany the areas from development to mass production and to produce for you in Germany. All our products fulfil the highest quality standards.

Our portfolio includes

Cell monitoring microscope for every incubator as an add on. Modular to use, transportable and easy to use. “zenCELL owl” – 24-channel microscope made for monitoring in the incubator, automation of cell counting and generation of alarms. Small, compact and plug and play.

Lab plastics – from standard plates, dishes and flask, we offer a variety of high-quality consumables. Competitive performance and unbeatable prices make us a real competition for established brands.

Lab Equipment – Sterile workbenches, freezers and CO2 incubators are now a part of the innoME portfolio. Simple handling, Italian manufacturing according to the motto ‘once purchased, it lasts a lifetime’. Our motto is also reflected in this co-operation. Simple, affordable and high quality.

CMO/OEM – overmolding, integration of sensors and standard high frequency plastic molds with bubble free guarantee.

With access to state-of-the-art injection molding production lines we offer a development service for your customised plastic solutions. From first ideas to mass production we support and accompany you. Besides standard and individual plastics we can also develop and produce sensor integrated plastics in large scale.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person

Telephone

Fax

Email

Website

Social Media

Number of Employees

Founded (year)

Type of Laboratory

Areas of Activity

InVivo BioTech Services GmbH

Neuendorfstr. 24a 16761 Hennigsdorf

Brandenburg

Dr Moath Al-Mekhlafi

+49-3302-86693-0

+49-3302-86693-62 info.invivo@bruker.com www.invivo.de

I approx. 90 1998

S1, ISO 9001:2015, ISO 13485:2016

| Contract manufacturing | Production and development of immunoassays

| Cell line development for pre-clinical and research use

| In vivo oncology products

| Cancer Antigens and InVivo products

Request for › Further Collaborations

Collaborations with research institutions and industrial partners

InVivo Biotech Services GmbH is your partner for solutions for your high-quality antibodies and recombinant proteins. Our capabilities and more than 25 years of expertise allow us to process highly specific monoclonal and recombinant antibodies as well as recombinant proteins and deliver them promptly in consistently high quality. The product of your choice can be expressed in bacterial and mammalian systems or from your own stable cell line in small to large scale production.

Service Portfolio

In vivo Oncology and Catalogue Products Cancer is a leading cause of death worldwide and has become a financial burden for all countries according to WHO. Scientists and pharmaceutical companies are developing and advancing therapies to help improve the lives of cancer patients. The pipeline of cancer monoclonal antibody therapy is enormously growing.

We dedicate ourselves to providing optimised solutions and high-quality products to make your research in oncology faster and easier. Because as you believe, we also believe there is a cure. To understand more about our catalogue products, visit our homepage: www.invivo.de

Monoclonal Antibody Production

InVivo provides monoclonal antibody production from hybridoma cell lines and also offers hybridoma development services in case the cell line is not available just yet. Antibody production occurs exclusively under serum-free conditions using our proprietary ISF-1 medium. Through optimised high cell-density fermentation, up to 1 kg of your monoclonal antibody can be produced in our facilities.

We are well experienced in handling challenging cell lines, and we can offer various strategies to rescue a badly producing hybridoma cell line. Either through single cell cloning or switching to a recombinant approach.

Transient Gene Expression in HEK Cells

InVEST, InVivo`s optimised system for large-scale transient gene expression, facilitates the fast production of mammalian-derived recombinant proteins. Combining our optimised host cell line HEK-INV with harmonised processes and consumables, we increase production rates up to 80-fold compared to commercially available systems. This makes InVest the perfect solution for medium-scale production of recombinant antibodies, antigens, and other complex proteins.

Stable Gene Expression in CHO Cells

For projects that require large quantities of recombinant antibodies and proteins, InVivo provides custom production services from stable CHO cell pools. Using a proprietary vector set and highly optimised processes, we generate high-yielding stable cell pools in only a few weeks’ time. Easy and flexible upscaling in bioreactors allows biomaterial production in the gram scale.

For long-term production of industry-scale quantities, e.g. for IVD kit manufacturing, InVivo offers the development of stable CHO cell lines (non-GMP).

Protein production in E. coli

Smaller peptides and proteins without posttranslational modifications, can be expressed in bacterial expression systems. Using E. coli as expression system offer several advantages, like a shorter timeline from cloning to protein recovery, inexpensive production process, high protein yields and a very flexible production scale that can be adjusted to your project needs.

We value quality!

As ISO 9001 and ISO 13485 certified company, we always aim for the highest quality standard. Our experience in downstream processing and protein purification together with a thorough quality control, will ensure that you get exactly the product you’re looking for.

We are convinced that the future of medicine begins with precise diagnostics and therefore we value excellent support of your project through our technical experts.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media ›

Number of Employees › Founded (year) ›

Areas of Activity ›

iOmx Therapeutics AG

Fraunhoferstr. 22 82152 Martinsried Bavaria

Dr Apollon Papadimitriou

+49-89-8999-7090-0 info@iomx.com www.iomx.com I 53 2016 | Next-generation cancer therapies | Drug development | Immuno-oncology

iOmx is a clinical-stage biotech company that harnesses deep tumour, T cell and myeloid biology insights along with its proprietary iOTarg™ target screening platform to generate novel treatments for the most prevalent solid tumour indications.

The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs with single agent activity. By applying its comprehensive drug discovery & development expertise, iOmx is committed to shaping the future of cancer therapy.

Next-generation immuno-oncology programs

Immunotherapy has become an essential pillar in cancer treatment with the field currently dominated by drugs targeting the PD-1/PD-L1 pathway. However, these agents show variable efficacy across tumour types, often falling short of cancer patients’ needs and leaving a gap in treatment options.

iOmx is addressing this gap with a differentiated approach that follows the route of new immune-evasion biology discovery and drug development. The company is developing first-in-class therapies with single-agent efficacy, focusing on targets that are biologically distinct and orthogonal to the PD -1/PD - L1 pathway.

iOTarg™ target discovery platform

In brief, iOTarg™ is a high-throughput target discovery & validation platform applied to cell types in the tumour microenvironment, such as tumour or myeloid cells, to identify the immune-regulatory potential of genes that can modulate the activity of co-cultured effector immune cells, e.g. T cells. Novel and druggable immune -regulatory targets are prioritised to run through an extensive suite of tailored and well - defined target validation & characterisation assays, ultimately leading to drug discovery campaigns.

iOmx’s pipeline

The company’s lead candidate, OMX - 0407, is a first- in - class, spectrum - selective SIK (salt- inducible kinase) inhibitor under investigation in a Phase Ia/Ib clinical trial. In a successful Phase Ia dose escalation study, OMX- 0407 demonstrated a favourable safety profile and signs of anti-tumour activity, including a durable complete response in a heavily pretreated patient. This clinical data has led to the initiation of a Phase Ib expansion study in kidney cancer and angiosarcoma. The expansion phase is currently evaluating the safety and single-agent activity of OMX- 0407 in these tumour types, with the objective response rate as the primary endpoint, and secondary objectives including duration of response and patient survival.

The mode of action of OMX- 0407 combines immune sensitisation and modulation of the tumour microenvironment with direct tumour cell - killing effects, thereby driving tumour eradication.

The company’s second program, IOMX - 0675, is a best- in - class antibody targeting the immunosuppressive receptors LILRB1 and LILRB2, part of the leukocyte immunoglobulin-like receptor (LILR) family. This receptor family is expressed on myeloid and immune cells. The fully human, cross-specific, high-affinity antibody neutralises these potent immune - suppressive receptors, while sparing closely related immune-activating members of the LILR family, such as LILRA1 and LILRA3. Neutralisation of these receptors results in a pronounced anti-tumour immune response by retuning the tumour microenvironment and activating T cells against cancer cells.

Outlook

iOmx is advancing its clinical program OMX- 0407 towards clinical proof-of-concept, with key data expected by Q1/2026 and a Clinical Trial Application (CTA) for the second program, IOMX- 0675, expected by the end of 2024.

Name ›

Address/P.O. Box › Postal Code/City › State ›

Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

ITM Isotope Technologies Munich SE

Lichtenbergstrasse 1

85748 Garching / Munich

Bavaria

Dr Konstantin Zhernosekov +49-89-329-8986-6000 businessdevelopment@ itm-radiopharma.com www.itm-radiopharma.com

more than 700 2004

Radiopharmaceutical biotech company | Oncology | Precision Medicine | Targeted Radionuclide Therapy | Nuclear Medicine

Targeted radiodiagnostics and therapeutics for cancer treatment

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hardto-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

Targeted Radionuclide Therapy or Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to normal tissue. In contrast to conventional external radiotherapy, Targeted Radionuclide Therapy is defined by the intravenous infusion of a radiopharmaceutical. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, like receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, thereby destroying the tumor. The highly precise localization enables targeted treatment with minimal impact to healthy surrounding tissue.

Often, the targeting molecule can be used in a “theranostic” approach for both therapeutics and diagnostics. For diagnosis, the targeting molecule is linked with a diagnostic radioisotope, for therapy with a therapeutic radioisotope. This allows tumors and metastases to be both precisely localized at an early stage, and subsequently treated following the same mechanism.

ITM is developing a proprietary portfolio and precision oncology pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, prostate cancer, as well as folate receptor α positive tumors like lung, ovarian or breast cancer. To validate the Targeted Radionuclide Therapy approach, efficacy and safety of the lead candidate n.c.a. 177Lu-edotreotide is currently being compared to standard treatments for patients with neuroendocrine tumors of gastroenteric or pancreatic origin in two Phase III clinical trials, COMPETE & COMPOSE.

The unique combination of ITM’s longstanding expertise, high-quality radioisotopes and global supply network enables ITM to develop new Targeted Radionuclide Therapy based treatment options for hard-to-treat cancer indications. ITM strives to positively impact the treatment algorithm currently in place for solid tumors and make a tangible impact in improving the treatment outcomes and lives of cancer patients.

For more information about ITM, please visit: www.itm-radiopharma.com

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Founded (year) › Areas of Activity ›

Patents › External › Collaborations Request for › Further Collaborations

Kosmas Therapeutics GmbH

Streitbaumweg 8 91077 Neunkirchen am Brand Bavaria

Georg Fey +49-151-2236-6573 georg.fey@t-online.de https://www.kosmastherapeutics.com 2018

Drug development; immunotherapeutics, cancer

https://patents.google.com/patent/ WO2018100139A1 https://patents.google.com/patent/ WO2011070109A1

John F DiPersio, Wash Univ St Louis Med Cntr USA

Matthias Peipp, Univ Schlsw Holst, Med Cntr Kiel, Ger

TA Fehniger, Wash Univ St Louis Med Cntr, USA

Prof E Ullrich, Univ Med Cntr, Frankfurt, Ger

Prof P Lang, Univ Med Cntr, Tübingen, Ger

Overall goals

Kosmas develops immunotherapeutic agents for the treatment of cancer, auto-immune- and inflammatory diseases. Our patent-protected Trilytes are a new class of tri-specific recombinant proteins designed for a safer and more efficient treatment of these diseases. The key innovation is their “dual-targeting” mode of binding to a select subset of target cells, for example Cancer Stem Cells (CSCs). Preferential killing of chosen subsets such as the CSCs is enabled by this novel molecular design and mode-of-action (MOA).

Unique new capability

The new molecular format uniquely permits a single trilyte molecule to bind simultaneously to a pair of 2 different targets, which are expressed on the surface of the select target cell (such as a CSC) in greater density than on other cells, such as bulk cancer cells and non-malignant cells. The trilyte engages Natural Killer (NK) cells of the patient’s immune system and mediates preferential killing of the selected target cells (US patent US11945863B2 approved April 2024; European & Canadian patents EP3548516A1, CA3045385A1 pending; advanced state of application process).

Lead agent to treat Acute Myeloid Leukemia

Our lead agent KT1 was designed to treat Acute Myeloid Leukemia (AML) with an enhanced ability to kill the relapse-inducing Leukemia Stem Cells (LSCs), while also having strong efficacy for bulk AML cells.

NK cells as killers confer a favorable safety profile

NK cells engaged by trilytes have a favourable toxicity profile compared with killer T cells frequently engaged in other immunotherapies. NK cells engaged by KT1 release a less toxic cocktail of inflammatory mediators. These two innovations together, mediated by a single molecule, are expected to achieve greater therapeutic efficacy together with a strongly improved safety profile.

Late preclinical development status of lead agent

Preclinical development of KT1 became possible through an M4 reward from the Bavarian Ministry for the Economy and Commerce. Scalable upstream and downstream processes for the production of clinical grade KT1 using standard components, transferable to GMP production, have been developed. Very good production yields, long-term storage stability in formulation buffer, and anti-leukemic efficacy in mice xenografted with a human AML in combination with transferred human NK cells, have been achieved. Mouse experiments have been performed together with expert collaborators at the Washington University Med Centre St Louis, USA.

Competent founders team

The expertise of Kosmas’ founders covers the needs for the late preclinical and early clinical development of KT1 (https://www.kosmastherapeutics.com).

Expert collaborations for clinical trials in place

The collaborative project with leading experts from Wash U St Louis and the U of Schleswig Holstein, Kiel, has received grant support from the US Leukemia and Lymphoma Society in 2024. Kosmas will acquire an exclusive license for the IP portfolio from the Univ of Erlangen, and searches for investor funding to bring KT1 to a first clinical trial to be led by oncologists from the Univ of Erlangen. A first scientific advice visit with the PEI (Paul Ehrlich Institute, regulatory authority), has taken place. For the further clinical development of KT1, Kosmas plans to continue the collaboration with Univ Med Centres Erlangen and Kiel, the AML study group Studien-Allianz Leukämie (SAL), the teams from Wash U St Louis, and the US Leukemia & Lymphoma Society.

Siteman Cancer Center, Washington University, St Louis, USA

University Medical Center Erlangen, Erlangen, Germany

Name

Address/P.O. Box › Postal Code/City

State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Type of Laboratory

KyooBe Tech GmbH

Max-Lang-Straße 56/1 70771 Leinfelden

Baden-Wuerttemberg Dr Andrea Traube +49-711-252-785-01 andrea.traube@kyoobe.tech www.kyoobe.tech I 25+ 2019

Rapid Prototyping, Mechatronics, Process Laboratory including an Electron Beam Irradiation Area

Areas of Activity

External › collaborations

Request for › Further Collaborations

Mechanical Engineering, Mechatronics and Automation, Biopharma Applications, Feasibility Studies & Media Fill Tests

Strongly cooperating with Bausch + Ströbel and the Fraunhofer Society

We are open to further Collaborations with Big Pharma, Small Biotechs, Adademia, and CDMOs

Based on our extensive expertise in the field of biomanufacturing, KyooBe Tech GmbH focuses on the development and commercialization of innovative production technologies for biopharmaceuticals. We develop pioneering, automated platform technologies that significantly increase efficiency and flexibility in biopharmaceutical production.

We combine state-of-the-art robotics, automation, and biotechnological expertise to create sustainable and integrated process solutions. Our interdisciplinary approach helps us understand our customers’ complex production processes and to address specific challenges.

Together, we are shaping the next generation of biopharmaceutical manufacturing.

Our activities focus on the areas of pathogen inactivation and the automated production of personalized cell and gene therapies. We address current challenges in these areas with two product lines: Our eFIT platform technology includes devices for reducing or completely inactivating pathogens and cells in a liquid solution. It uses low-energy electron irradiation (LEEI) to destroy genetic material reliably.

The eFIT Lab device is suitable for both research (R&D) and small-scale manufacturing processes. It can be used in vaccine production or contamination control strategies (CCS), such as pathogen depletion in biologicals, process media, and blood-derived components, including sera.

eFIT Pro, a large-scale manufacturing machine, is the next level to address throughputs of up to 100 L per hour.

MOSAIC is a cube-based modular production system for cell and gene therapies. The cubes are mobile aseptic incubation units. They can be easily docked onto isolators or biosafety cabinets. For small-batch production in personalized medicine, the cubes ensure safe segregation from each patient batch. The cubes can be used for adherent cell culture processes and suspension cells, processes that need a temperature-controlled environment, or just stable conditions for material transport.

With its vision to revolutionize biopharmaceutical manufacturing through innovative automation, in combination with strong bio expertise, KyooBe Tech is driving change in the industry and positioning itself as a trusted partner for forward-thinking companies.

Name ›

Address/P.O. Box

Postal Code/City

Contact Persons

Telephone

Fax

Email Address

Internet Website

Social Media

Number of Employees

Founded (year)

Type of Laboratory

Areas of Activity ›

Lonza Cologne GmbH

Nattermannallee 1 50829 Cologne North Rhine-Westphalia

Dr Karl Clasen

Gerhard Muster

+49-221-99199-0 +49-221-99199-111 Info.cologne@lonza.com https://bioscience.lonza.com

| BioAssay Products | Electrophoresis

| Mycoplasma Detection and Prevention

| Primary Cells and Media | Transfection

| QC Testing Solutions

Lonza is a preferred global partner to the pharmaceutical, biotech, and nutrition markets.

Our business provides a wide range of products and services spanning early-phase discovery to custom development and manufacturing of active pharmaceutical ingredients and innovative dosage forms. With our scale and resources, we offer a one-stop solution to our customers so they can help people get well, feel well, and stay well.

Founded in 1897 in the Swiss Alps, Lonza is now a global company with more that 30 sites and approximately 18.000 full-time employees. One of our four Divisions, the Lonza Cell & Gene Division, provides the biotech market with CDMO services as well as tools for life sciences researchers to develop, test, and manufacture therapies. Lonza’s Bioscience portfolio ranges from cell culture and discovery technologies for research to quality control tests and software for biomanufacturing.

Research tools for biologically relevant results

Lonza provides a range of solutions for working with human and animal primary cells. Primary cells more accurately reflect the condition and behaviour of cells within an organism compared to commonly used laboratory cell lines, making them important model systems for both basic and clinical research.

At the BioCampus in Cologne, Lonza Bioscience develops and markets the Nucleofector ® Technology, a non-viral gene transfer solution for primary cells and hard-to-transfect cell lines. Introduced in 2001, the Nucleofector ® Technology has continually evolved through innovation. Our current portfolio comprises the 4D-Nucleofector ® Platform and the HT Nucleofector ® System, which enable transfection of hard-to-transfect cells in various formats and scales, with cell numbers ranging from 2 x 10 4 to 1 x 10 9 cells per reaction, and throughput ranging from a single reaction up to 384 reactions per experiment.

LONZA COLOGNE

Lonza Biosciences also offers a comprehensive portfolio of high-quality human and animal primary cells and cell culture media for a variety of research applications throughout the drug discovery value chain. By providing primary cells and media that are pre-qualified, we help customers to reduce the time and money spent on evaluating primary cells for specific laboratory experiments.

Increase efficiency in your QC microbiology lab

Lonza’s wide range of pyrogen and endotoxin testing solutions helps customers efficiently meet regulatory requirements for the safety of all injectable drugs and implantable medical devices.

In 2023, Lonza expanded its QC instrumentation portfolio with the Nebula ® Absorbance Reader and Nebula ® Multimode Reader. Powered by a new version of WinKQCL® Software, these readers, as well as our PyroTec ® PRO Automated Robotic System, meet data integrity requirements and help to streamline QC laboratory workflows. Lonza also offers a range of endotoxin tests that deliver premium testing performance, from our absorbance-based endotoxin assays – the PYROGENT®-5000 Kinetic-Turbidimetric LAL Assay and the Kinetic-QCL® Kinetic-Chromogenic LAL Assay – to our sustainable recombinant PyroGene ® rFC Assay for fluorescence-based endotoxin detection.

The recent launch of the PeliKine human IL-6 Rapid ELISA Kit enhanced the classic PyroCell® Monocyte Activation Test (MAT) System and the new PyroCell® MAT Human Serum System, offering customers an improved testing protocol that increases the speed, simplicity, and efficiency of rabbit-free endotoxin and non-endotoxin pyrogen testing.

Name ›

metabion international AG / metabion GmbH

Address/P.O. Box › Postal Code/City › State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

Semmelweisstr. 3 82152 Planegg/Steinkirchen Bavaria

Diana Yulafci

+49-89-899-363-0 info@metabion.com www.metabion.com

I 70 1997

Small-, mid- and large-scale oligonucleotide components for in vitro diagnostics (IVD)/analyte-specific reagents (ASRs), as well as mid-/ large-scale oligos for R&D and therapeutic applications (GMP grade)

Custom Third Party and OEM Services: Contract Manufacturing & Kitting in the Diagnostics and RUO space

metabion is a biotechnology company, globally renowned as a “boutique” and best-in-class provider of custom high-quality oligos. With more than 25 years of experience, metabion offers the production of a wide range of synthetic DNA and RNA oligonucleotides according to customers’ requirements, as well as the supply of standard life science products.

metabion operates two state-of-the-art manufacturing sites in greater Munich:

› Headquarter in Planegg – dedicated to small scale R&D oligos and ds gene fragments;

› Modern facility in Kirchheim b. München - dedicated to small-scale oligonucleotide components for diagnostic/IVD/ASRs, to mid-/large-scale oligos for R&D/ therapeutic applications.

metabion is certified according to the standards of DIN

EN ISO 9001:2015, ISO 13485:2016 and EXCiPACT ® GMP/GDP:2021. Successfully translating the highest quality standards into everyday practice is the core of metabion’s corporate philosophy and the key to its popularity at the same time – dedicated to enhance scientific excellence and to support diagnostic and therapeutic solutions – in this together!

Custom Synthesis of High-Quality Diagnostic/IVD Oligonucleotides

› Small-, mid- and large-scale production of diagnostic/ IVD oligos – from nmoles to mmoles

› ISO 13485 and cGMP compliant manufacturing

› Primers – unmodified and modified – vast range of special moieties meeting respective assay requirements

› qPCR and dPCR Probes (dlps and dqps) including a fully-fledged portfolio of reporters and quenchers

› nGS oligonucleotides for diagnostic applications

› Hybridisation Probes for FISH applications.

Custom Synthesis of High-Quality Therapeutic Oligonucleotides

› From R&D to GMP grade manufacturing of small-, mid- & large-scale oligos and oligonucleotide-based additives and APIs, from Research to Clinics

· Lead Discovery · Lead Optimisation

· Preclinical Development

· Clinical Trials (phase I and II)

› Support and Services include

· Design of Experiment (DOE)

· Process Characterisation · Process Development

· Process Validation · IND & NDA Filing support

› Scale-up & Process Transfer – from µgrams to several hundreds of grams

› Covering most prevalent types of therapeutic oligonucleotides

· Immunostimulant ONs/CpG oligonucleotides (ISOs)

- excipients/adjuvants

· Antisense oligonucleotides (ASOs)

· siRNAs · Gapmers/RNA-DNA Chimera

· miRNAs · Aptamers

· sgRNA for CRISPR/Cas technology

· Oligonucleotide-peptide/lipid/sugar conjugates for tissue specific API delivery

› Exhaustive panel of QC Analytical methods and services

› Custom formulation, Fill & Finish support and services with an extensive downstream processing equipment and capabilities.

Custom Synthesis of High-Quality R&D

Oligonucleotides and Gene Fragments

› „Oligonucleotide boutique“ with most complete standard portfolio (ss and ds DNA/RNA, single tube/ plates, low/medium/high throughput, modifications)

› „Very special“ oligo manufacturing capabilities upon inquiry

› ds gene fragments (m-blocks) up to 3kb upon inquiry.

Custom Third Party/Contract Manufacturing and OEM Services

› Custom mixes of individual oligonucleotides

› Custom formulations and aliquotation/replication in tubes or plates

› Custom filling of diagnostic assay components including third party reagents and components

› Custom labelling and complete assay/kit assembly

› Custom logistics including drop-shipping to your customers

› Custom application programming interface for inte gration with ordering and billing systems.

Name

Address/P.O. Box

Postal Code/City

State

Contact Person

Telephone

Email Address

Internet Websites

Social Media

Number of Employees

Founded (year)

Areas of Activity

Mettler-Toledo GmbH

Ockerweg 3

35396 Gießen Hesse

Carmen Wiederuh

+49-641-507401

Carmen.Wiederuh@mt.com www.mt.com www.mt.com/global/en/home.html

F I 

~18.000 (2022) 1989

Manufacturer and marketer of precision instruments and services for many applications in research and development, quality control, production, logistics, and retail to customers around the world.

UV/VIS Micro-Volume Spectrophotometry with Rainin specialised high-quality tools

OneDrop UV/VIS Spectrophotometry, the Life Sciences Specialist

The UV5Nano micro-volume spectrophotometer from METTLER TOLEDO stands out with its innovative technology and intuitive usability coupled with modern design. FastTrack™ technology combines a long-lasting light source with state-of-the-art array technology and enables very fast, accurate, and precise measurements. Only a minimal amount of sample (concentration ranges: 6 ng/µL to 15,000 ng/µL of dsDNA) is required for accurate measurements. Large volumes are measured in the cuvette slot.

Spectrophotometry with LockPath™ Technology

› Wide concentration ranges without further dilutions

› Automatic or manual pathlength selection

› Secure locking of the arm during measurement minimises errors

› No drying out of sample during measurement for increased repeatability

Predefined bio-applications

The One Click user interface includes many predefined applications for the analysis of bio-molecules. Nucleic acids like dsDNA, ssDNA, or RNA can be easily tested for purity or concentration. For protein analysis, the One Click user interface provides direct determination at 280 nm and indirect determination with dyes or the commonly used assays (e.g.: Lowry, Bradford, Biuret, or BCA).

Advanced liquid handling solutions

Through its Rainin brand, METTLER TOLEDO is a leading provider of advanced liquid handling solutions for life scientists worldwide. We offer a wide selection of pipettes, BioClean Ultra LTS and universal pipette tips, and expert pipette services. It is a complete pipetting solution that we call Pipetting 360°. Our commitment to quality, innovative design, and state-of-the-art production result in superior pipette products that deliver years of reliable operation. Rainin developed the Lite Touch

System (LTS) to increase the accuracy and precision of pipettes while decreasing friction, making Rainin pipettes a leader in pipetting ergonomics. The risk of repetitive strain injuries (RSI) is greatly reduced when using ergonomic Rainin LTS pipettes and tips.

The PipetteX 4.0 asset management software covers the customer along almost the entire workflow – from creating high-quality asset lists to preparing for an all-lab audit. With just a few clicks, the user knows immediately which pipettes need service and calibration over the next month, quarter, or year. Customers can now pull up a pipette’s entire history, including certificates, in one click. From there they can download certificates and other data.

Process analytical solutions for pH, dissolved oxygen and carbon dioxide

Control of pH and dissolved oxygen during the fermentation process is essential for quality, yield, and batch-tobatch consistency. The concentration of dissolved carbon dioxide has become another important parameter and can now be measured in situ directly in the bioreactor instead of in the off-gas with a BGA, thus providing the exact activity of CO2 in the media.

Our digital online sensors using ISM (Intelligent Sensor Management) technology provide correct measurements as well as sophisticated diagnostics information about sensor performance, such as DLI (Dynamic Lifetime Indicator), ACT (Adaptive Calibration Timer), TTM (Time to Maintenance), SIP/CIP counter, and hours of operation. With the iSense software tool the registration, maintenance, and calibration of a sensor is easily documented for quality purposes.

All sensors can be integrated in controllers for benchtop bioreactors in the R&D environment, used in combination with modern transmitters in the scale-up process, and finally used in large-scale fermenters in the production area. Sensors for O2 are available with classic amperometric technology or with modern optical technology based on fluorescence quenching.

Name ›

Address/P.O. Box ›

Postal Code/City

State

Contact Person

Telephone

Fax

Email

Website

Social Media

Number of Employees

Founded (year)

Type of Laboratory

Areas of Activity

Microcoat Biotechnologie GmbH

Am Neuland 3 82347 Bernried Bavaria

Dr Ingrid Wanninger (Business Development)

Dr Michael Kroder (Business Development)

+49-8158-9981-0

+49-8158-9981-10 info@microcoat.de www.microcoat.de I > 200 1992

S1/S2, GLP, GCP, GMP, ISO 9001, EN ISO 13485

| Contract manufacturing | Custom development | Laboratory services | Endotoxin and pyrogen testing service

External

Collaborations

Request for › Further Collaborations

Business-to-business with industrial partners in the pharmaceutical industry, diagnostic industry and life science industry

Microcoat seeks joint projects and service partnership with pharmaceutical, biotech and diagnostic companies, as well as with players in the field of food safety testing, crop science and instrumentation (medical devices).

Company profile

Microcoat offers a wide range of individual and specialised services for the diagnostic and pharmaceutical industry. In close cooperation with our customers, we aim for best performance, building on a complete range of advanced technologies and uncompromised quality standards.

For pharmaceutical companies, we leverage our profound expertise in in-vitro diagnostics and assay development in order to become a preferred partner in early development, pre-clinical and clinical phases of drug development and patient sample testing. For food safety, environmental testing and other specialised diagnostic fields, Microcoat aims to be the preferred OEM-partner for the development and manufacturing of reliable test components and kits.

Contract manufacturing

Microcoat is an approved original equipment manufacturer (OEM) for diagnostic test kits, bulk and finished components. We manufacture according to ISO and IVD standards. Since all critical test components are produced and modified in house, we are able to control quality at all stages of the production process.

Production technologies:

› Fermentation (30 litre scale)

› Downstream processing

› Protein chemistry

› Microplate and particle coating

› Dispensing/filling/labelling

› Freeze-drying

› Kit assembly

Product categories:

› Coated microplates

› Lateral flow test strips

› Recombinant proteins/antigens

› Antibody/protein conjugates

› Liquid components

› Dried/lyophilized components

› Diagnostic kits

B2B Diagnostics

Custom development

Microcoat offers unique expertise in diagnostic assay and product development. A broad spectrum of methods, skilled staff and intensive communication with the customer are the cornerstones of successful project execution. Development projects are based on detailed milestone plans and follow standardised development guidelines through the five project phases (feasibility, development, verification, validation and manufacturing).

We develop for you:

› Immunological assays

› Molecular assays

› Sample and matrix preparation protocols

› Depletion protocols

Laboratory services

In our certified facilities, we conduct a broad spectrum of GLP/GCP services to support drug development starting from early discovery to post-marketing surveillance. As an independent contract research organisation and preferred provider we serve pharma and life science industries worldwide. Based on long lasting experience in endotoxin and pyrogen testing, Microcoat offers a set of proprietary methods and skilled scientific personnel for GMP release testing as well as non-routine projects. Services are run as flexible customer-specified projects including the search for root causes, exploration of realization alternatives, development of product-specific adaptions and GMP compliant validation of newly established methods.

Our services include:

› Biomarker testing

› Immunogenicity/PK assays

› Endotoxin and pyrogen testing

› Assay development and validation

Business model

Microcoat is focused on business-to-business with industry customers, seeking a reliable and long-lasting partnership for outsourcing projects such as contract manufacturing (OEM), assay and product development, and bioanalytical testing in the context of pre-clinical and clinical studies.

Name ›

Microsynth Seqlab GmbH

Part of Microsynth AG

Address/P.O. Box ›

Postal Code/City

State

Contact Person

Telephone

Fax

Email

Website

Founded (year)

Type of Laboratory

Areas of Activity

Maschmühlenweg 36

37081 Göttingen

Lower Saxony

Dr Aaron M. Nuss

+49-551-370-00-10

+49-551-370-00-12

info@microsynth.seqlab.de

www.microsynth.com

1989

S1/S2, GMP/GLP

| Oligonucleotide synthesis

| Sanger sequencing

| Next generation sequencing

| DNA/RNA isolation

| PCR, qPCR, digital PCR

| Genotyping

| Contract research/outsourcing

Contract Research ›

| Assay Development | Assay Validation (ICH Guidelines)

l GxP analysis of customer test items (Sanger, NGS, qPCR & dPCR)

| Process outsourcing | Genomics research

The Company

Microsynth is a leading European company in the field of nucleic acid synthesis and analysis. Its main activities involve oligonucleotide synthesis, DNA/RNA analysis and sequencing, as well as contract research. For over three decades, the company’s goal has been to serve its customers by delivering products and services of the highest quality, on time, while offering outstanding service – and all this at competitive prices. Microsynth has subsidiaries in Germany (Microsynth Seqlab GmbH), France (Microsynth France SAS), Austria (Microsynth Austria GmbH), and Switzerland (Ecogenics GmbH). In total, Microsynth employs a staff of more than 130 people.

Oligonucleotide Synthesis

Microsynth is a premier expert in oligonucleotide manufacturing, providing solutions for diverse applications. From research primers to diagnostics and therapeutic oligos (ASOs, siRNAs) for drug discovery and preclinical testing, we meet your needs. Choose from various backbones (DNA, RNA, 2’-MOE, 2’-OMe, LNA, PTO), >250 modifications (MGB, GalNac, Palmitate), and purification options. Backed by decades of expertise, we drive innovation through technology and protocols. High-throughput platforms and rigorous processes ensure quality, while skilled chemists optimize strategies. Whether it’s a specific project or complex demands, trust Microsynth for tailored oligonucleotide solutions.

DNA/RNA Analysis

With over 30 years of experience, Microsynth is a leading provider of DNA Sanger sequencing services in Europe. Our strategically located Sanger sequencing laboratories in Switzerland, Germany, France and Austria enable efficient and environmentally friendly sample collection. Our commitment to innovation is exemplified by Ecoli Nightseq®, a groundbreaking service offering faster and more cost-effective E. coli plasmid sequencing.

Microsynth’s expertise extends beyond Sanger sequencing. We embrace next-generation sequencing technologies and offer comprehensive support for Illumina and ONT platforms. Our services cover a wide range of applications, from DNA and RNA sequencing

Analytical Testing of Novel Biological Drugs

Key Focus Areas

• Advanced Therapies: Cell and Gene Therapies

• Vaccines: mRNA and DNA Vaccines

• Biologics: Cell Bank Characterization

Overview of Our Analytical Portfolio

• Identity Testing: Sequence and Strain Identity

• Copy Number Analysis: Vector and Transgene Copy Number (VCN)

• CRISPR Analysis: Translocations, On-Target-Assays, and Off-Target- Assays

Key Certificates

• ISO 13485:2016

• EN ISO 17025:2017

• GMP certified (Swissmedic) for testing of TpP/TP/GMO

for various organisms to plasmids and cosmids. We accommodate projects of all sizes, from single loci to complex metagenomic studies. Our commitment to excellence doesn’t end with data generation; our customised bioinformatics pipelines and comprehensive support ensure accurate and user-friendly results. In addition to sequencing, we excel in nucleic acid isolation, PCR (from classic to digital), fragment length analysis, and genotyping by sequencing.

Contract Research

Over the past decade, Microsynth has evolved into a globally renowned contract research organisation, offering cGMP services in assay development, qualification, validation, and sample testing. Our team has extensive knowledge and experience working with scientists, QA/QC professionals, and project managers from top notch pharma and biotech companies to achieve critical milestones cost-effectively and on time. Particularly, in the burgeoning domain of advanced therapy medicinal products, including gene, cell, and RNA therapies, we have carved a distinctive niche. Here, we have excelled in the development and application of nucleic acid-based analytical methods, establishing a noteworthy reputation.

Quality Management System

Microsynth prioritizes continuous production process enhancement with a focus on regulatory compliance. We have ISO 9001:2015 certification across all branches. Moreover, our NGS, Sanger, and fragment length analysis (FLA) departments at Balgach and Vienna (Sanger and FLA) are ISO/IEC 17025:2017 accredited (STS 0429), showcasing our commitment to precision. All our genetic analyses platforms are certified by Swissmedic as GMP-compliant for quality control (chemical, physical, biochemical and biological) of medicinal products as contract laboratory. The scope includes transplant products (TpP), gene therapy drugs (GT), as well as medicinal products involving genetically modified organisms (GMOs) or containing GMOs, all of them with intended use in humans. Lastly, we maintain ISO 13485:2016 certification for production and distribution of nucleic acids and components for medical use and provision of associated activities.

Name ›

Address/P.O. Box

Postal Code/City

State

Contact Person

Telephone

Email

Website

Number of Employees › Founded (year) › Type of Laboratory ›

Miltenyi Biotec

Friedrich-Ebert-Straße 68 51429 Bergisch Gladbach North Rhine-Westphalia

Svea Lübcke +49-2204-8306-0 MACSsales@miltenyi.com www.miltenyibiotec.com www.miltenyibioindustry.com 4900 worldwide 1989

| S1/S2 | L1/L2 | cGMP

| clean room facilities A/B/C/ | fully automated laboratory (collaboration with Tecan® Group Limited)

Areas of Activity

| Sample preparation

| Cell separation

| Flow cytometry

| Cell sorting

| Cell culture and stimulation

| Spatial biology

| Imaging and microscopy

| Lentiviral vector transduction

| Cell analysis

| Cell processing

| Therapeutic apheresis

| Cryopreservation

| Cellular therapy

| Lab automation

Customised Applications

Collaborations

Check out our collaborations on our website https://www.miltenyibiotec. com/DE-en/about-us/partners-andcollaborators/grant-projects.html

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative portfolio enables scientists and clinicians to obtain, analyse, and utilise the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our 35 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support and expert training. Today, Miltenyi Biotec has 4,900 employees in 24 countries.

MACS ® Sample Preparation

Start smart with innovative solutions for your tissue preparation. gentleMACS™ Dissociators and MACS ® Tissue Dissociation Kits enable standardised sample preparation from almost any tissue source.

MACS ® Technology

MACS Technology is the gold standard in manual and automated immunomagnetic cell separation with tens of thousands of publications proving its power in biomedical research and clinical settings. Frequently occurring cells, rare cells, and specific cell subsets can be isolated from blood or tissue samples, from virtually any species.

MACS ® Flow Cytometry

The MACSQuant ® Instruments include ultra-compact flow cytometers and the MACSQuant ® Tyto ®, a microchip-based cell sorter, and provide unrivalled ease of use for multisampling and multiparameter analysis and sorting. Our large portfolio of antibodies, including REAfinity ® Recombinant Antibodies and Vio ® Dyes, comprise a family of conjugates with high fluorescence intensities and stain indices.

MACS ® Imaging and Spatial Biology

The MACSima™ Platform, powered by MICS (MACSima Imaging Cyclic Staining) technology, enables researchers to fully explore spatial biology with its advanced protein multiplexing capabilities. The UltraMicroscope Blaze™ Platform allows automated 3D imaging at a cellular level, from rodent organs or organoids to samples as big as a human kidney or whole mouse models. To complement these technologies, we offer a growing collection of recombinant antibodies that have been pre-tested for fluorescence microscopy.

MACS ® Cell Culture and Stimulation

Our cell culture media, cytokines, growth factors, and reagents for stimulation, expansion, and differentiation of a variety of mammalian cells are also available up to GMP grade, thus enabling GMP-compliant, cellular product manufacturing.

Clinical products and services

Miltenyi Biotec’s comprehensive portfolio for advancing translational research and therapy includes the FDA approved CliniMACS CD34 Reagent System as well as a range of CliniMACS Reagents for cell separation and processing and MACS GMP products for cell culture and stimulation. The CliniMACS Prodigy ® platform is a unique cell processing solution that enables the fully automated and integrated manufacture of a GMPcompliant cell product in a closed environment. Miltenyi Bioindustry is our global CDMO service department helping biopharmaceutical companies and advanced clinical centres from process development into commercial scale, GMP-compliant manufacturing of viral vectors and cell and gene therapies. The CliniMACS Cell Factory ® facilities are located across North America, Europe, and China and in close proximity to customers.

Name ›

Address/P.O. Box › Postal Code/City › State

Contact Person

Telephone

Fax

Email

Website

Social Media

Number of Employees › Founded (year)

Areas of Activity

Molzym GmbH & Co. KG

Mary-Astell-Straße 10

28359 Bremen

Bremen

Marina Linow

+49-421-69-61-62-0

+49-421-69-61-62-11 info@molzym.com www.molzym.com

I 35 2003

Manufacturer and supplier of products:

| CE IVD kits for infection diagnosis

| Microbial DNA isolation (manual and automated solutions)

| DNA-free PCR reagents, assays, and polymerases

| Customised master mixes | OEM business

Request for › further collaborations

Molzym is interested in the following partnerships or collaborations: | Development and production of individualised, pre-analytical, and analytical solutions, including automation | Service providers and companies in the field of Next Generation

Sequencing, e.g. to establish and improve NGS-based workflows for pathogen identification directly from clinical samples

Scientific Rigor Driving Innovation

Since 2003

Nucleic acid extraction is an important step in molecular microbiological processes as it significantly influences the entire downstream workflow. Molzym focuses on culture-free detection of infectious agents that can cause severe diseases and developed a unique technology for targeted enrichment and extraction of microbial DNA from clinical samples.

Since 2003, Molzym’s sole aim has been to avoid the GIGO effect and to provide laboratories with solutions for highly sensitive and broad detection of pathogens.

Molzym relies on 2 processes that ensure the most efficient extraction: (1) the depletion of non-target human DNA from clinical samples and (2) the production of ultra-pure reagents.

Based on these special characteristics, various highquality products for molecular microbial analysis by PCR- and NGS-based methods are available in over 30 countries.

Products & Automation

From CE IVD-marked broad-range molecular diagnostic kits, host DNA depletion technology, MolYsis™, to ultra-clean PCR reagents and assays, Molzym is one of the leading providers of culture-independent molecular solutions.

Our technology enables the detection of microbes directly from body fluids, tissues, and swabs using PCR or NGS-based methods. Pathogens can be identified within hours, significantly improving the management of patients with rapid, pathogen-targeted antimicrobial therapy.

MolYsis™ is Molzym’s proprietary technology of host DNA depletion allowing targeted isolation of microbial DNA from a great variety of samples. Ultra-pure, DNA-free PCR reagents and master mixes allow for the precise detection of microbes from human samples and animal models. Complete assays for the broad-range amplification of selected regions of the 16S and 18S rRNA genes of bacteria and fungi are available. Basic and dye master mixes can be used with custom primers for PCR and Real-Time PCR analysis.

The latest development is a walk-away robotic system, SelectNA™plus, for the fully automated host DNA depletion and extraction of microbial DNA from clinical and other material. SelectNA™plus conveys utmost technical advances to the demands for contamination-free and low-hands-on processing of samples.

With SepsiTest™-UMD and Micro-Dx™, Molzym offers two CE-marked in vitro diagnostic solutions for the culture-independent detection of pathogens causing various diseases. Both kits include reagents for the depletion of human DNA and the targeted isolation of microbial DNA from a variety of clinical samples, e.g. whole blood, CSF, BAL, joint aspirates, tissue biopsies, abscesses and other specimens. Manual DNA isolation can be accomplished with SepsiTest™-UMD and with Micro-Dx™ the process is fully automated on the SelectNA™plus robot. Precise detection is performed with broad-range 16S/18S PCR and sequencing analysis to identify the pathogens down to the species level. Both assays are especially applicable for samples which were negative after culturing, e.g. due to prior antibiotic treatment or fastidious growth requirements.

The Molzym team appreciates your interest and is at your disposal for further information about our products and developmental projects. Please call at: +49-42169-61-62-0 or send your inquiries to info@molzym.com.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Areas of Activity ›

MucosaTec GmbH

Am Nußkopf 39 66578 Schiffweiler Saarland

Dr Anja Himmelstein

Dr Marius Hittinger +49 15566 363997

anja.himmelstein@mucosatec.de marius.hittinger@mucosatec.de www.mucosatec.eu

I

8 full-time employees 2023

Manufacturing and analytical laboratory, antiviral therapy, mucus engineering, protective and therapeutic treatment against pathogens, versatile platform technology

Company overview

MucosaTec GmbH is an innovative biotechnology company focused on enhancing the body’s natural protective barrier – the mucus layer. Founded within the Federal Agency for Disruptive Innovation (SPRIND), MucosaTec is dedicated to developing cutting-edge strategies to prevent and treat respiratory infections, with a particular emphasis on viral pathogens such as influenza.

Technology and innovation

At the heart of MucosaTec’s approach is its novel platform technology, which employs bifunctional constructs. These constructs are engineered to bind simultaneously to viral pathogens and the mucus lining, effectively trapping and immobilising the viruses. This innovative mechanism prevents the further spread of viruses within the body, offering a new, scalable, and cost-effective solution to viral infections.

Product pipeline

MucosaTec’s product development currently focuses on promising drug candidates targeting influenza. The lead candidate, AntiFlu-001, has demonstrated antiviral activity in preclinical studies. MucosaTec’s vision extends beyond influenza, with plans to adapt its versatile platform to address other viral threats (e.g. coronaviruses). An in-house integrated screening platform enables rapid adaptation to newly emerging or mutating viral strains.

Recognition and awards

In 2024, MucosaTec was awarded with the prestigious BioRegions Innovation Prize. This award, which recognizes groundbreaking advancements in biotechnology, highlights the importance of the company’s versatile platform. The accolade underscores MucosaTec’s leadership in antiviral research and its contribution to preparing for future epidemics and pandemics.

Locations and collaborations

MucosaTec operates from two key locations in Germany. The company’s headquarter in Schiffweiler is dedicated to formulations and analytics, while the research and production activities are based in Berlin. This geographic distribution enables the company to leverage partnerships with academic institutions and industry players, accelerating the development of its cuttingedge technologies.

Future vision

MucosaTec is committed to innovation, research, and the urgent need for proactive antiviral solutions. With the adaptable platform technology, the company is wellpositioned to tackle the growing challenges posed by modern viral epidemics. In addition to the antiviral focus, the platform technology is currently being expanded to target the bacterial kingdom, specifically combating Pseudomonas aeruginosa. By advancing innovative therapies, MucosaTec is playing a pivotal role in safeguarding global health.

Name

Address/P.O. Box

Postal Code/City

State

Contact Persons

Navigo Proteins GmbH

Heinrich-Damerow-Straße 1 06120 Halle/Saale

Saxony-Anhalt

Josephine Hammerlindl (Business Development Manager Precision Capturing)

Michael Hamm (Head of Business Development Precision Targeting )

Telephone

Social Media

Number of Employees

Founded (year)

Type of Laboratory

Areas of Activity

Biological patent

External

collaborations

Request for

Further Collaborations

Florian Settele (Head of Business Unit, Precision Capturing) +49-345-27996330 info@navigo-proteins.com www.navigo-proteins.com

Affinity ligands for protein purification and targeted therapeutic applications

Navigo Proteins is a premier protein engineering company, specialized in creating novel affinity ligands for custom affinity purification of complex biologics (BU: PRECISION CAPTURING®) and as target binders for developing targeted therapies in precision oncology (BU: PRECISION TARGETING). The technology platforms are based on proprietary scaffold proteins which are small, stable, and highly engineerable to achieve different binding characteristics and combinations with a variety of effector modalities to develop a broad range of therapeutic and diagnostic applications.

Affinity chromatography for GMP-compliant protein purification

S1/S2

| Custom affinity resin development | Affilin® -based Precision Medicine

extensive patent portfolio around proprietary affinity ligand technology

Repligen, eleva, Novavax, Mannin, ITM, Nostrum Biodiscovery

Licensing, Partnerships, Research Collaborations

Scientists continuously face pressure to purify biologics with maximum yield while minimizing costs and developing processes as quickly as possible. Downstream processing (DSP) often accounts for more than half the cost of goods overall and significantly impacts manufacturing timelines. Affinity Chromatography manages to achieve high purity and yield and allows a simpler process architecture. Precision Capturing ®, extends the benefits of Protein A chromatography beyond just antibody purification. It covers both recombinant protein and monoclonal antibody (mAb) purification under the platform names Precision X ® and Precision A ® , respectively.

Over the years, Protein A has continued to evolve to keep up with increased performance pressure and Precision A® contributed a major step to this evolution of next-generation antibody purification by the launch of the first two products: NGL Impact ® A, the leading product for emerging antibody developments, and NGL Impact ® A HipH, an industry-first ligand enabling mild elution conditions.

The Precision X® platform brings the advantages of Protein A to non-mAb protein purification. Precision X® based affinity resins are used for large-scale manufacturing with FDA and EMA approval. The ligands bind to non-antibody proteins making affinity chromatography a game changer in protein DSP development. Custom resins are generated in 4 months and manufacturing partners scale-up production in 5 additional months.

Targeted therapeutics based on Affilin ® target binding proteins

Precision Medicine relies on the precise targeting of molecular structures like Tumour Associated Antigens (TAAs) and checkpoint signalling pathways. Under its Precision Targeting Business Unit, Navigo brings together its expertise in protein engineering and drug design, with an unwavering commitment to developing innovative targeted therapeutics.

With a clear focus on oncology, Precision Targeting is developing next-generation targeted therapies, based on the unique, proprietary Affilin® platform. Affilins® are a novel class of target binding proteins, that effectively mimic the target binding function of antibodies but bring to the table several additional advantages.

Affilins ® can be easily customized as mono, bi-/ or multi-specific ligands and can be seamlessly coupled to functional moieties like cytotoxic payloads and radioactive isotopes to orchestrate highly targeted and potent anti-cancer therapeutics against Tumour Associated Antigens (TAAs) as well as immuno-oncology (I/O) targets. The growing portfolio of Affilin® assets with their unique pre-clinical data address some of the key challenges in targeted therapeutics, like fine tuning of biodistribution as well as targeting low or medium expressing tumours with exceptionally high and sustained tumour-specific accumulation, out-performing current benchmarks.

With a drive to bring best-in-class therapies to patients and address the unmet medical need, Precision Targeting leverages the unique features of Affilins® to advance targeted therapeutics towards clinical development.

Name ›

Address/P.O. Box › Postal Code/City › State ›

Contact Person › Telephone › Telephone › Email › Website ›

Number of Employees › Founded (year) › Type of Laboratory ›

Neovii Biotech GmbH

Am Haag 6+7 82166 Gräfelfing

Bavaria

Sebastian Hofmann

+49-89-898888-0

+49-89-898888-16 info.germany@neovii.com www.neovii.com

150 2003

BioStoffV S3**

cGMP certified production facilities, EU (Annex 1 EU-MP guideline) up to grade A respectively ISO5 (according to EN-ISO 14644-1)

The company

The company Neovii Biotech GmbH – as part of the Neovii Group – is dedicated to delivering targeted biopharmaceutical treatment options in transplantation medicine and haematological oncology. The focus of its activities is the development and commercialisation of immunologically active biopharmaceutical therapeutics based on innovative antibody technologies. All the manu facturing activities are located in Gräfelfing/ Germany.

Neovii has a presence in more than 40 countries worldwide.

For further details please visit: www.neovii.com

Research and Development

Areas of Activity › External › Collaborations

| Transplantation Medicine | Haematological Oncology

Academic research institutions and other companies

Neovii supports research and development activities in the fields of solid organ transplantation, stem cell transplantation, and immune and haemato-oncological disorders. Neovii actively seeks in-licensing and acquisitions opportunities. We are looking to expand our portfolio of products with novel life-transforming therapies that address severe unmet medical needs, in particular in the areas of transplantation, haemato-oncology, and immune disorders.

Areas of interest

Since its inauguration Neovii Biotech has been manufacturing and commercialising a medicinal product for the prevention of graft-versus-host-disease after stem cell transplantation and prevention/treatment of acute organ rejection following solid organ transplantation.

The main fields of our operations are:

› Stem Cell Transplantation

› Solid Organ Transplantation

› Aplastic Anaemia

› Autoimmune Diseases

Transplantation: ATLGs (Anti-human T-lymphocyte immunoglobulins) – polyclonal antibodies

ATLGs are antibody-based medicines for the targeted suppression of immune responses (immunosuppressants).

They suppress immune responses by multiple mechanisms, such as immune cell depletion, inhibition of T-cell function, and induction of regulatory immune cells. Their immunosuppressive properties are used mainly in solid organ transplantation and stem cell transplantation. In stem cell transplantation (SCT) polyclonal antibodies are indicated for the prevention of graft-versus-hostdisease (GVHD).

GVHD is recognised as a severe complication following SCT that negatively impacts on the patient’s quality of life and is a major cause of morbidity and mortality. In GVHD, transplanted immune cells attack the recipient’s body, causing tissue and organ damage. By suppressing these immune reactions, ATLGs significantly lower the incidence of GVHD (Finke J, et al‚ Lancet Oncot 2009;10(9)1855—64).

In solid organ transplantation (SOT), polyclonal antibodies are indicated either for the prevention of organ rejection or to suppress active, acute rejection reactions. The rejection of a transplanted organ is primarily caused by immune cells of the recipient that start attacking the grafted organ, because it is recognised as foreign. By suppressing these immune reactions, ATLGs limit organ damage and prevent graft loss (Kaden J, et al. Ann Transplant. Jan 10 2013;18:9-22).

©Eva Orthuber

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website ›

Founded (year) ›

New England Biolabs GmbH

Brüningstr. 50 – Geb. B852

65926 Frankfurt am Main Hesse

Dr Carsten Lanwert

+49-69-305-23140

+49-69-305-23149 info.de@neb.com www.neb-online.de 1981

NEB – Passion for Science

Created by scientists for scientists, New England Biolabs is proud to be a world leader in the discovery and production of enzymes for molecular biology applications. Since our establishment in 1974, we have remained committed to developing high quality, innovative products that not only empower your research but also our own. Our profits have always funded an extensive research program, which we believe is critical for staying connected to our customers and helping to drive scientific breakthroughs. From our founding principles to our unique corporate culture, NEB’s philosophy can be distilled down to three core values: passion, humility and being genuine.

Enzyme Technology Innovations

Our outstanding expertise in protein engineering and evolution has led to the creation of unrivalled enzymes and unique workflows in the library preparation and target enrichment for the NGS space. These products set the benchmarks for optimal performance and ease-of-use in modern molecular biology laboratories. Moreover, NEB’s specialised offerings for alternative DNA assembly, isothermal amplification as well as novel reagents for CRISPR/Cas9 based genome editing makes us a first- choice supplier for today’s molecular biologists.

Customised Solutions/GMP –Grade & Lyophilisation

NEB’s customised solutions unit has been delivering tailor-made enzyme formulations and packaging solutions to biotech, pharma and diagnostic customers for over 30 years. Building on this extensive experience, our GMP-grade manufacturing capabilities offer a range of customised products at scale, enabling commercial customers and partners to use NEB’s world- class products in their specific applications and to support them in their efforts to access regulated markets. The recently established subsidiary NEB Lyophilisation Sciences combines expert knowledge in the design, development and manufacture of innovative enzyme solutions for ambient store products to meet our customers small- to large-scale lyophilisation needs.

Enzymes and Reagents for Molecular Biology Applications

Largest selection of enzymes for genomic research

Research-grade and GMP-grade production

Large to small scale lyophilization capabilities

ISO 9001 and 13485 certified

Formulations without components such as BSA, detergents or glycerol

Enzymes at user defined concentrations

Custom aliquoting, kitting, packaging & private label (OEM)

www.neb-online.de

ISO Certified Quality

NEB is dedicated to providing research products of the highest quality. Our integrated quality management systems are certified to meet the requirements according to the standards ISO13485 and ISO9001.

Social Responsibility & Sustainability

While our passion for science helps us to drive discovery, we continue to be guided by our responsibility to each other and our community. We continuously strive to promote ecologically sound practices and environmental sustainability in order to protect our natural resources. As an additional measure, NEB has received ISO14001 certification, a quality standard for environmental management systems. We also recognise that we must work together to build a more equitable society and improve diversity, equity and inclusion in our workplace.

Basic and Applied Science

At NEB, over 30 labs participate in research projects, which are aided by post-doctoral fellows and students in Masters and Ph.D. programs. NEB researchers have authored or co- authored over 1,450 publications to date. With a dual focus on basic and applied research, NEB’s culture is both collaborative and academic.

Scientific Customer Service

NEB always was conceived to be a part of the scientific community by providing top quality tools and experimental expertise. This philosophy has continued to the present day. Our support model is unique as it utilises technical support scientists, scientist responsible for product development or manufacturing, and product line experts. As such, customers are supported by scientists and often experts in the product or its application.

New England Biolabs GmbH

The NEB subsidiary in Germany represents the service hub for Central Europe. From our location in Frankfurt, we serve scientists and industry customers in Germany, and Austria and support our network of distribution partners across Europe.

For further information please visit our website at www.neb-online.de.

Address/P.O. Box

Postal Code/City

Contact Person

Telephone

Fax

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

NIPPON Genetics EUROPE GmbH

Mariaweilerstraße 28a

52349 Düren

North Rhine-Westphalia

Dr Jakob Maciejko, Dr Verena Krieger

+49-2421-55496-18

+49-2421-55496-11

jmaciejko@nippongenetics.de, vkrieger@nippongenetics.de https://www.nippongenetics.eu/

Innovation for you!

NIPPON Genetics EUROPE is a young, dynamic and forward-thinking company dedicated to providing high quality laboratory products to researchers and scientists across the world. With two decades of experience, we are specialists for life science and biotechnology solutions and have become a trusted partner in the scientific community. Our mission is to deliver innovation and support to help scientists to achieve their goals and make a positive impact on the world.

A German-Japanese success story

Founded in 1988 Tokyo, Japan, NIPPON Genetics has more than 35 years of experience in the life science sector. NIPPON Genetics stands for the highest quality and innovation from Japan. In 2005 NIPPON Genetics EUROPE was established in Düren, Germany, in the heart of Europe. With more than 30 employees, we distribute our products from here directly in Germany and Austria, as well as in more than 70 countries worldwide with the help of our distribution partners. We are committed to maintaining outstanding quality, delivering customer value and ensuring reliable service.

Our life science portfolio

Our extensive product range is at the forefront of life science technology and includes instruments such as gel documentation systems, real-time PCR systems and spectrophotometers. But that’s not all. We also offer a comprehensive range of DNA and protein electrophoresis reagents, nucleic acid purification kits, PCR enzymes, plastic consumables, cell biology products, and much more. For these products, our own FastGene ® brand stands for incredible quality and life science expertise. Another highlight is the best-selling Bambanker™, a serum-free cell cryopreservation medium trusted by researchers worldwide. Our team of experts is always excited to work with researchers on custom solutions to ensure that unique experimental needs are met.

Quality made in Germany

We manufacture selected products locally in Düren, Germany, cooperating with local suppliers of metal parts and electrical components. We are committed to developing new products for our customers and commit to listening to their needs and requirements. Specified new products are tested, developed and continuously improved in our own level 1 biosafety laboratory.

FastGene

® FAS-X – safe and innovative

technology

We’re particularly proud of our latest breakthrough made in Germany: the FastGene ® FAS-X gel documentation system. With its elegant design and simple user interface, it has been honoured with the German Innovation Award 2024. Our unique Blue/Green LED technology is completely safe compared to conventional UV light and delivers perfect results with incredible sensitivity.

Why NIPPON Genetics EUROPE

Our products are subject to rigorous quality control, ensuring reliability and consistency from batch to batch. Our dedicated customer support team is always available to assist with technical queries, troubleshooting, and product advice. We offer efficient shipping to avoid delays in your research, while providing cost effective solutions. Additionally, we are committed to environmental responsibility, actively working to reduce our ecological impact.

Contact us

NIPPON Genetics EUROPE is your trusted partner for all your laboratory needs. Join the scientific community that chooses quality, innovation, and reliability. Contact us today to find out more about our products and services or to discuss how we can support your research.

Name ›

Address/P.O. Box ›

Postal Code/City › State

Contact Person

Telephone

Fax

Email

Website

Number of Employees

Founded (year)

Areas of Activity › Annual Turnover ›

Nordmark Pharma GmbH

Pinnauallee 4

25436 Uetersen

Schleswig-Holstein

Dr Jan Heyland

+49-4122-712-907

+49-4122-712-545

projects@nordmark-biotech.de www.nordmark-biotech.de

~ 700 1927

l Process development

l Microbial fermentation

l Mammalian cell culture

~ €130m

Founded in 1927, Nordmark is an internationally leading specialist for the development, manufacturing, and commercialisation of active pharmaceutical ingredients (APIs) and drug products of biological and biotechnological origin under GMP conditions. Headquartered in Uetersen near Hamburg (Germany), and family owned again after a management buyout from the BASF group in 2001, Nordmark today employs around 700 employees and generates revenues of around EUR 130 million.

Inspired by the organisation and high-quality standards of our former parent company, as an independent pharmaceutical enterprise, we successfully develop and produce biological active pharmaceutical ingredients and drug products through all stages of the value chain.

Nordmark Biotech, the biotechnological division of Nordmark, is a specialist for providing tailor-made solutions for the development and manufacturing of biopharmaceuticals from lab to production scale. In this context, we are able to offer expertise in both systems – microbial as well as mammalian – to our customers.

Services cover the entire value chain from process development to marketed drugs:

› Strain and Cell Line Development

› Microbial Fermentation – Upstream Process Development

› Mammalian Cell Culture – Upstream Process Development

› Downstream Process Development

› Formulation and Filling – Pharmaceutical Development

› Biomanufacturing under GMP Conditions

› Analytical Services

› Regulatory Service

Nordmark Biotech connects flexible partnerships with a unique expertise and know-how in developing and delivering drugs to market. As a family-owned business we work with maximum care and attention and with fast and simple decision-making processes. We are focused on success – regardless of project size.

Nordmark can refer to a significant track record in the industry with different successful process development and manufacturing projects in various stages of clinical development as well as approved and marketed products for more than 40 international partners. With more than 90 years of excellence and commercial success, Nordmark is the ideal partner to bring your ideas to market.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone

Email

Website › Social Media ›

Number of Employees › Founded (year) › Areas of Activity ›

Nova Biomedical GmbH

Hessenring 13A, Geb. G 64546 Mörfelden-Walldorf Hesse

Silke Hohmeier, Managing Director

+49-6105-4505-0 de-info@novabio.com novabiomedical.com

F I Q  I

1,500 1976

Cell culture analysis, autosampler, upstreaming, automation, cell counter, glucose reference analyzer US-FDA in-vitro diagnostics, point-of-care testing, blood gas analysis, critical care, diabetology, emergency medicine

Innovation empowering life science

Nova Biomedical develops, manufactures, and commercialises analytical systems for cell culture and whole blood testing. The company is headquartered in Waltham, MA, USA. Worldwide, more than 1,500 people are employed by Nova, which operates direct subsidiaries in 11 countries and factory-trained distributors in more than 110 countries.

Our commitment to scientific innovation and product quality has made Nova Biomedical a world leader in the development of whole blood analyzers for clinical applications and cell culture/fermentation analyzers for biopharma for more than 40 years.

Cell Culture Analysis

Request for › Further Collaborations

Kidney disease screening & monitoring partners

GMP-compliant cell culture analysis made easy Nova offers the latest in maintenance-free cell culture analyzer technology – BioProfile ® FLEX2. FLEX2 provides fully automated analysis of key chemistries and gases, cell density, cell viability, and osmolality with one sample and a single data output stream in under 4.5 minutes. The full 16- test menu includes: Gluc, Lac, Gln, Glu, NH4+, Na+, K+, Ca++, pH, PCO2, pO2, total cell density, viable cell density, viability, cell diameter, and osmolality.

The system can be flexibly configured to meet diverse and changing needs with the optional and field upgradeable pH/gas, CDV and osmolality modules. sampling from 96-well plates, syringes, or a 24-position external “load-and-go” sample tray provides maximum workflow flexibility and efficiency for cell culture monitoring.

FLEX2 is the only cell culture analyzer designed for online sampling from micro-scale vessels through large-scale commercial manufacturing SIP/CIP systemsand integration with the ambr ® 15 and 250 cell culture systems. An optional Sample Retain Collection system automatically collects cell culture samples from the On-Line Autosampler and stores them in a refrigerated environment to enable further offline testing. IQOQ support can be offered by the local Nova representative.

BioPro fi le Analyzers for Fermentation

BioPro fi le 300 series analyzers offer a total of nine measured tests, including glucose, lactate, phosphate or glycerol, acetate, ammonium, pH, sodium, and potassium, plus calculated osmolality. The analyzer is offered in two versions: the BioPro fi le 300A which includes a phosphate assay, and the BioPro fi le 300B with glycerol testing. These systems offer measurement ranges speci fi cally suited to monitor bacterial and yeast cultures. A conversion kit is available for easy interchange between the 300 A and B versions.

BioProfile FAST CDV analyzer

BioProfile FAST CDV is a high-throughput, fully automated viable cell density and viability analyzer with a throughput of 45 samples per hour on 100µL of sample volume. The analyzer performs all sample dilutions internally, enabling cell culture samples up to 140e6 c/ mL to be analysed without any external sample dilution. Cell culture samples can be analysed via the external 32 position load-and-go tray or via an innovative 96-well plate option.

BioProfile FLEX2 Basic Analyzers

FLEX2 Basic analyzers provide multiple test menus for chemistry analysis in cell therapy, gene therapy, vaccine development, and alternative foods applications. The FLEX2 Basic A test menu consists of Gluc, Lac, Gln, Glu, NH4+, Na+, K+, Ca++, pH, PCO2, pO2 with automatic dilutions and an extended range. The FLEX2 Basic B provides the same test menu with standard ranges. Flex2 Basic C offers an 8-test menu of Gluc, Lac, Na+, K+, Ca++, pH, PCO2, pO2 with standard ranges.

Glucose Reference Analyzer

Nova Primary Whole Blood Glucose Reference Analyzer

Nova Primary fills the need for a replacement to the discontinued YSI STAT PLUS 2300 Glucose and L-Lactate analyzer. Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 20-900 mg/dL. It uses a small, 25 µL whole blood or plasma sample and provides results in under 2 minutes.

Name ›

Address/P.O. Box ›

Postal Code/City › State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

Omicron-Laserage Laserprodukte GmbH

Raiffeisenstrasse 5e

63110 Rodgau

Hesse

Natalie Stühler

+49-6106-8224-0 sales@omicron-laser.de www.omicron-laser.de

F I  I 99 1989

Laser, LED, Light Sources, Diode Lasers, Medical Lasers, Medical Systems, CW Light Sources, Customised Laser Systems, Photonics, Laser Development, Laser Solutions, Customised Light Sources, Biotech, Life Sciences, Microscopy, Spectroscopy

Flexible Laser & LED Light Sources for Industry & Science with 36 Months Warranty

Omicron-Laser has been developing, manufacturing, and distributing innovative laser and LED light sources since 1989 and is one of the leading manufacturers for demanding applications in biotechnology, microscopy, microlithography, medicine, and many more.

Based in Germany, Omicron is specialised in customised solutions in addition to its broad product portfolio. Product development and production comply with European and US guidelines and are conducted according to the ISO9001 and ISO13485 quality standards. Omicron offers CW light sources as well as high-speed modulated systems in the nanosecond and picosecond range, both as single and multi-wavelength solutions.

Important developments based on ISO 9001 and ISO 13485 include:

› the LightHUB® laser beam combiner series

› the LedHUB® high-power LED light engine

› the QuixX® picosecond pulsed diode laser

› the PDT medical laser system for cancer treatment

› the BrixXLAB multichannel desktop laser for laboratory applications

› BrixXHUB Ultra® Highly Integrated Multimode HighPower Light Engine

Highly Integrated Multimode High-Power Light Engine: BrixXHUB Ultra®

As the first highly integrated multimode high-power laser light engine on the market, the BrixXHUB Ultra is the perfect fit for applications in widefield laser illumination. The new device is a highly integrated multimode highpower laser light engine with up to 6 high-power BrixX lasers at its core, offering a wide range of wavelengths between 375 and 1550nm at up to more than 5 Watts per wavelength. This, combined with 6 analog and digital modulation inputs, provides unique flexibility to meet dynamic project needs. The system is designed for user-friendly operation and comes fully equipped with all essential accessories, enabling users to promptly

start their projects without any delay. In addition, its user-upgradeable design allows for easy customisation, enabling individuals to adapt to evolving project requirements effortlessly.

Flexible Multi-Wavelength Solutions:

LightHUB+®, LightHUB Ultra®, LedHUB® Omicron’s innovative LightHUB+® and LightHUB Ultra® laser light engines represent a new form of laser light sources for science, research, and industry based on the ultra-compact LuxX (LuxX+) laser series. The highperformance systems can be equipped with one to six (LightHUB+®) or seven (LightHUB Ultra®) laser modules of different wavelengths from UV to the near IR range and offer rapid analogue intensity modulation with up to 1.5MHz (3MHz and 250MHz digital) and digital full ON/ OFF modulation with a switching time of <1µs for each channel. The individual laser modules can easily be exchanged and added by the user. Hence the systems can be adapted to changing application requirements and are future-proof.

The Omicron LedHUB® is a high-power LED light source for biotech, industrial, and analytical applications. With up to 6 different wavelengths between 340 and 940nm it can be used in applications like widefield microscopy, optogenetics, chemical analysis, forensics, and many more. The modular principle of the LedHUB® provides the possibility to start with only one or two wavelengths initially and upgrade by further wavelengths at a later stage. The capability of rapid switching between wavelengths and high-speed analogue modulation of intensity is a key feature for demanding applications.

Name ›

Address/P.O. Box › Postal Code/City › State ›

Contact Person

Telephone

Email

Website

Social Media

Number of Employees › Founded (year) › Areas of Activity

PAN-Biotech GmbH

Am Gewerbepark 6

94501 Aidenbach

Bavaria

Patrick Frick

+49-8543-6016-30 info@pan-biotech.de https://www.pan-biotech.com/

86 1988

| Cell culture and Biosolutions (Media, Serum, Reagents, Buffer, WFI)

| Serum Replacement & Serum Free Systems

| Media development & BE Customised Production

| Contract manufacturing/OEM

| Seamless Transition from RUO to GMP

| GMP Annex 1 (EU) Manufacturing

| Stability Studies

| Treatment and Testing

| Support in Upstream and Downstream Production

| Cell & Gene Therapy Solutions (Personalised Medicine)

| Vaccine Production Solutions

| mRNA Technology Solutions (RNase & DNase free productions)

| Antibody production Solutions

| Customised Packing and Shipping (incl. Storage)

| Cultured Food

| Sustainability & PET Recycling

Request for › Further Collaborations

With a strategic location in the heart of Europe, PAN-Biotech serves as a gateway for global customers seeking to access the European biotechnology market.

| Market Access | Distribution Hub

| Partnership Opportunities

PAN-Biotech, a global leader in manufacturing sterile liquids and cell culture media, upholds stringent GMP standards and “Made in Germany” quality. It supports the entire product lifecycle – from development through commercialisation – offering extensive, customised solutions in bio production, pharmaceutical applications and cell culture, with nearly four decades of industry dominance.

PAN-Biotech was founded in 1988 with a mission to produce top-quality biotech products and promote scientific discovery. The company set out to revolutionise biotechnology with innovative solutions that contribute to enhance human health and well-being.

› Vision: Pioneering Cell Culture.

› Mission: Development of serum-free media and serum-replacement solutions to enhance cell culture performance and reliability.

Latest product strategy:

PAN-Biotech is actively advancing its capabilities and product offerings in the following key areas:

› Cell and Gene Therapy: Development of specialized media and reagents to support the growth and production of cells and genes for therapeutic applications, enhancing the efficacy and safety of cuttingedge treatments.

› Vaccine Production: Expansion into vaccine production technologies, providing the necessary tools and solutions for the rapid and efficient development of vaccines, including those targeting emerging diseases.

› mRNA Technology: Innovation in mRNA technology, including the development of optimised media and delivery systems, to support the burgeoning field of mRNA-based therapeutics and vaccines.

› Antibody Production: Enhancement of products and processes for the production of high-quality antibodies, catering to research, diagnostics, and therapeutic applications.

Supporting the development of medical products

PAN-Biotech plays a crucial role in the development and production of medical products, drugs, and vaccines. Our innovative solutions are designed to meet the demanding requirements of the pharmaceutical and biotechnology industries, providing the essential tools needed to drive progress in human health. To fully support the approval and certification processes of medical applications, PAN-Biotech has implemented a state-ofthe-art and industry-unique supporting process:

› Research and Development Stage: During the stage of research and development, the usage of standard RUO (Research Use Only) products is recommended. The PAN-Biotech catalogue includes over 1,800 products, with 85% available in stock and ready for worldwide shipping within 2 days.

› Pre-Clinical Stage: It is highly recommended to swiftly switch from RUO to GMP-ready products during the pre-clinical stage to ensure compliance and quality consistency.

› Clinical Development and Commercialisation: During clinical development (Phase I-III) and for commercialisation, it is essential to use products that meet EU GMP Annex 1 quality standards. This ensures the highest level of safety, efficacy, and regulatory compliance for medical applications.

Conclusion

Through its diverse offerings and commitment to innovation, PAN-Biotech empowers scientists and industry leaders to drive progress in biotechnology. By providing customised solutions and supporting sustainable practices, PAN-Biotech is at the forefront of advancing scientific discovery and improving global health.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone

Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity › External › Collaborations

Pantherna Therapeutics GmbH

Neuendorfstrasse 20b 16761 Hennigsdorf

Brandenburg

Dr Gerrit Maaß

+49-3302-202-240-0 contact@pantherna-therapeutics.com www.pantherna-therapeutics.com

11 2017 S1

mRNA therapeutics utilising lipid nanoparticles (LNP) for functional nucleic acids delivery

Bayer, Wacker, Biospring, Provirex GmbH

Academic collaborations with Helmholtz, Charité Universitätsmedizin, Universitätsmedizin Rostock and others

Our Company:

Pantherna Therapeutics GmbH is a privately-held biotechnology company, developing first-in-class therapeutics based on its proprietary PTXmRNA-LNP technologies. Pantherna is based in Hennigsdorf (Brandenburg) with research laboratories at Bayer Campus, Berlin.

Our Mission:

mRNA therapies are becoming potent pharmaceutical modalities – even beyond vaccination – to close the gap between existing medical approaches such as biologics and viral vectors. Delivering therapeutic mRNA to the desired cell type is a prerequisite for an effective and safe therapy. Pantherna uses and develops advanced lipid nanoparticle PTX∆LNPs® – carriers for novel mRNA therapeutic applications. Our primary goal is to treat diseases with dysfunctional vasculature, to restore endothelial function in the acute setting of lung injury. Other interests include medical conditions from rare diseases. New approaches are being designed to develop mRNA therapies for local administrations, such as intramuscularly.

Request for › Further Collaborations

Co-development of mRNA therapeutics; interest in research collaborations to explore new therapeutic modalities in various indications; strategic partnerships for developing and evaluating new LNPdelivery technologies

Our Technology Platforms:

PTXmRNA® – distinct mRNA expression modules:

› Combination of potent, short untranslated sequences (PTX_UTRs) that flank the coding region of the desired therapeutic protein for enhanced expression

› Superior protein expression over standard mRNA constructs

PTX∆LNPs® – Lipid nanoparticle carriers designed for selective organ targeting

› various LNP-formulations based on different physico-chemical properties

› LNPs with cationic, neutral or anionic surface charge

› next-generation formulation candidates for tissuespecific delivery of mRNA

› employing both ionizable & permanently charged lipids

PANTHERNA THERAPEUTICS

› covering formulations for local and systemic mRNA administration

› optimized process development to obtain monodisperse particles

Our Pipeline:

Pantherna’s first clinical development candidate: PAN004: A systemically administered, first-in-class locally acting mRNA-LNP as therapeutic Tie2-agonist for the prevention and treatment of pulmonary oedema in Acute Respiratory Distress Syndrome (ARDS):

› mRNA delivery to capillary endothelium of the lung

› activates Tie2-signalling pathway in a highly spatial manner in the pulmonary endothelium

› designed to prevent ARDS progression at an early stage

› in vivo Proof-of-Mechanism and Proof-of-Concept established

› CMC and IND-enabling studies in preparation

Pantherna is currently pursueing the characterization of additional drug candidates derived from the PTX∆LNP platform on the pre-clinical level for other medical conditions besides ARDS to strengthen its pipeline.

Name

Address/P.O. Box

Postal Code/City

State

Contact Person

Telephone

Fax

Social Media

Number of Employees

Founded (year)

Areas of Activity

PELOBiotech GmbH

Behringstr. 10 82152 Planegg Bavaria

Dr Peter Frost

+49-89-517-286 59-0

+49-89-517-286-59-88 info@pelobiotech.com www.pelobiotech.com I 10-15

2012

One-stop cell culture shop for Human & Animal Primary Cells, Adult Stem & iPS Cells, Media & Tools, R&D, GMP, GMP-like; Lot reservation

PELOBiotech GmbH: Empowering Research, where Customers come First

At PELOBiotech, our mission is clear: to empower scientists by providing world-class products, solutions, and expertise while putting the customer at the center of everything we do. As a global leader in cell culture products, we offer one of the most extensive portfolios, tailored to meet the diverse needs of biomedical researchers. Whether you’re focused on human or animal primary cells, adult stem and iPS cells, or specialised 2D and 3D cell culture systems, we are here for your journey from bench to bedside.

Wide variety of human & animal cells

Our strength lies in offering a comprehensive selection of over 18,000 hand-picked cell culture products from our exclusive partners. These include modified and tagged cells, diseased cells, and customised solutions with options for R&D, GMP-like, and GMP-quality media. Researchers may also reserve their cell lots from certain batch so they can work consistently.

PELOBiotech also develops and produces specialised cell culture media and supplements for tumor stem cells, ensuring that researchers can always find the right tools for their projects. We focus on the research field extracellular vesicles.

Speed up your project with dependable and proved solutions

At PELOBiotech we understand the challenges scientists face today: Both Dr. Lothar Steeb and Dr. Peter Frost, our managing directors, bring nearly 50 years of combined expertise to the table, ensuring that every solution we offer is rooted in reliability, success, and real-world application. As Dr Peter Frost emphasizes, “I know how difficult it is to get promising results that you needed yesterday to get your paper out.” He has worked with several 3D cell system companies, e.g. In-Sphero, Switzerland. The Rhinelander focuses on technologies to ultimately make research reliable, predictable and successful for the industry.

Where Cells meet Innovation

Beyond our extensive product offerings, we are proud to serve as a trusted partner in advancing the future of research. Our in-house Cellovations ® product line is designed with heart, experience, and knowledge, allowing researchers to accelerate their work and achieve impactful results. We also provide a full range of humanbased products and extracellular vesicles for EV isolation, supporting the growing demands of the evolving EV research landscape.

At PELOBiotech, our focus is always on the customer. We believe in building lasting relationships, communicating scientist-to-scientist, and providing everything researchers need from a single source. This commitment to personalised service and top-quality products has made us a leading provider of research solutions worldwide.

PELOBiotech GmbH – More than Competence4Cells. Empowering your research, from discovery to delivery. PELOBiotech GmbH is one of the leading suppliers worldwide of Human & Animal Primary Cells, Adult Stem & iPS Cells, Media & Tools. www.pelobiotech.com

PELOAcademy: Check out our webinars to stay on top of science: https://www.pelobiotech.com/webinars.html Be one step ahead, become a PELOClub-Member. https://www.pelobiotech.com/our-newsletter.html

Name ›

Address/P.O. Box › Postal Code/City

State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

PharmaLex GmbH

Basler Straße 7 61352 Bad Homburg vor der Höhe Hessen

Melanie Ludwig 06211815-380 melanie.ludwig@pharmalex.com www.pharmalex.com

I 330 1994

Consulting, Outsourcing and Services in: Regulatory Affairs, Pharmacovigilance, Clinical Development, Market Access, Quality Management, Medical Affairs, Project Management

About Us

Needing a partner to launch products with confidence? Looking for an experienced service provider to bring the promise of your therapies to life? PharmaLex, a Cencora company, supports on the path to commercial success. Our services are aimed to deliver expertise to pharmaceutical and medical device companies throughout the product lifecycle. We navigate through the complex regulatory landscape and leverage our extensive knowledge and global presence to guide small and medium-sized companies through the complexities of product development and regulatory requirements. By offering scalable, tailored solutions, PharmaLex empowers companies to successfully bring innovative pharmaceutical and medical device products to market and thereby improving patient outcomes and advancing healthcare.

Key Service Areas for SMEs

Regulatory Affairs:

Comprehensive support in regulatory strategy, submissions, and communications with health authorities.

› Developing regulatory roadmaps that align with the company’s product development plans.

› Providing strategic advice on the best regulatory pathways to expedite market entry.

› Assisting with the preparation and submission of regulatory documents, including INDs, NDAs, MAAs, and 510(k)s.

Pharmacovigilance:

Safety monitoring, risk management, and compliance services to ensure patient safety and regulatory adherence.

› Setting up and maintaining robust pharmacovigilance systems.

› Conducting risk assessments and developing risk management plans.

› Managing safety data, including adverse event reporting and signal detection.

Development Consulting and Clinical Development: Guidance on product development, clinical trial design, and market access strategies.

› Designing and managing clinical trials, from earlyphase studies to post-market surveillance.

› Ensuring compliance with Good Clinical Practice (GCP) and other regulatory requirements.

› Offering statistical analysis and data management services.

Market Access:

Conducting health economics and outcomes research (HEOR) to support reimbursement and pricing strategies

› Developing medical communication plans to effectively convey scientific and clinical information to stakeholders

› Supporting the creation of medical and scientific publications

Quality Management:

Quality assurance, compliance, and commercialisation services to meet international standards.

Medical Affairs:

Medical writing, scientific communication, and strategic consulting to support clinical data and product launch.

Project Management and Outsourcing:

› Offering project management services to oversee product development timelines and ensure milestone achievement.

› Providing flexible outsourcing solutions to augment internal teams with specialised expertise.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person ›

Telephone › Fax › Email

Website

Social Media ›

Number of Employees › Founded (year) ›

Areas of Activity ›

PHARMAPLAN GmbH

Siemensstraße 21 61352 Bad Homburg Hesse

Anna Fey, Head of Business Development

+49-6172-8502-100 +49-6172-8502-501 germany@pharmaplan.com https://www.pharmaplan.com

I I

250 (PHARMAPLAN D), 1,000 (TTP Group) 1974

| Project Management

| GMP & Quality Consulting

| Process Engineering

| Manufacturing IT & Automation

| Laboratories

| Facility-Building & Infrastructure

| Facility-Technical Services

Project Phases ›

| Feasibility Study

| Conceptual Design

| Basic Design

| Detail Design

| EPCM(V)

| Procurement Support

l Construction Management / Supervision

| Installation and Commissioning Support

| Qualification

PASSION FOR PHARMA ENGINEERING: This is what PHARMAPLAN stands for. As one of the leading pharmaceutical consulting and engineering companies in Europe, we are specialized in the integrated and holistic planning and realization of pharmaceutical and biotech production buildings and facilities as well as laboratories and thus shape the future of our industry. With our highly qualified employees working in areas such as project management, process engineering, GMP, laboratory planning, architecture, building services, and digital factory, we set the course for the global supply of medicines of tomorrow.

Operating under the umbrella of TTP Group with around 1,000 employees at 27 international locations, we support the pharmaceutical and biotechnology industry with flexible, GMP-compliant, and future-proof solutions. From initiation to construction to handover, we handle projects of all sizes on behalf of our clients. All major global pharmaceutical manufacturers and several small-sized pharmaceutical companies have been counting on our expertise, our latest know-how, technology, and trends for years.

OUR SERVICES

PHARMAPLAN is a consulting and planning company that – preferably as a General Design Contractor –provides integrated services in the disciplines GMP, PROCESS, LABORATORY, AUTOMATION, BUILDING & INFRASTRUCTURE, TECHNICAL SERVICES and PROJECT MANAGEMENT tailored to the needs of the pharmaceutical industry from a single source and close to the customer. PHARMAPLAN is divided into three business units:

Consulting & Front End Projects

Execution of capability reviews, site master planning, feasibility studies and conceptual design studies, analyses, and consulting concerning product portfolio, production capacity, and regulatory compliance. The objective is to develop standard facility and equipment designs, modular concepts, and optimal project execution strategies on a global level and then translate them into the site and project-specific concepts and requirements.

Investment Projects

Implementation of investment projects of all sizes, from reconstruction projects to the construction of entire production sites. PHARMAPLAN is usually responsible for the entire project as General Design Contractor and construction manager (EPCMV-partner) and has a huge in-house pool of seasoned project managers and engineers, who are also experienced in the fast-track execution of large projects.

Site Projects

Once an investment project is completed, PHARMAPLAN continues to support the site with a broad portfolio of services. The services include engineering for product changeover, capacity optimization, and all kinds of plant renewals or conversions as well as (re-)qualification and validation services including the preparation of all necessary GMP documentation and the execution of qualification and validation. Our departments and team structure reflect typical work packages of our projects:

› Project Management (Project Management, Engineering Management, BIM Management, Project Controlling, Document Management, Project Procurement, HSE Management & Sustainability Construction Management)

› GMP & Quality Consulting

› Process Engineering (Biotech, Bio & Chemical API, Fill & Finish, OSD, Packaging & Logistics, Process & Clean Utility, BIM & CAE Process)

› Manufacturing IT & Automation

› Laboratories (Laboratories General, Laboratories Biotech)

› Facility-Building & Infrastructure (Design & Process Architecture, Construction Architecture & Civil Engineering, BIM-Building & Infrastructure)

› Facility-Technical Services (HVAC & Utility, Electrical, Building Automation Systems, BIM-Technical Services)

TTP GROUP is a group of companies specializing in engineering services for the process industry. In 2019 the holding company TTP GmbH united the operating brands PHARMAPLAN and TRIPLAN under one roof. This has created one of the leading engineering companies for the process industry in Europe.

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Person › Telephone › Fax › Email Address › Internet Website › Number of Employees › Founded (year) › Areas of Activity ›

Phyton Biotech GmbH

Alter Postweg 1 22926 Ahrensburg Schleswig-Holstein

Kai Schütte

+49-4102-4906-64

+49-4102-4906-69

kai.schuette@phytonbiotech.com www.phytonbiotech.com

75 1993

Comprehensive services for the development and commercialisation of high-value compounds using our award-winning Plant Cell Fermentation (PCF ®) Technology.

Established in 1993, Phyton Biotech offers comprehensive process development and commercial manufacturing services for fermentation-based products at its GMP facility near Hamburg with more than 200.000 liters of installed bioreactor capacity. Best known for our award-winning and environmentally responsible Plant Cell Fermentation (PCF®) platform, we have expanded our profile into other cell systems, offering development and supply services for a wide array of products including phytochemicals, biopharmaceuticals, and other high-value compounds. This PCF ® technology coupled with our extensive experience allows Phyton Biotech to serve a variety of global markets, including pharmaceutical, traditional medicines, agricultural, food ingredients, natural health, and cosmetics industries.

Our PCF® technology PCF ® promotes the natural processes of plant cell growth and biosynthetic pathway expression of plant material in a controlled and fully defined bioreactor environment. Starting material is sourced without any environmental impact and the optimal cell cultures are developed in-house. Selected cell lines are scaled up in stirred tank bioreactors without the sunlight requirement. Finally, Phyton Biotech’s specialised product recovery and downstream technology allows for the preparation of extracts and purification of molecules.

Utilising this cutting-edge technology, Phyton Biotech offers a time, risk, and cost balanced path to commercially viable production processes, adding sustainability, reliability, quality, and scalability to the supply chain.

Our unique capabilities address the entire development chain. Phyton Biotech maintains one of the world’s largest plant cell culture collections, allowing for the unique selection and sourcing of plant material. Subsequent cell line development, process development, downstream development, chemical processing, scaleup, and commercial GMP production in up to 75,000L bioreactors guarantees Phyton Biotech’s position as the global leader in PCF®

Specialty fermentation solutions

Phyton Biotech’s commercial-scale fermentation facilities can produce large volumes of high-quality fermentation-derived products (max. bioreactor size is 75,000L; more than 200,000L of installed capacity). We offer flexible production schedules and a range of fermentation vessel sizes to meet the needs of our clients. Our facilities are designed to meet the highest quality and regulatory standards, ensuring our clients receive the best quality products possible. Coupled with 30 years of experience in development and production this enables us to carry out other Specialty Fermentation projects beyond PCF® hand-in-hand with our customers – from first cells to scale-up and through to product recovery. We offer comprehensive services for the development and commercialisation of manufacturing processes for high-value compounds including small molecules and biologicals.

Our API business

Phyton Biotech operates two GMP-certified, FDA and EDQM inspected facilities in Germany and Canada with full in-house QA/RA and QC capabilities, and supplies substantial amounts of Paclitaxel and Docetaxel with full control over the entire upstream and downstream production process. By providing a safe, reliable, high-quality supply of finished Active Pharmaceutical Ingredient (API) product that meets USP and EP standards, Phyton Biotech is the largest global commercial provider of Paclitaxel and Docetaxel API via PCF® to a customer base of pharmaceutical manufacturers around the world.

In summary

Through our expertise and experience, Phyton Biotech continues to offer world-class development, supply, and commercial manufacturing solutions in an environmentally responsible and sustainable way through our PCF® and Specialty Fermentation services for a wide range of high-value fermentation-based compounds.

Name

Address/P.O. Box

Postal Code/City

State

Contact Persons

Telephone

Fax

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

PlasmidFactory GmbH

Meisenstr. 96

33607 Bielefeld

North Rhine-Westphalia

Dr Martin Schleef/Dr Marco Schmeer

+49-521-2997-350

+49-521-2997-355

info@plasmidfactory.com www.plasmidfactory.com

I  50 2000

| Contract Manufacturing of plasmid and minicircle DNA in different quality grades for research up to clinical applications

| High Quality Grade plasmid and minicircle DNA as starting material for GMP productions, e.g. of mRNA or viral vectors, also in gram scales

| In Stock Service for AAV Helper & Packaging Plasmids (pDG/pDP) and for further plasmids and minicircles (e.g. reporter genes)

| Analysis of plasmid topology

| GMP quality for late clinical phase and market supply

Biological Patents

External

Collaborations

Request for › Further Collaborations

PlasmidFactory owns any relevant know-how, patents, and licences for plasmid and minicircle manufacturing

Fruitful long-term cooperations with renowned academic and industrial institutions in the fields of gene and cell therapy and vaccination

PlasmidFactory is always interested in working in long-term and strategic collaborations with pharmaceutical and biotech companies as well as academic institutes that require plasmid or minicircle DNA for (pre-) clinical applications.

The better way to DNA!

PlasmidFactory is the leading contract manufacturer of plasmid and minicircle DNA and the driving force in the development of gene vectors for gene and cell therapy and genetic vaccination. PlasmidFactory’s research and development as well as the complete services are located in Bielefeld, Germany.

Customised plasmids and minicircles

PlasmidFactory’s individual manufacturing service is frequently used by researchers from the fields of transfection and drug delivery, virus production, nanobiotechnology, gene therapy, cell or tumour therapy, and RNA or DNA vaccination. The company offers the production of plasmid and minicircle DNA in several quality grades: Research Grade and ccc Grade qualities for research purposes and pre-clinical applications, High Quality Grade as starting material for e.g. GMP production of RNA, viral vectors and CAR-T cells. GMP will be available from Q1 2025.

In Stock Services

Our In Stock products are deliverable immediately off-the-shelf – e.g. reporter genes (gfp, lacZ, luc), AAV Helper & Packaging plasmids (2-Plasmid-System, pDG/ pDP family, several serotypes) or pEPI / pEpito plasmids (containing S/MAR elements).

Other services

On request, plasmid DNA storage and logistics can be organised, supplementing the company’s service portfolio.

PlasmidFactory’s proprietary method for quantification of the structural diversity of plasmid DNA by means of capillary gel electrophoresis (CGE) is the only reliable method able to determine the stability of plasmid DNA, e.g. during storage.

Plasmid & Minicircle DNA

From Research to GMP grade

Minicircle – a safe vector system

Minicircles (MC) are circular DNA molecules that are generated e.g. by an intramolecular (cis-) recombination from a parental plasmid (PP). The difference between MC and standard plasmid vectors for gene therapy or nucleic acid vaccination is that the MC contains neither the bacterial origin of replication (needed only in bacteria for the amplification of plasmids in cell division) nor any antibiotic resistance markers or other selection systems to keep the plasmid in high amounts within the producer cell.

Hence, minicircles are the most promising tools to achieve both increased efficacy as well as regulatory requirements for future clinical applications.

PlasmidFactory is the exclusive owner of all relevant patents and IP in this field and provides service production of these supercoiled monomeric constructs, according to clients’ requirements.

Starting material for mRNA vaccines in large quantities

In particular, the High Quality Grade production of plasmid DNA as a starting material for the production of RNA vaccines has gained in importance, especially in the context of the COVID-19 pandemic, as RNA is a promising vaccine candidate for the prevention of certain virus infections, with the additional advantage of not integrating into the genome of the cell and thus remaining as a potentially effective molecule in a patient’s body in the long term.

PlasmidFactory has developed and established the process for the production of the corresponding plasmid DNA containing unstable polyA stretches.

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Person › Telephone › Fax › Emails › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

ProBioGen AG

Herbert-Bayer-Str. 8 13086 Berlin Berlin

Dr Alfred Merz (CEO/COO)

+49-30-322-935-100 +49-30-322-935-400 info@probiogen.de cdmo@probiogen.de www.probiogen.de

280 1994 S1, S2

l Biopharmaceutical development and GMP production facility

l Proprietary technologies for improving product characteristics and process efficiency

l Designer cell lines

l Vector platforms

Biological Patents › External › Collaborations Request for › Further Collaborations

ProBioGen holds numerous international patents on technologies to improve product quality/potency and enhance cellular productivity.

With many international companies and research organisations, e.g. Boehringer Ingelheim, Bayer, CRISPR, Novartis, etc.

ProBioGen works with biotech and pharma companies that develop (complex) therapeutic proteins and antibodies or viral vaccines and viral vectors.

Intelligent biopharmaceutical solutions

ProBioGen is a Berlin based CDMO, specializing in the development and manufacturing of biopharmaceutical active ingredients, viral vectors and vaccines through proprietary technologies to improve product quality and features. Combining state-of-the-art development services and intelligent product-specific technologies results in biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and GMP-compliant manufacturing is performed by a highly skilled and experienced team.

Unique services

Cell line & process development for therapeutic proteins

› CHO.RiGHT® expression system

› DirectedLuck® transposase for efficient gene delivery & high titers

› Proprietary chemically defined (CD) media platform/ multiple suppliers

› Robust and economic platform processes

› Classic and intensified processes

› Reports to support investigational new drug (IND) filing

› Modular services and open source concept

(GMP) Manufacturing for therapeutic proteins

› Cell banking (MCB/WCB)

› Up to 1000 L Tox manufacturing

› Up to 1000 L GMP manufacturing

› Disposable, stirred tank bioreactors

Development services for various viral vectors

› Tailor-made solutions for the production of e.g. lentiviral and adenoviral vectors, AAV and MVA

› Suitable cell substrates for the propagation of various viral vectors in suspension processes using CD medium

› Robust upstream and downstream processing supported by comprehensive analytical tools

› Cost-effective non-cGMP production for preclinical development phase

(GMP) Manufacturing for various viral vectors

› Cell Banking (MCB, WCB) and Virus Banking (MSV/WSV)

› Up to 200L Tox manufacturing

Your Biologics. Elevated.®

› Up to 200L GMP manufacturing (up to biosafety level 2)

› Aseptic filling of drug product and diluent under GMP conditions

Analytics, bioassays & quality management

› Integrated analytical development

› Validation according to bioanalytical guidelines (EMA/FDA)

› Stability studies in accordance with ICH Q1

› Wide range of cell based and binding activity assays

› Various cell based and instrumental analyses for content and identity testing of viral vectors and vaccines

Innovative technologies

GlymaxX® ADCC enhancement & glyco-engineering

› Prevents antibody fucosylation

› Boosts ADCC cell-killing activity against tumors and infected cells

› Applicable to both novel and existing producer cell lines

› Allows adjustment of fucose, galactose, and sialic acid levels in glycoproteins

DirectedLuck® – Transposase system

› Proprietary transposase for efficient gene delivery

› Generates high-titer clones (up to 8 g/L)

› Superior heterodimer rates for bi-specific mAbs

Lenti.RiGHT® packaging and producer cell line

› GMP qualified starter cell bank based on HEK 293

› Efficient LV production in CD medium (107-108 TU/ml)

› No requirement of GMP-grade plasmid DNA or transfection reagent

› Straightforward purification of lentiviral particles for e.g. CAR-T therapies

AGE1.CR® Designer cell line & MVA viral vaccine

manufacturing platform

› Avian suspension cell line permissive for numerous human and veterinary viral vaccine strains

› GMP-compliant chemically defined media and scalable suspension processes

› Proprietary MVA strain, transgene expression design, and technology for rapid generation of recombinants

Name ›

Process Sensing Technologies PST GmbH

Address/P.O. Box › Postal Code/City

State

Contact Person

Telephone

Email

Social Media

Founded (year)

Areas of Activity

Einsteinstrasse 17-23

76275 Ettlingen

Baden-Wuerttemberg

Jan Wendel, Sales Manager

Christoph Arnswald, Key Account Manager

+49-7243-383-250

info@rotronic.de www.processsensing.com

I 1965

Measurement Instruments and Environmental Monitoring Solutions

FDA 21 CFR Part 11/EU Annex 11 compliant

GxP services including qualifications (thermal mappings), ISO17025 calibrations and validations.

Process Sensing Technology (PST) brings together well-established brands, each of which are trusted for the precision and reliability of their products, strong innovation and focus on customer service. Rotronic was founded in Switzerland in 1965 and is part of PST since 2017.

Within the Group, Rotronic is positioned as the competence centre for humidity & temperature measurement and environmental monitoring systems. This enables PST to offer its customers a uniquely broad range of measurement technology products that perfectly meet the requirements of biotechnology.

Biotechnology companies are subject to strict regulatory requirements and guidelines to ensure the safety and quality of their products. Environmental monitoring helps comply with regulations by tracking and documenting environmental conditions that could impact product quality and safety. Accurate and comprehensive environmental monitoring data is essential for maintaining data integrity and traceability.

Environmental monitoring of a laboratory and laboratory equipment is an integral part of the quality management system. It helps promote the quality and validity of data generated during the testing process and prevents fraudulent practices.

Trust in PST’s real-time monitoring experience and our wealth of knowledge of all critical environmental parameters to comply with the GLP/GSP/GMP/GDP regulations and ICH/FDA guidelines.

Applications

› Fridges

› Freezers

› Incubators

› Autoclave

› Cryogenic storage

› Laboratories & Cleanrooms

› Rooms in general

› Storage & Transport

PROCESS SENSING TECHNOLOGIES

Measurement types

› Temperature range: -200...850 °C

› Relative humidity

› Carbon dioxide CO2

› Oxygen O2

› Differential pressure

› Particle counting

› Light (lumens, PAR, lux, etc.)

› Door monitoring (open/closed)

› Webcams (pictures)

Additional services

› Calibration

We offer a range of ISO-17025 and traceable calibration services, both within our facilities and onsite.

› Qualification

PST offers qualification services for rooms and equipment to help ensure the perfect environment throughout all facilities. The qualification will ensure the placement of the sensors within the various environments to ensure the highest quality of measurement data.

› Validation

Validation includes the provision of documented evidence that a system was planned/produced according to quality guidelines, is tested against specifications and has been operated in a qualified manner since it was introduced. The PST real-time monitoring solutions are validateable and PST offers complete documentation, including IQ/OQ and PQ, to fully validate the systems.

› Consulting

PST offers a range of consulting services from the start of a project, including the URS, through the complete validation master plan, including developing SOP’s and risk analysis. Maintenance and support ensure the long-term stability and accuracy of your system.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity › External › Collaborations

Request for › Further Collaborations

PROGEN

Maassstrasse 30

69123 Heidelberg

Baden-Wuerttemberg

Ruth Roschatt

+49-6221-8278-0

+49-6221-8278-24 info@progen.com www.progen.com

I

40+

1983

S1 class laboratories, DIN ISO 13485 certification for the production of in vitro diagnostic kits and research reagents.

AAV gene therapy analytical tools and antibodies, antibodies and reagents for biomedical research, in vitro diagnostics, ELISA, antibody phage display technology, density gradient media

Strong network with industrial and academic institutions

PROGEN is actively seeking partners for the advancement and distribution of its gene therapy and antibody-based products & services.

Immunochemicals that advance gene therapy and life sciences

PROGEN supports the gene therapy community with high-quality analytical tools to help scientists worldwide make new discoveries and to conduct breakthrough research. It is our underlying mission, to help progress new gene therapies safely, quickly and affordably, so together we can provide solutions to people suffering from poor health and affected by disease every day.

As a manufacturer and provider of Adeno-AssociatedVirus (AAV) analytical tools, research antibodies, density gradient media and phage display technologies, we strive to understand what scientists need in research and gene therapy development. It is our goal that our products offer solutions for the manifold challenges in academia, biotech, and pharma along the complete value chain – from basic research to manufacturing and quality control, thereby enabling progress.

High quality tools for AAV gene therapy

Labs attempting to find treatments for genetic disorders worldwide face obstacles such as a limited availability of accurate & reliable techniques for the characterization of AAV vectors. PROGEN is a leading manufacturer and exclusive provider of AAV antibodies and analytical tools for AAV titer determination, which facilitate the development of safe and efficient gene therapies. The density gradient media provided by us ensure a high yield purification of viral particles during production, while our AAV antibodies enable multi-step monitoring in vector manufacturing resulting in superior vector preparations. Exclusive AAV ELISA kits and controls allow an accurate capsid titer quantification that is critical for dose assessment. The pre-screening of patient sera for AAV-neutralizing antibodies using our AAV particle antibodies improves clinical safety and efficacy.

Making gene therapy better. Together.

Antibodies

Serving the urgent need for premium research antibodies

High-quality antibodies which allow the generation of reliable and reproducible data are indispensable tools for the life science community. The four PROGEN founders came together in 1983 to fulfil exactly that requirement – high-quality antibodies for biomedical research, which can generate reproducible data time and time again. Initially a spin-off from the German Cancer Research Center and the University of Heidelberg, PROGEN has expanded to become a DIN ISO 13485 certified company, which to date continues to serve the life sciences community with over 600 high-quality antibodies worldwide.

Reliable partner for life sciences

Starting as a pioneer antibody manufacturer, PROGEN has now become a globally operating biotech company and a reliable partner for academia, biotech and pharma. What still drives us after all these years is the continuous dialogue with researchers so that we can offer advanced products that truly make life science better.

PROGEN is a 100% subsidiary of R-Biopharm AG, based in Darmstadt/Germany, a developer of test solutions for clinical diagnostics and food & feed analysis. This corporate affiliation provides continuity for the growth of our product & service portfolio, which has been established for the last 41 years. CEOs Katja Betts & Maik Lander continue to expand their broad network and join forces with academia and industry to develop new solutions that add value.

Name

Address/P.O. Box

Postal Code/City

State

Telephone

Fax

Email

Website

Social Media

Founded (year)

Type of Laboratory

ProJect Pharmaceutics GmbH

Fraunhoferstrasse 22

82152 Martinsried Bavaria

+49-89-45-22-89-700

+49-89-45-22-89-717 info@project-pharmaceutics.com www.project-pharmaceutics.com

2010

Contract research and development (CRO); cytotoxic (≤OEL4); BSL-1; BSL-2; fee-for-service business model; 2-4 weeks start up time; slim and reliable timelines; GLP-like quality standards; submission-compliant documentation

Areas of Activity

Biological Patents

External

Collaborations

Analytical characterisation; preformulation screening; formulation development; freeze drying cycle development; lyophilisation process and scale-up; technology transfer Several patents in freeze drying and formulation

| Network for seamless development from pre-clinic to fill/finish and market.

| Formulation specialist for DS and DP CMOs worldwide.

| Process specialist for scalable drug products ensuring manufacturability.

| Cross-country competence hub with business partners in Asia.

| Credited laboratory for Wyatt Technology in Europe.

Request for

Further Collaborations

| Small biotechnology/mid-size pharma companies, large top players in pharma/biotechnology.

| From DSP development to early and late drug product phases up to life cycle management.

| Customised solutions for challenges in formulation, analysis or process.

ProJect Pharmaceutics is a leading independent European CRO specialised in formulation and manufacturing process development for injectables: biologics (rec. proteins, antibodies, fusion proteins), peptides, ADCs, cytotoxics, small molecules, generics, viral therapeutics, ATMPs, VLPs and other nanoparticular drug delivery systems. We apply innovative, quality-by-design based, rational concepts of pharmaceutical development according to ICHQ8 and other guidelines. We support our global customers in developing a consistently high-quality pharmaceutical product that is transferable, scalable and manufacturable under GMP conditions. ProJect Pharmaceutics is managed by experts with >30 years of experience in the pharmaceutical industry. In about 850 m2 we operate special laboratories for biologics, cytotoxics and a BSL-2 unit, equipped with dedicated industrial HOF pilot freeze dryers.

Protein

formulation

› Predictive formulation analytics: a QbD-based highthroughput approach for accelerated development

› Pre-formulation, early state & late phase formulation

› Liquid & lyophilised formulation (DoE-based)

High concentration protein formulation

› Low viscosity formulation for s.c. application

› UF/DF process development

› Syringeability evaluation

Cytotoxic small molecules

A deep understanding of the challenges when processing highly potent drugs, such as limited solubility in water and rapid degradation, paired with long-lasting experience and comprehensive know-how of lyophilisation from various organic solvents enables us to provide specific solutions for high potency & cytotoxic drugs.

Antibody-drug conjugates (ADCs)

› Predictive, high-throughput formulation development

› High-end freeze-drying technology

By combining protein formulation and process know-how with cytotoxic drug expertise the company holds unique assets to develop ADCs. On top we offer complementary formulation and process development of intermediate antibody & linker-payload bulk.

PROJECT PHARMACEUTICS

Peptide formulation

› Formulation and lyophilisation cycle development

Innovative liposome technology

› High encapsulation efficiency (hydro- & lipophilic APIs)

› GMP-compatible manufacturability with standard equipment

Viral therapeutics

› Lyophilised formulation and cycle development

In-use stability studies

› Evaluation of DP compatibility with IV line equipment

Freeze drying

› In vials, dual chamber systems, syringes, cartridges, bulk trays or bags, containers in nest&tub configuration

› Out of organic solvents

› Rational cycle development (robust, collapse-safe, cost & time efficient, tailored to the formulation)

› Bulk lyophilisation (solid or powder)

› SEM structural analysis of lyo cake

› Time lapse video & IR thermal camera monitoring

› Aseptic pre-clinical batch manufacturing

› Robustness & design space evaluation

› Smooth technology transfer to GMP

Process development and manufacturing

› DSP: Smart optimisation of UF/DF & purification steps targeting common BDS/DP formulation

› Container closure system compatibility

› Forced stress, in-use & accelerated stability studies

› Detergent & excipient quantification

› Sterile filtration study

› Manufacturability assessment

› Fill&finish process mock-up

› Aseptic pre-clinical batch manufacturing

Fill&finish

As state-of-the-art development experts we are teamed up with state-of-the-art contract manufacturing experts to provide high-quality parenterals from pre-clinical to clinical and commercial scale.

Name ›

Address/P.O. Box › Postal Code/City › State ›

ProtaGene GmbH

Inselwiesenstr. 10

74076 Heilbronn

Baden-Wuerttemberg/NRW

Otto-Hahn-Str. 15

44227 Dortmund

Im Neuenheimer Feld 582

69120 Heidelberg

Site Burlington:

4 Burlington Woods Drive Burlington, MA 01803, USA

Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity ›

Dr Roland Moussa; Michael Stump, Ph.D. +49-7131-74504-0 +49-7131-74504-299 contact@ProtaGene.com www.ProtaGene.com

220

1997

Protein Analytical Laboratories (GMP compliant)

Genetic Analysis Laboratories (Biosafety Level 2, GCP)

Analytical Services for Biopharmaceutical Development: Antibodies, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, Biosimilars, FAB Fragment, Fusion Proteins, Vaccines, Other Protein Formates, New Biological Entities (NBEs), Cell and Gene Therapy Analytics: Viral Particles, LNPs, GeneWerk Integration Site Analysis, Vector Characterization, Bioinformatics, Sequencing Data Analytics, On-/Off-Target Analysis, Immune Repertoire Analysis, Gene Expressions Analysis

| Comparability Demonstration | HCP Analytics

| Method Validation and Verification

| Forced Degradation Studies | Stability Testing

| Release Testing

| Cell-based Bioassays

ProtaGene

is a world-leading analytical CRO partner for developing biotherapeutics and advancing therapy medicinal products. For over 25 years, the group has worked alongside clients ranging from Startups to Top Ten pharmaceutical companies to bring medicines to market. They have been part of the story for novel blockbuster products, as well as rare and orphan drugs. ProtaGene is rooted in deep science and hands-on execution, which allows for an intelligent and agile approach to meet the needs of the increasingly complex medicines being developed today. Their experience is demonstrated best with their Biosimilar analytical strategies that cut years off creating the required analytical data package. They also operate the gold standard of gene safety testing methods (Integration Site Analysis), which has generated critical data for gene and cell therapy market authorization. To support all phases of drug development, ProtaGene works at all quality levels (GMP, GCP, GLP, and RnD) to ensure the data is to the required standard but balanced with lean processes to ensure speed of delivery. ProtaGene is the deep science partner for modern medicines.

Analytical

reports

are regularly accepted by multiple regulatory authorities worldwide including FDA (USA), EMA (EU) and others, spanning all stages of development from scientific advice to phase I – III, and up to market authorization. By means of standard and innovative analytics, customized and applied by our highly experienced teams within the FDA and EMA territories, we focus on delivering analytic excellence in advancing, de-risking and accelerating all stages of drug development including innovative areas such as HDX-MS, in-vivo CQA mapping and Integration Site Analysis (ISA).

ProtaGene provides you with the full range of analytical services for protein-based products from drug discovery and development to release testing and regulatory compliance:

Protein quantification by means of amino acid analysis and extinction coefficients

Protein primary structure analysis, which involves a combination of different techniques (i.e. peptide map -

ping, de-novo sequencing, intact mass, N/C-terminal sequencing and disulfide linkage)

Glycosylation analysis to identify common and biologically relevant modifications (i.e. N-linked glycosylation, O-linked glycosylation, sialic acid, site of modification, quantification, monosaccharides)

Impurities analysis, based on state-of-the-art HPLC methods (IEX, SEC, HIC, RP), to assist you with the purification of proteins and to enable their usage in research and in medical applications

Forced degradation studies, helping you to understand the potential consequences a degradation effect can have on your biopharmaceutical’s safety and efficacy

MAM (Multi Attribute Method) as a powerful MS-based approach that allows for extracting a large number of different quality parameters of a protein within a single analytical approach

HCP (Host Cell Proteins) MS, enabling the conclusive identification of process-related impurities

Vector Analytics to determine identity, quantify impurities, assess replication competence, and minimize the risk for patients

Integration Site Analysis (ISA) to determine the integration site position and frequency of viral vectors with unmatched precision and sensitivity

Bioinformatics to gain deep biological insights with regard to specific safety concerns

Our analytical services for gene therapy-based products

provide best-in-class molecular diagnostics and analysis services to ensure the safety of novel cell and gene therapies focusing on insertional mutagenesis and genotoxicity. Highly sensitive platforms and bioinformatics tools determine fusion sequences adjacent to known DNA or RNA fragments in minimal tissue samples down to the single cell level. Applications include clonality and safety of (viral) vectors in gene therapy, on-target specificity of designer nucleases, immune repertoire studies in T cells and B cells and next generation sequencing (NGS). Drawing on our unique worldwide experience in gene therapy studies, bioinformatics, NGS, and associated regulatory demands, we help our customers by designing solutions entirely tailored to their needs.

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Person › Telephone › Fax › Email › Website ›

Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

Peptide Specialty Laboratories GmbH

Im Neuenheimer Feld 515

69120 Heidelberg

Baden-Wuerttemberg

Dr Adrian Glas

+49-6221-889612

+49-6221-889613 info@peptid.de www.peptid.de

7 2000

Peptide Synthesis

Customised peptide synthesis and peptide-specific antibodies

Peptide Specialty Laboratories

Peptide Specialty Laboratories (PSL) GmbH is located in the Technology Park in Heidelberg, Germany. It was founded in August 2000 by Dr H.-R. Rackwitz as a spinoff laboratory of the German Cancer Research Center (DKFZ). The team of PSL has gained a long wealth of experience in peptide synthesis and antibody preparation. Since 2022 Peptide Specialty Laboratories GmbH has been a subsidiary of Reaction Biology Europe.

The main goal of PSL is based on the production, to a very high standard, of unmodified as well as modified peptides from mg to gram amounts and with lengths of 2 to more than 100 amino acids. PSL guarantees that peptides are all HPLC purified and analysed by mass spectrometry. PSL also offers syntheses of peptides with rare amino acids, unnatural amino acids, peptides with fluorescent moieties, biotinylated peptides, branched peptides, and cyclic peptides. Furthermore, PSL produces bio-conjugates between peptides and proteins as well as column matrices, and is a main contributor of peptide specific antibodies for scientific and industrial research. PSL antibodies are primarily produced in rabbits or guinea pigs and other species on request. In addition, PSL is specialised in the production of phosphospecific antibodies.

Peptide-specific antisera service

We offer a customised peptide-specific antisera service. By using high-quality peptide conjugates for the preparation of our antisera, we have achieved a high success rate in generating of specific antisera.

Fast, flexible and a capable consultation partner

The success of your research project is our goal. To achieve this, we provide you with individual support from the outset and are alwas ready to provide you with direct consultation.

Modifications & special services

We have the capacity to incorporate modified or special amino acids into peptides (i.e. acetylated, myristoylated, phosphorylated, stable isotope amino acids, etc.). We also provide different labels (i.e. fluorescent dyes, toxins, chelators). Furthermore we offer stapled peptides and cyclic peptides (i.e. head-to-tail, side-chain-to-sidechain, disulphide).

Synthesis scale

We provide peptide services in which you can select from different amounts. Peptides are available in different scales. To obtain a specific amount of a peptide you may choose from a minimum scale of below 1 mg up to a gram scale of an HPLC purified peptide.

Purification

We believe that unpurified peptides are not appropriate for immunisation or other research purposes. That is why our peptides are provided with a purity of >90 %. Higher purities are available upon request. We do not routinely provide unpurified peptides. If customers have their own purification facilities we may also provide unpurified peptides on special request.

Delivery

It will take approximately two to three weeks to receive your product once the order has been confirmed.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity › External › Collaborations

ReliaTech GmbH

Lindener Straße 15

38300 Wolfenbüttel

Lower Saxony

Dr Markus Heine

+49-5331-8586-987

+49-5331-8586-989

orders@reliatech.de www.reliatech.de

I Q <10 1999 S1, DIN ISO 9001:2015

Production of growth factors, cytokines, soluble receptors and antibodies

Cell culture ( E.coli, Sf9, HEK293)

Cell line development for research and preclinical use Process development Contract development

Collaborations with research institutions and industrial partners

Our story

Since its foundation in 1999, ReliaTech has developed into one of the leading European manufacturers of growth factors, cytokines, receptors, mono- and polyclonal antibodies for life science research and industry.

Our biggest aim is to satisfy our customers with products of the highest quality. For this reason, close contact with our customers is very important to us. A short and reliable communication as well as fast reagent supply efficiently support our business.

Our values

We are competent

We competently and promptly advise our customers by using our in-house expertise. If needed we further support our knowledge by a network of experts of various scientific fields. Our know-how is based on a long-term personal experience and the close collaboration with partners from science. These arrangements allow us to offer a broad range of products.

We are cooperative

We stand for a trustful, open and honest cooperation. Our customers can expect speed, flexibility and reliability to support their work. We listen to them carefully and find individual solutions for individual problems.

We are proactive

We are interested in smooth processes and useful product offerings. To achieve this goal we keep contact with our customers and actively care to keep in line with actual demands in trade and science.

We are fair

Our customer relationship is founded on trust, respect and honesty. An open dialogue, engaged at the same level, is important to us.

Our proteins and services

Proteins for research and preclinical applications

From development and production to formulation and quality control, our proteins and antibodies are handled by experienced scientists. With over 25 years of experience, our processes are well optimised. A product release is always based on clear specifications, such as purity, cell-based activity and impurity profile. All products are available in customised filling sizes and quantities.

Animal-free products

A growing number of proteins in our portfolio is produced without any raw materials of animal origin. We are thus making an important contribution to reducing the risk associated with the use of animal-derived adventitious agents.

Contract manufacturing

With our in-house system for transient and stable expression in different expression systems, including process development for cultivation and purification, we offer our customers a customised solution for the production of their protein of interest. The customised protein production is based on a flexible, modular system that allows for an individual selection of different service options depending on your specific needs.

Bioassay service

We offer our extensive expertise in cell proliferation assays to check the biological activity of customer proteins or even the responsiveness of customer cell lines to a specific growth factor. This assay is frequently used as a first step to check the biological activity of a protein up to a validated assay with international standards.

Our quality promise

As an ISO 9001:2015 certified company, achieving the highest quality standards is very important to us. We are constantly working on improving our quality standards and optimising our service. We regularly derive our quality measures from the ICH guidelines and are guided by the specifications of our internal QP

Name ›

Address/P.O. Box ›

Postal Code/City

State

Contact Person

Telephone

Fax

Email

Website

Social Media

Number of Employees

Founded (year)

Type of Laboratory

Areas of Activity

Rentschler Biopharma SE

Erwin-Rentschler-Str. 21 88471 Laupheim

Baden-Wuerttemberg

Dr Latika Bhonsle-Deeng, Global Head of Communications +49-7392-701-0 +49-7392-701-300 communications@ rentschler-biopharma.com www.rentschler-biopharma.com

1,400 1872 S1

Contract development and manufacturing organization (CDMO) for biopharmaceuticals, including complex therapeutic proteins, mRNA and viral vectors

A world-class biopharmaceutical CDMO

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA and Stevenage, UK. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma’s focus on sustainability.

Your trusted partner from concept to market

External

Collaborations

Request for › Further Collaborations

Strategic alliance with Leukocare AG, located in Munich, Germany, for bestin-class formulations

Strategic collaboration with Vetter, headquartered in Ravensburg, Germany, for high quality aseptic filling and secondary packaging

Rentschler Biopharma offers bioprocess development and cGMP manufacturing solutions from concept to market for pharma and biotech companies in long-term collaborations and strategic collaboration settings.

The company offers process development and manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma is highly experienced in the development and cGMP manufacturing of monoclonal antibodies, designer proteins, and other therapeutic proteins in compliance with international standards (EMA/ FDA). Working collaboratively with its clients, Rentschler Biopharma provides customised solutions with optimised work packages for each development stage. State-of-the-art cGMP facilities and cell culture processes are leveraged for manufacturing for both, clinical studies and commercial supply. Consistent monitoring of the international regulatory landscape and in-depth understanding of the necessary regulatory documentation (CMC), ensures that each project is properly documented in accordance with international regulatory requirements. In order to offer value-adding solutions across the entire process chain, the company has entered into a strategic alliance with Leukocare for formulation development. Another strategic collaboration is with Vetter for aseptic manufacturing and packaging. The desired goal of the collaboration with Vetter is the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.

Bioprocess development

› Fast and efficient supply for multiple candidate screening

› Robust and scalable CHO cell lines for cGMP manufacturing

› Efficient cell culture and purification processes

› Well-established analytical methods

› Advanced formulation development exclusively by Leukocare AG

Best-in-class formulation development

Rentschler Biopharma’s strategic alliance with Leukocare offers best-in-class formulation development considered at every step of the biopharmaceutical development and manufacturing process.

cGMP biomanufacturing

› Multiple stainless steel bioreactor lines, including a twin system with 2x 3,000 L

› Flexible single-use bioreactor lines up to 2,000 L

› State-of-the-art purification processes

› Guaranteed product quality and purity in accordance with cGMP guidelines

Our newly expanded, state-of-the-art Milford, MA site primarily focuses on the production of highly complex molecules for international clients and is fully operational. Thanks to a 22,000 square feet of manufacturing cleanroom space and four 2,000 L single-use bioreactors, we meet our clients’ changing needs by building design to accommodate future adaptions for scale and capacity.

As a world-class solution provider, we ensure optimum time-to-clinic and time-to-market by accelerating timelines to create competitive advantage for our clients. For seamless market approval, we consult and assist clients with regulatory queries, develop optimised strategies, and generate complete documentation for approval of clinical studies and market launch.

Name ›

Address/P.O. Box ›

Postal Code/City › State › Contact Person › Telephone › Fax › Email ›

Social Media › Number of Employees › Founded (year) › Areas of Activity › Biological Patents › External › Collaborations

Request for › Further Collaborations

Richter BioLogics

Suhrenkamp 59

22335 Hamburg Hamburg Dr Thilo Kamphausen

+49-40-55290-451

+49-40-55290-888

BusinessDevelopment@ richterbiologics.eu

I > 370 1987

Contract development and manufacturing organisation (CDMO)

Several patents on manufacture of proteins and pDNA (pART process)

Biotech and Pharma companies worldwide

Richter BioLogics offers CDMO services from gene to finished product. Our teams provide top level solutions to bring your product to market. Contact us for more details.

High class GMP-compliant microbial production of biopharmaceuticals –Plasmid DNA and Proteins

Richter BioLogics is a leading and expanding Germanybased contract development and manufacturing organisation (CDMO) specialised in a broad range of products derived from bacteria and yeasts. With a 35-year track record in cGMP manufacturing, Richter BioLogics provides its clients with a unique knowledge base in process and analytical validation, process performance qualification (PPQ) procedures, commercial production of therapeutic proteins, antibody-like scaffolds (e.g., VHH/ Nanobodies, Fab-fragments), bacterial vaccines, and plasmid DNA (pDNA) products.

Your product – our competence and dedication

Our focus is on our customers, their needs, timelines and quality requirements. Our seasoned, highly educated, and motivated teams support the global pharmaceutical and biotechnological industries with one-stop-shop services ranging from strain/process development to analytical development, manufacturing, QC testing and filling of finished product. In addition to our headquarters, we operate two GMP-compliant production sites with total bioreactor capacities of 2x 1,500L and 2x 300L to provide manufacturing solutions for large and commercial scales. Further space and connections exist to install more capacity as needed by the customer.

Quality is our DNA

Richter BioLogics consistently works to the highest standards of pharmaceutical quality as verified by major regulatory bodies including but not limited to EMA, FDA, PMDA, ANVISA, MFDS, and more, as well as by numerous customer audits. Throughout the company teams have excellent expertise in the development and cGMP-compliant production of biopharmaceuticals. To ensure efficient, timely and transparent work, we apply professional project management methods and an integrated Quality Management System. The quality system

at Richter BioLogics meets the strictest standards of quality in biopharmaceutical production.

Products and services

Our process development team possesses extensive experience in developing and optimising fermentation and purification processes. For initial strain development, a variety of proprietary E. coli expression systems are available to support strain selection. Small-scale models of existing processes provide helpful tools for trouble shooting, process characterisation, and validation and ensure a smooth scale-up to large-scale cGMPcompliant manufacture.

Additionally, our in-house QC testing covers development and validation of a variety of analytical methods (incl. biological assays), performance of stability studies, and characterisation of reference standards.

Richter BioLogics offers a full range of biopharmaceutical manufacturing services:

› Establishment of cell banks (MCB/WCB)

› In-house QC testing and release

› Stability studies according to ICH guidelines

› Strain and process development

› pART proprietary process– pDNA for different purposes at scales needed

› cGMP manufacturing for clinical phases I to III

› Commercial cGMP manufacturing

› Process validation and PPQ procedures

Thanks to the broad knowledge of Richter BioLogics’s experts and many decades of experience gained from different kinds of projects, Richter BioLogics works out tailor-made solutions for its customers worldwide, which include large pharmaceutical companies as well as advanced biotech companies.

We manage each of our customer projects individually and with the utmost dedication and flexibility - a guarantee for a successful and ongoing partnership.

Roche Diagnostics GmbH

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website ›

Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

Nonnenwald 2

82377 Penzberg Bavaria

Dr Johannes Ritter

+49-8856-60-2600

+49-8856-60-3417

Annual Turnover › Relevant R&D Budget › Request for › Further Collaborations

CHF 58.7 bn (Group) CHF 13.2 bn (Group) www.roche.com/innovation/ partnering/ Name ›

deutschland.kommunkation@roche.com www.roche.de/ueber-roche/standorte/ penzberg

7,730 1896 (Group) S1–3

Biotechnology based research, development, production of diagnostics and raw materials (including Custom Biotechs), active pharmaceutical ingredients

Company profile

Penzberg is the Bavarian location of Roche Diagnostics GmbH. Situated south of Munich on 590,000 m 2, and with a workforce of more than 7,700 employees, it is one of Europe’s largest biotech centres for research, development and the production of active pharmaceutical ingredients and diagnostics. With more than 50 years of experience, this site is a pioneer in the industrial scale of the biotechnology discipline. At the same time, Roche at Penzberg is the largest employer with significant economic impact in the region. Roche continues to expand the biotechnology competence in Penzberg. This is how the site has been strongly expanded over the past years. Investments focused on production capacities for active pharmaceutical ingredients, diagnostics and overall infrastructure. This well exceeds a total of a total of €1,3bn in the last five years that Roche has invested in the Greater Munich biotechnology.

Personalised Healthcare

The Penzberg Biotech Center is the only Roche location in the world that performs research, development and production for both Roche Divisions: Diagnostics and Pharma. This results in extensive synergetic crossnetworking between the two divisions and thus Roche is uniquely positioned to drive Personalised Healthcare (PHC) forwards. PHC is about providing the right treatment for the right group of patients. Roche’s strengths in pharmaceuticals and diagnostics along with advances in science and technology have made fitting treatments for patients possible. Previously, only five out of ten patients, on average, benefited from their treatment. Today, up to 80% of patients respond to their targeted therapies.

Targeted treatments are based on the molecular causes of disease. That means treatments are based on the presence of biomarkers and through companion diagnostic tests indicating mutations or genetic expressions in the patients’ tissue. For example, in the past, nonsmall cell lung cancer (NSCLC) was just diagnosed as NSCLC. Today, over a dozen gene mutations are known to play a role in this type of cancer. The detection of biomarkers via diagnostic tests allows for a more targeted treatment that patients can benefit from.

ROCHE DIAGNOSTICS

Diagnostics

For the Roche Diagnostics Solutions business unit, Penzberg performs research, development and production of systems reagents and control sera for automated analysers in a professional lab environment or hospital related use. Growth drivers are immunological tests, the development of new biomarker tests and enzymatic clinical chemistry tests. Examples are thyroid parameters, lipid analysis, glucose metabolism, osteoporosis markers, cardiovascular diseases, women’s health and fertility, infectious diseases and tumour markers. All components of the immunological tests and control sera are manufactured on site. Operations in Penzberg therefore produce over 1.000 different raw materials for all Diagnostics business units. It is safe to say that nearly all Roche Diagnostics tests contain components from Roche Penzberg. Furthermore, Roche is a renowned partner for custom biotech solutions in various fields.

Pharma

The Greater Munich site also stands for units of Pharma Research and Early Development. The Roche Innovation Center Munich focuses on therapeutic proteins, including next generation monoclonal antibodies, and innovative gene therapy concepts. The portfolio comprises Roche’s five major focus areas: oncology, immunology, infectious diseases, ophthalmology and neuroscience. Biological and preclinical research for immuno oncology, biomarkers, the identification of tissue markers and histopathology are also located here, as is the management of clinical studies up to phase II.

The department Technical Development Europe is at the cutting edge in developing manufacturing processes of high quality drug substance, parenteral drug product, devices, packaging and robust control strategies. It brings game-changing therapies from clinical phase I into the market. That core business is supported by a strong technical science and innovation pipeline assuring end-to-end technical excellence.

And moreover, Roche at Penzberg in the Greater Munich area is a large scale biotechnological production facility of active pharmaceutical ingredients (API), including monoclonal antibodies. Therapeutic APIs made in Penzberg target disease areas like cancer or anemia.

Name › Address/P.O. Box ›

Postal Code/City › State ›

Contact Persons › Telephone › Fax › Email › Website ›

Number of Employees ›

ScheBo ®• Biotech AG (Head office)

ScheBo ®• Biotech UK Ltd.

ScheBo ®• Biotech USA Inc.

Netanyastrasse 3

35394 Giessen Hesse

René M. Kröger, PhD

Sonja Scheefers

Jeffrey Scheefers

+49-641-4996-0 +49-641-4996-77 schebo@schebo.com www.schebo.com

48

The academic staff has many years of experience in the research and development of diagnostics

Founded (year) ›

Areas of Activity › Biological Patents › External › Collaborations Awards › and Certificates

1989

Development, production and marketing of diagnostics

ScheBo ®• Biotech AG holds many international patents in the above fields and owns a good intellectual property-position.

ScheBo ®• Biotech AG has academic alliances with several universities and university hospitals in Europe, the USA, Japan, Israel and Canada.

1993 – Hessian Innovation Award of the MBG

1998 – Hessian Innovation Award of the MBG

2002 – “Hidden Champion 2002”

2002 – “Innovationspreis der deutschen Wirtschaft“ (4 certificates)

2004 – Among the finalists for the “Innovationspreis der deutschen Wirtschaft”

Company profile

ScheBo®• Biotech AG is an innovative biotech company that is active in the fields of development, production and marketing of diagnostics. ScheBo ®• Biotech AG’s mission is to improve quality of health care by providing the best diagnostics with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION and SIMPLICITY.

ScheBo ®• Biotech AG was founded by the biochemists and molecular biologists Ursula Scheefers-Borchel, PhD, and Hans Scheefers, PhD.

Subsidiaries

ScheBo ®• Biotech UK Ltd., founded: 1999

ScheBo ®• Biotech USA Inc., founded: 2001

The company

› is completely privately funded and independent, › operates internationally, › develops innovative diagnostics.

25 years of leading innovations

R&D and manufacturing led to the successful launch and sales of the following products:

› ScheBo ®• Pancreatic Elastase 1 Stool Test

› ScheBo ®• Pancreatic Elastase 1 Serum Test

› ScheBo ®• Tumor M2-PK™ EDTA Plasma Test*

› ScheBo ®• Elastase Canine Test

› ScheBo ®• Quick-Prep™

› ScheBo ®• Tumor M2-PK™ Stool Test*

› ScheBo ®• M2-PK Quick™ (lateral flow test)*

› ScheBo ®• 2in1 combi (M2-PK + Hb)™ (lateral flow & ELISA test)*

› ScheBo ®• Pancreas Elastase 1 Quick™ (lateral flow test)

› ScheBo ® • Pancreas Elastase 1 Quick™ Canine (lateral flow test)

› ScheBo ®• Hb Smart™

› ScheBo ®• Lactoferrin Smart™ Stool Test

› ScheBo ®• Calprotectin Smart™ Stool Test

› ScheBo®• SARS-CoV-2 Quick™ IgM/IgG (lateral flow test)

› ScheBo ®• SARS-CoV-2 Antigen ELISA Test

› ScheBo ®• SARS-CoV-2 Antigen (lateral flow fluorescence test)

* www.metabolic-database.com

Unique selling proposition

Innovative diagnostics

1993 ScheBo ® • Biotech AG launched the world’s first non-invasive, cheap routine test procedure for monitoring the exocrine function of the pancreas. Today highlyregarded clinicians and medical text books regard the ScheBo ® • Pancreatic Elastase 1 ELISA, based on two monoclonal antibodies, as the “gold-standard” for noninvasive pancreatic exocrine function testing. ScheBo®• Biotech AG is world market leader for this FDA-cleared product. In 2013 the ScheBo ® • Pancreas Elastase 1 Quick™ test has been introduced as a point of care rapid test for the fast and reliable diagnosis/exclusion of Exocrine Pancreatic Insufficiency. Continuous innovation and strong customer focus have made ScheBo ® • Biotech AG a leading molecular diagnostic company.

Closing a gap

The ScheBo®• Tumor M2-PK™ EDTA-Plasma Test is the first test in the world which detects a metabolic state, specific to 11 cancer entities. The predictive value of Tumor M2-PK reflects tumour activity and aggressiveness. Thus, the ScheBo ® • Tumor M2-PK™ EDTAPlasma Test closes a gap in the clinical practice of cancer treatment management.

Fighting cancer, colorectal cancer screening

The ScheBo®• Tumor M2-PK™ Stool Test is the first test detecting pyruvate kinase in stool, an excellent biomarker for colorectal cancer screening. This test has a sensitivity of 85% and a specificity of 95%. In 2012, ScheBo ® • Biotech launched ScheBo ® • 2in1 Quick™ (M2-PK+Hb), a brand new innovative combined rapid test to simultaneously detect the enzyme biomarker M2-PK and human haemoglobin for improved colorectal cancer screening. By simultaneously testing for M2-PK and haemoglobin (Hb), both non-bleeding and bleeding colorectal cancers and polyps can be detected.

Name ›

Address/P.O. Box › Postal Code/City

State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

SciRhom GmbH

Am Klopferspitz 19 (IZB) 82152 Martinsried Bavaria

Dr Jan Poth

+49-89-614241230 info@scirhom.com www.scirhom.com I 9 2016

Preclinical and early clinical development of therapeutics with novel mode of action, treatment of autoimmune and inflammatory diseases, key inflammation pathways, iRhom2/TACE signal transduction biology

Biological patent

External

collaborations

Comprehensive international patent portfolio

Hospital for Special Surgery, New York, expert academic collaborators, highly reputable Contract Research Organisations

SciRhom and its Vision

SciRhom is a pioneering biotech enterprise with the vision to translate advanced scientific findings into game-changing therapies for the treatment of autoimmune and inflammatory diseases.

Based on a decade of ground-breaking research by Prof. Carl Blobel, M.D., Ph.D., co-founder of SciRhom and Director of the Arthritis and Tissue Degeneration Program at Hospital for Special Surgery, New York, SciRhom is developing first-in-class antibodies against the cellular target protein iRhom2 for the selective inhibition of the inflammatory master switch TACE.

SciRhom’s Approach

TACE (TNFα converting enzyme or ADAM17) controls several major signalling pathways in health and disease, including TNFα , IL-6R, and EGFR signalling, and has therefore been considered a highly attractive target to block pro-inflammatory pathways. However, direct inhibition of TACE causes severe side effects, such as skin and intestinal lesions, since it leads to the blockade also of physiologically important and protective pathways. Very recently, iRhom2 (inactive Rhomboid 2, RHBDF2) was discovered as the exclusive key regulator of TACE for the disease-associated release of TNFα , IL-6R, and HB-EGF from immune cells. In contrast, the activation of TGFα as a crucial mediator of skin and intestinal barrier function is supported by both iRhom2 and its closely related family member iRhom1. SciRhom’s highly specific antibodies against only iRhom2 open the exciting opportunity to selectively and simultaneously target the iRhom2-mediated pro-inflammatory activities of TACE, while preserving its iRhom1-supported protective functions important for normal physiology. This new mode of action allows for a highly efficacious but safe treatment of various disorders, including major debilitating autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and lupus glomerulonephritis.

SciRhom’s Asset

SciRhom’s key asset is a series of first-in-class humanised monoclonal antibodies (mAbs) against iRhom2 with excellent physicochemical, pharmacokinetic, and pharmacological properties. Reflecting the simultaneous blockade of several disease-driving pathways and the restoration of immune-balancing mechanisms, our antibodies have proven superior efficacy over the current standard of care single pathway inhibitors Humira, Remicade, RoActemra, and Skyrizi in various disease mouse models. Further to the unique mode of action, our anti-iRhom2 antibodies promise a better tolerability and a real disease-modifying effect. The CMC development of the clinical candidate SR-878 and its toxicological assessment were successfully completed, and CTA approval of a first clinical study was obtained. Based on a recently closed series A financing round, SciRhom has entered SR-878 into clinical development with the goal to ultimately demonstrate clinical proof-of-concept in two indications. SciRhom’s antibodies are protected by four strong patent families that cover the antibodies themselves, their iRhom2 target epitopes, as well as their therapeutic use until 2039.

SciRhom’s Management

Our management team unites several decades of biotech and big pharma experience in advancing therapeutics into early clinical development and beyond, and consists of

› Jan Poth, Ph.D., Managing Director & CEO

› Jens Ruhe, Ph.D., Co-Founder, Managing Director & COO

› Matthias Schneider, Ph.D., Co-Founder & CSO

› Jürgen Reeß, M.D., Ph.D., CMO

The Innovation & Gründerzentrum Biotechnologie (IZB) in Martinsried near Munich, home of a number of biotech companies (© IZB)

Illustration of iRhom1/TACE and iRhom2/TACE complexes and their role in driving inflammatory processes (iRhom2/TACE) as well as protecting the skin & intestinal barrier (iRhom1/TACE and iRhom2/TACE)

Inhibiting iRhom2/TACE complexes by binding our antibody to iRhom2 simultaneously blocks a number of pathways driving inflammation, while the physiological effects, such as skin & intestinal barrier protection, are preserved through the activity of unaffected iRhom1/TACE complexes

Name ›

Address/P.O. Box › Postal Code/City › State ›

Contact Person › Telephone › Fax › Email › Website ›

Number of Employees › Founded (year) › Areas of Activity ›

SERVA Electrophoresis GmbH

Carl-Benz-Straße 7

69115 Heidelberg

Baden-Wuerttemberg

Dr Barbara Müller

+49-6221-13840-0

+49-6221-13840-10

info@serva.de www.serva.de 45 1953

Laboratory (reagents, instruments), electrophoresis (precast gels, stains, markers, reagents and consumables, equipment); protein analysis (IEF, SDS PAGE, 2D, Western blotting)

Who we are

“SERVA Serving Scientists” is our mission to supply top quality products that meet the demands of the life sciences research community. The SERVA portfolio comprises fine biochemical reagents and products for the separation of biomolecules with a focus on electrophoresis specialties. All processes are subject to SERVA’s quality management system certified according to ISO 9001:2015.

The name “SERVA” has been well-known for more than 70 years. SERVA Electrophoresis GmbH was founded in 1998 as a mid-sized private-owned entity. As the successor of the former SERVA Feinbiochemica GmbH & Co KG originally established in 1953, the know-how and expertise in biochemistry and protein separation stay with us until today. The company is located in the heart of Heidelberg, a centre of excellence in life sciences research. Heidelberg is situated within the enlarged Rhine-Neckar metropolitan region, a multi-industrial area where many biotech companies, pharmaceutical, and chemical enterprises are based.

What we do: continuing product development in electrophoresis

Our strategy is to provide a comprehensive assortment of traditional as well as innovative specialties – all you need for your experiment. Well known in the community of Isoelectric Focusing (IEF) are the SERVALYT™ carrier ampholyte buffers. At SERVA, we develop and produce special reagents for protein electrophoresis, e.g. precast gels (SERVALYT PRECOTES™, FocusGel), markers, solutions, and stains. One of our latest and most famous technologies is “HPE™” (High Performance Electrophoresis) – a workflow in protein analysis which combines horizontal conventional electrophoresis with superb resolution by applying a large gel format using a unique equipment (HPE™ BlueHorizon™ flatbed system). Based on requests from customers we have developed the complete workflow and protocols for various applications, e.g.:

› Isoelectric Focusing, analysing samples from food, plant, seeds, and diagnostics (e.g. urine, EPO)

› SDS PAGE 1D and 2D / DIGE Western blotting (proteomics, HCP coverage analysis)

SERVA ELECTROPHORESIS

› Fluorescent, colorimetric and chemiluminescent detection and documentation

But that’s not all. SERVA offers everything for common slab gel mini electrophoresis, calling it “PRiME TM” (Premium Resolution in Mini Electrophoresis) – precast gels, gel media, buffers, and blotting. Our equipment line called “BlueLine” supports electrophoretic separation and is exclusively available from SERVA and “made in Germany”. You have protocols in place that utilise products that are no longer available? Looking for replacement of “ExcelGel™”, “PhastGel®”, or “Multiphor™ II” or even an automated gel-staining device? No problem. We have the solution (and the products) to transfer those applications to state-of-the art technology utilising HPE™.

As new technology in 2024, we continue to distribute FreeFlow Electrophoresis. This technology works without a gel matrix and thus also bigger molecules, like membranes and organelles, can be separated in an aqueous continuous buffer flow. Combined with the HPE™ technology this results in an yet unreached narrow separation.

What we offer: service and support –our application specialists are ready

Our technical service department supports you with online services, videos, webinars, and workshops. Need assistance beyond the standard support? Our experts can help you to establish your workflow – e.g. antibody separation by IEF or 2D Western blot-based HCP analysis. From sample preparation to evaluation we provide confidential consultation for our customers – our know-how for your success.

Quality matters

Particularly in biotechnological production, compliance with quality standards is crucial for companies. SERVA offers qualification services (IOPQ) for our equipment line “BlueLine”. It is a unique service only available with us, carried out by our experts – from installation and ope ration quality assurance to process quality assurance within the framework of maintenance contracts, adapted to your needs at the silver, gold, or platinum level.

Evaluation of FFE-IEF-Separation. Fractions of MAP 7.6 after FFE-IEF separation on SERVA FocusGel pH 3-10 displays the narrow separation power of FreeFlow Electrophoresis

FreeFlow Electrophoresis Unit. A device for electrophoresis in a continuous aqueous film without a solid matrix to separate proteins, membranes, particles and organelles.

SERVA HPE™ BlueHorizon™ Flatbed Electrophoresis Chamber, with BluePower™ 3000 HPE™ PowerSupply

Name ›

Address/P.O. Box

Postal Code/City

State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

SGS Analytics Germany GmbH

Schwanthaler Str. 115

80339 Munich

Bavaria

Samir Barral El Gaoui

+34-664502248

samir.barralelgaoui@sgs.com

https://sgs-institut-fresenius.de/en/ health-nutrition/health-science

I 35 1994

Central Lab services / clinical lab testing

Leading innovation in clinical trials: Accuracy, reliability, confidence

Driving excellence in your clinical trials through SGS

Central Lab services

In a world where clinical trials are becoming more and more important and more complex, we offer highest quality services, reliability, and customised solutions. We provide guidance through our laboratory experts to deliver the best solutions to our clients of the biotech and pharma industry as well as clinical CROs.

Our portfolio includes:

Project and data management

› Experienced and dedicated team assumes ownership of our clients projects

› High quality standards

› Local expertise and global oversight

› Lab reports highly customisable

› High flexibility of data transfer formats

› Automated upload for eCRFs

Study services

› Support of study sites by providing customised and easy to read site-specific instructions

› Supply of easy-to-use site and visit-specific kits and ancillary materials to sites

› Worldwide samples logistics at ambient, cooled, and frozen temperatures

› Sample storage: -20°C, -80°C, or in liquid N2

› Global study database

› Secure online access

Customised lab services

› Assay development

› Method validation incl. ICH M10 or FDA guidelines

› PBMC/BMMC cell isolation

› Biomarker screening

Analytical services

› 24/7 lab service for early phase trials (e.g. hematology, biochemistry, serology)

› PK, PD

› Immunogenicity

› Biomarkers

› Immunological analysis

› Genetics incl. NGS

› Histopathology and cytology

› Large allergy testing panel

› Experience with various matrices (e.g. serum, plasma, CSF, ascites, bone marrow)

Quality Assurance

› GCP, GCLP compliant

› Independent QA department

› Periodic audits from customers as well as inspections by the most relevant agencies incl. FDA

› 21 CRF Part 11 compliant software

Why SGS?

Adaptability

› Every project is unique for us

› We always strive to find ways to support both, sites and sponsors, creating customised solutions.

Streamlining

› We reduce the complexity of clinical trial management for sponsors

› Our main mission is to make the lab related work as easy as possible for the sites

Experience and reliability

› 30 years of experience

› Repeat business with more than 90% of our customers

Best Location

› Strategic location of our Central Lab site in Munich makes us ideal for European trials

› Our network of partner laboratories allows us to succeed in global trials

Additional SGS services for drug development and production control

Clinical CRO services

› Phase 1 unit, including human challenge studies

› Specialised unit for dermatology/ophthalmology

› Strong expertise in the area of biostatistics and biometric services

› CDMO services

Production control services (GMP)

The clinical trial services are complemented by our contract laboratory services to support our clients during the development and production of the IMP/ authorised drug. Our services include CDMO quality control, stability studies, and characterisation as well as impurity analysis, nitrosamines, and Leachables & Extractables.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Areas of Activity ›

Sino Biological Europe GmbH

Düsseldorfer Str. 40

65760 Eschborn North Rhine-Westphalia

Bin Hu, Ph.D.

+49-6196-96786-56

+49-6196-96786-57 order_eu@sinobiologicaleu.com www.sinobiological.com

About Sino Biological

An internationally recognised reagent supplier and contract research organisation, specialising in recombinant protein production and antibody development.

Sino Biological works at the forefront of both the bioreagents and contract research services industries, providing a full slate of high-quality recombinant proteins and antibodies, as well as custom development and production solutions for particularly difficult projects backed by its over 17 years of expertise. The company is headquartered in Beijing, China, and has established subsidiaries in the US, Germany, and Japan, and South Korea. Sino Biological became a public company in August 2021, when it successfully completed an IPO on the stock exchange ChiNext, a subsidiary of the Shenzhen Stock Exchange (Sino Biological, 301047). In April 2024, the company has successfully concluded its acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc. (“SCB”). Sino Biological has acquired 100% of SCB shares in a deal valued at $48M USD, inclusive of all assets, assumed indebtedness, and net of cash deposits.

Sino Biological offers a vast portfolio of about 9,100+ recombinant proteins, 14,000+ antibodies, 49,000+ genes, and multiple serum-free mammalian cell culture media products. These reagents are used by worldwide customers from pharmaceutical and biotechnology companies to research institutions in over 90 countries and regions worldwide. Sino Biological’s proprietary technology platforms also enable customised end-toend solutions for customers with complex protein and antibody needs.

Strengths of Sino Biological

Led by a group of experienced scientists, the Company is constantly striving for growth, quality, and innovation. Sino Biological’s team is continuously growing and currently has over 1000 members, among whom a

The World Leader in Kinases

• Enzymes, Proteins, Compounds, Substrates and Assay Reagents

• Customized Enzyme Development & Compound Profiling Services

third have masters or doctoral-level degrees. In recent years, the Company has expanded to over 355,000 square feet, including 215,000 square feet of R&D and production facilities and over 53,000 square feet of GMP-level manufacturing workshops and laboratories, where over 2,000 new protein and antibody products are developed every year. Many of these new products are best-in-class on the market, including GMP-grade cytokines, enzymes and kinases, and full-length multi-transmembrane proteins. The Company has also achieved ISO9001, ISO13485, CNAS, CMA certification, and GMP compliance certification.

Sino Biological has long been recognised for its contribution to the field of infectious disease research. The Company’s ProVir™ reagent collection is the world’s leading viral antigen bank, featuring thousands of antigens and antibodies covering a wide range viral types including influenza, RSV, and coronavirus strains. Many of these reagents have been used to manufacture rapid antigen and antibody diagnostic tests around the globe. In addition, the Company has received CiteAb’s “Supplier Succeeding in SARS-COV-2 Research” and “Protein Supplier to Watch” awards for two consecutive years. Sino Biological aims to advance life science and improve human health through the provision of superior quality research reagents and CRO services. The Company will continue to develop new products to address the unmet needs and demands from today’s biomedical

Sino Biological Europe is located in Frankfurt, Germany, providing the close-to-customer local services. If you have any questions, please feel free to contact our local team in Germany (order_eu@sinobiologicaleu.com).

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Person › Telephone › Fax › Email Address › Internet Website › Number of Employees › Founded (year) › Areas of Activity ›

Sirius Fine Chemicals SiChem GmbH

Fahrenheitstr.1

28359 Bremen

Bremen

Dr Miriam Rittner

+49-421-2208-228

+49-421-2208-226

mrittner@sichem.de www.sichem.de 17 2001

l Tools for Life Sciences

l Custom syntheses

l Purification / (Enantio)separation

Sirius Fine Chemicals SiChem GmbH (SiChem) is a privately held company founded in 2001 in Bremen.

SiChem’s unique expertise is based on the synthesis of masked derivatives of compounds with biologically and pharmacologically increased bioavailability (prodrugs) that are usually not suitable for drug development. The masked drug candidates are successfully tested against several pathological conditions, for instance cystic fibrosis (CF), diarrhea, and inflammation. Some products have tested positively in animal and ex-vivo patient experiments.

Custom

synthesis / contract research

To complete complex projects for clients mainly from the biochemical, biomedical, and pharmaceutical sector requires concentration, flexibility, innovation, and also creativity. SiChem’s extensive experience in the area of custom synthesis / contract research helps to find optimum solutions for new tasks as well.

The SiChem team assists its clients competently until the agreed objectives are met, keeping in dialogue with them. Professional documentation is a matter of course.

SiChem’s chemical and technical know-how, which is constantly growing due to numerous custom syntheses from the pharmaceutical industry and biotech companies, is made available for new synthetic tasks and innovative research. Support is offered in the following areas:

› classical custom synthesis (building blocks and target structures) for medicinal research, pharmaceutical development, lead compound, and prodrug development from mg to kg scale.

› Synthesis of (API) metabolites (made synthetically or enzymatically) or stable labelled isotopes.

› FTE based research & development

Custom purification / enantioseparation

(www.prep4U.de)

SiChem offers comprehensive services around preparative HPLC:

› Purification of compounds (e.g. purification of APIs and intermediates, pesticides, natural produts / isolation of API impurities and metabolites

› Enantioseparation of racemic mixtures

SiChem has profound and longstanding experience in the area of preparative HPLC – regardless of whether it is 100mg or 100kg that needs to be separated and regardless of whether this is reversed phase (RP) or normal phase (NP). Columns of (almost) every size and various stationary phases from polar to nonpolar and chiral are available. For sensitive compounds, supercritical fluid chromatography (SFC) with CO2 as solvent is used. This technology makes a valuable contribution to the environment (Green Chemistry).

Tools for life sciences

SiChem synthesises fine chemicals and diagnostic tools for biochemical, biomedical, and pharmaceutical research. The core expertise is in the field of intracellular signaling, e.g. on derivatives of inositol phosphates. SiChem constantly develops new tools for R&D, especially photoactivatable and fluorescent compounds for which there is a fast growing demand.

The portfolio is complemented by innovative tools for click chemistry (Si-Click ®):

› clickable unnatural amino acids

› clickable dyes (Si-DYEs®)

› bi- and trifunctional clickable lipids

› clickable (PEGylated) tools

Address/P.O. Box

Postal Code/City

State

Head office

Telephone

Social Media

Number of Employees

Founded (year)

Areas of Activity

SPT Labtech

In den Brückenäckern 4

07751 Großlöbichau

Thuringia

Melbourn Science Park

SG8 6HB

Melbourn, Hertfordshire, UK

44-1223-627555

marketing@sptlabtech.com www.sptlabtech.com

F I  400 1997

Lab automation, liquid handling, sample management, sample preparation, consumables

SPT Labtech: Inspiring ingenuity in the life sciences

SPT Labtech makes products that transform the way scientists work. For over 25 years, we have been pioneering automation for liquid handling, sample preparation and sample management, to accelerate research and make a real difference to human health. By working closely with customers and application leaders, we build trusted partnerships worldwide to deliver personalised solutions that tackle real-world challenges in the lab.

Advanced liquid handling: Our automated liquid handling solutions eliminate the need for tedious manual pipetting to streamline tasks and ensure precise, consistent results. Using true positive displacement technology, we deliver unrivalled accuracy at ultra-low volumes, enabling reaction miniaturisation to extend the reach of costly reagents and valuable samples.

Streamlined sample management: As labs expand, managing and storing samples becomes increasingly complex. Our automated systems alleviate this burden by handling repetitive tasks, helping labs stay organised and ensuring the accuracy and integrity of research. This reduces the risk of human error and frees up time and resources to focus on critical research.

Innovative sample preparation: Cryo-electron microscopy (cryo-EM) is essential in structural biology, and our solutions are designed to deliver high-quality results consistently. With top-performing sample support grids and next-generation grid preparation systems, researchers can obtain better images, making the most of every experiment.

Supporting your research every step of the way

Scan

Our portfolio is backed by comprehensive service and support from our reliance ® engineering team, who partner with you throughout the lifetime of your instrument to maintain optimal performance and productivity. Additionally, you’ll have access to technical expertise from our dedicated applications support team, who will work with you to develop custom experiments and ensure you get maximum value from your instrument.

Harness the full power of genomics with automation

The strength of our technology and expertise lies in streamlining genomics workflows, which are particularly suited to automation due to the repetitive nature of sample preparation for next-generation sequencing (NGS) and PCR. Automating and miniaturising these workflows boosts research output, allowing labs to meet the everincreasing demands on throughput, scale and budget. Automation allows labs to fully harness powerful emerging technologies, such as single-cell and spatial biology methods, to their maximum potential.

firefly ® : The all-in-one genomics solution

firefly provides all the tools you need to automate and streamline genomics workflows. Our all-in-one liquid handling platform emphasizes accessibility and ease of use—no automation expertise is required.

Discover what sets firefly apart

› Compact benchtop footprint with multiple on-deck tools for pipetting, non-contact dispensing, shaking, and temperature-controlled incubation.

› Cloud-sharing capabilities for easy collaboration, allowing users to create and modify protocols from any PC.

› Access to a growing library of automation-verified protocols from leading kit providers, giving researchers a head start in their NGS workflows.

› Leading genomics labs around the world trust firefly, including researchers at Harvard Medical School, who have streamlined library generation to meet the throughput demands of their sequencing core facility.

Name ›

Address/P.O. Box › Postal Code/City › State ›

Contact Person › Telephone

Email

Website › Social Media › Number of Employees › Founded (year) › Areas of Activity ›

Tebubio GmbH, part of Tebubio Group

Berliner Str 257 63067, Offenbach Hesse

Dr Giulia Fienga +49 69 8010130 germany@tebubio.com www.tebubio.com

I 100 1953

| 3D Cell Culture

| Advanced Biological Tools

| Animal Welfare Policy

| Biological Research

| Biomarker Analysis

| Cell Line Engineering

| Contract Research Services

| Custom Research Solutions

| E-procurement Solutions

| Ethical Sourcing

| Human Biological Samples

| Innovative Research Tools

| Life Sciences Solutions

| mRNA Production

| Pan-European Support

| Protein Production

| Scientific Expertise

| Supply Chain Management

Facilitating Life Sciences Research Every Day

We empower Life Sciences Research, contributing to a brighter future for science. Through our local offices across Europe, we support researchers in Life Sciences and Biotechnology with a holistic range of solutions to advance their projects faster:

› Cutting-Edge Biological Solutions: We provide access to biological solutions sourced from renowned global suppliers, carefully selected by our Scientific Team for their ethical and legal compliance.

› Contract Research Expertise: We accelerate research with expertise in mRNA production & delivery, cell line engineering & protein production, cellular studies, and biomarker analysis.

› Streamlined Ordering Process: Our e-procurement solutions and extensive supply chain expertise simplifies ordering processes, saving researchers time and avoiding administrative complexity.

With Tebubio, focus on what matters most: your research.

Who We Are

We are a Pan-European company founded in 1953, family-owned with over 100 employees and local offices throughout Europe.

› Innovation-Driven: Our DNA is rooted in innovation. We are deeply integrated into the EU Life Sciences ecosystem, exemplified by our partnerships like Bio Deutschland in Germany.

› Committed to Ethical Sourcing: We adhere to the highest ethical standards, sourcing only from OEMs. Our Corporate Social Responsibility initiatives include an animal welfare policy, ISO certifications (ISO 14001 / ISO 9001), and a Decarbonation Program.

A Holistic Range of Solutions

› Biological Solutions Portfolio: Our Scientific Team helps researchers source, select, and use over 1,300,000 references from trusted suppliers, ensuring compliance with ethical and legal standards.

› Custom Solutions: We offer both catalogue and custom options tailored to specific research needs.

Areas of Expertise

› Cells & Tissues: Primary cells, melanoma cell lines, human biological samples

› Biomarkers: Profiling, quantification, biostats

› Immuno Tools: Cytokines, antibodies, ELISAs, and arrays

› Live Cell Imaging: Cytoskeleton probes, mitochondrial probes

› Nucleic Acids: mRNA synthesis, CleanCap® capping technology

› Functional Assays: Reporter cell lines, FRET assays, activity assay kits

› Innovative Tools: 3D matrix, 3D plates, microfluidics devices

› Biochemicals: Inhibitors, compound libraries, FDAapproved compounds

Outsource and Accelerate Your Research

Our Contract Research Services facility in Europe delivers expert support, ensuring project success in areas such as:

› mRNA production & delivery

› Cell line engineering & protein production

› Cellular studies

› Biomarker analysis

Streamline Your Ordering Process

Partner with Tebubio for tailored agreements and benefit from our robust supply chain management, including:

› IATA-certified shipping

› Compliance with human and animal biological solution handling

› Sourcing outside existing suppliers

› Warehousing services

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Person › Telephone › Fax › Email › Website ›

Number of Employees › Founded (year) ›

Areas of Activity ›

Tosoh Bioscience GmbH

Im Leuschnerpark 4

64347 Griesheim Hesse

Regina Roemling

+49-6155-7043700

+49-6155-8357900

Info.tbg@tosoh.com www.tosohbioscience.de >20 1989

Supplier of chromatography media, HPLC and UHPLC columns

Application support in analysis and purification of biomolecules.

Tosoh Bioscience is an acknowledged global leader in the field of liquid chromatography with a focus on bioseparations. For more than 30 years, Tosoh Bioscience is providing cutting-edge solutions to meet the needs of customers developing and producing new biologics, biosimilars or biobetters, such as plasma products, monoclonal antibodies, recombinant proteins, vaccines and oligonucleotides.

Our product portfolio encompasses SEC instruments and a comprehensive line of media and prepacked process development, HPLC, and UHPLC columns. These products are popular in the biotech and biopharmaceutical industry and used in R&D, downstream processing, and quality control. Typical applications comprise the purification of therapeutic proteins in lab, pilot, and commercial scale, as well as their characterisation by HPLC or UHPLC. Latest developments comprise SkillPak columns pre-packed with best-in-class TOYOPEARL resins for quick and reproducible development and scale-up of purification methods and a holistic multicolumn chromatography solution for DSP intensification, the Octave BIO/PRO instrument and dedicated SkillPak BIO/PRO columns. For antibody characterization, we introduced novel TSKgel size exclusion columns suited for native separation with MALS or MS detection and a hydrophobic interaction column for ADC analysis.

Headquartered in Griesheim Germany, in the Frankfurt/ Rhine-Main Metropolitan Region, Tosoh Bioscience’s European operations offer extensive technical support like application development, on-site training and workshops. One of the services that stand out in the industry is the Tosoh Chromatography Workshop Series providing a comprehensive background to the chromatographic purification of biomolecules.

Tosoh Bioscience is part of the Tosoh Group, a Japanese chemical and speciality products and materials group, founded in 1935, which comprises over 100 companies worldwide and a workforce of more than 12,000 people.

Our brands TOYOPEARL® and TSKgel ® are renowned for their quality and reliability. The stationary phases cover all common modes of liquid chromatography, including ion exchange, hydrophobic interaction (HIC), mixed-mode, reversed phase, hydrophilic interaction (HILIC), size exclusion (SEC) and affinity.

Name ›

Address/P.O. Box › Postal Code/City › State › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity ›

TRIGA-S Scientific Solutions

Mühltal 5

82392 Habach

Bavaria

+49-8847-695-78-0 info@triga-s.de www.triga-s.de

I  I 120+

1998

Contract laboratory (BSL 2)

Analytical and clinical performance

studies of in vitro diagnostics (IVD) and companion diagnostics (CDx):

| Laboratory testing services

| Sample management (sourcing, processing, storage)

| Study management

| Study monitoring

| Biostatistics and Data management

| Study logistics

External › Collaborations

Research institutes, clinics, contract developing, and manufacturing organisations, and regulatory consultants

Request for › Further Collaborations

TRIGA-S seeks synergistic collaborations in the field of IVD development

TRIGA-S is a full-service Contract Research Organisation (CRO) for in vitro diagnostics. As a well-established partner of the diagnostics industry, we create solutions for robust and efficient IVD development pathways. Our GCP/GCLP-qualified teams work according to IVDR, CFR and national regulations and guidelines.

How we support IVD development (ISO 13485)

We support manufacturers in all stages of the IVD product development process from early design phase through feasibility, verification and validation phases up to post-market -performance-follow-up activities. Our expertise includes design and conduction of feasibility studies, analytical and clinical performance studies, and applicable risk management activities.

Enabling IVDR compliance

TRIGA-S supports IVD manufacturers with:

› Classification of products / gap assessment for legacy products

› Development of IVDR compliance strategies

› Analytical and clinical performance studies

› Project management that coordinates client requirements, development partners, suppliers and the liaison with notified bodies/regulatory authorities

TRIGA-S supports pharmaceutical companies with:

› biomarker hypothesis testing for Companion diagnostics (CDx) / Complimentary diagnostics (CoDx)

Covering all aspects of an IVD study

Study Management:

› Project management for performance studies

› Medical writing (study plans / protocols and reports)

› Risk-based planning and surveillance of processes

› Regulatory consulting

Study monitoring:

› Selection of study sites, study initiation, regular monitoring (onsite or remote) and close out

› Site training

› Source data verification

Biostatistics and Data management

› Statistical consulting on study design

› Determination of the sample size based on current guidelines or calculation

› Development of the statistical analysis plan (SAP) and report (SAR)

› EDC set-up and maintenance

Contract laboratory (S2):

› Measurements on several platforms for clinical chemistry, immunology, NAT, ELISA and PCR

› Client-specific analytical performance experiments

› Feasibility testing and exploratory studies

Study logistics:

› Coordination for worldwide shipments of samples and study material

› Full traceability and temperature control

Sample processing

› Sample kit preparation, very small to large quantities

› Collections of clinical samples

› Sample management (LIM-System)

› Pooling and aliquoting

Sample storage:

› Long-term storage of human samples and study materials at -80°C, -20°C, 2-8°C, RT and 37° C

› Temperature monitoring 24/7 and backup systems

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Person

Telephone

Email

Website

Social Media

Number of Employees › Founded (year) ›

Areas of activity ›

Valicare GmbH

Eschborner Landstrasse 130-132

60489 Frankfurt on the Main Hesse

Dr E. Sons-Brinkmann +49-69-153-293-700/709 info@valicare.com www.valicare.com

I > 100 2002

GMP Services for Pharma, Biotech, & Medical Device Industries

Valicare – ONE-STOP SHOP for Quality and GMP Services

Valicare GmbH is a GMP service provider headquartered in Frankfurt/Main since 2002 and a subsidiary of Syntegon Technology GmbH, a leading supplier of process and primary packaging technology for the pharma and food industries. Valicare is ISO 9001:2015 certi fi ed and has a subsidiary (joint venture) in Turna/ Slovakia. Multidisciplinary teams of engineers, scientists, pharmacists, experienced project managers, and senior GMP consultants enables support customers in the pharma, biotech, and medical device industries and particularly manufacturers of Advanced Therapy Medicinal Products (ATMPs). More than 5.000 GMP projects have been successfully completed worldwide thus far, ranging from ISO and GMP compliance consulting to hands-on qualification and validation support.

Our approaches are always risk-based and ef fi cient –according to the motto: as little as possible, as much as necessary.

Together with our quali fi cation, validation, and documentation services, we offer high-level GMP (and GxP) consulting support:

› GMP and ISO compliance consulting based on your needs

› Structuring and moderation of workshops (e.g. risk analysis, risk assessment)

› Design and planning of GMP-compliant project work flows

› De fi nition of high-level process or project specifications (URS), GMP for new and rebuild projects

› Establishment, adaptation, and optimization of comprehensive GMP quality assurance systems

› Individual concepts for topics such as risk, change, or deviation management and validation strategies

› GMP, GAP, and target-performance analyses for every topic in the GxP-regulated environment and for quality systems according to DIN EN ISO 9001 and DIN EN ISO 13485

We offer risk-based, integrated qualification and validation support in compliance with GMP guidelines, especially Annex 15 of EU GMP. Our services include, but are not limited to:

› Design reviews, plant-specific technical and process risk analyses, qualification of equipment from laboratory to large machines and (clean-) rooms, FAT, SAT, preparation of qualification documentation and definition of test conditions, calibration and requalification after modernization, HMI upgrades after format change

› Quali fi cation and validation of biodecontamination processes in isolators as well as systems for optical control (one of our special competences)

› Validation of manufacturing processes, cleaning processes, analytical methods, and computer systems

Our passion: GMP for Advanced Therapy Medicinal Products (ATMPs) –support throughout the whole life cycle

Our service packages offer expert advice on the development, transfer, and implementation of straight and GMP-compliant ATMP manufacturing processes. Our turnkey manufacturing concept (cult.tainer), consisting of fully equipped GMP-compliant cleanroom modules, enables aseptic process development and manufacturing of ATMPs on-site, accompanied and supported in all GMP issues by our experts.

Due to our large number of successfully finalized projects in very different GMP subject areas, we have sound experience with a variety of efficient and pragmatic solution approaches. Benefit from our expertise!

Name

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone

Email

Vetter Pharma International GmbH

Eywiesenstrasse 5

88212 Ravensburg

Baden-Wuerttemberg

Andrea Wesp

+49-751-3700-0

EU and other international inquiries: info@vetter-pharma.com

US inquiries: infoUS@vetter-pharma.com

Website › Number of Employees › Founded (year) › Areas of Activity ›

Asia Pacific inquiries: info@vetter-pharma.com www.vetter-pharma.com

6,600 1950

Drug Product Development, Aseptic clinical and commercial fill and finish, Device Assembly and Packaging, Analytical Services, Regulatory Support, Logistic services

External › Collaborations

Strategic collaboration with Rentschler Biopharma SE, headquartered in Laupheim, Germany, for bioprocess development and API production

We place heightened focus on your success as your strategic partner

We produce aseptically prefilled syringes, cartridges, vials and dual-chamber systems as a globally operating CDMO partner. We are a family-owned, independent company rooted in 70+ years of history. We do not manufacture our own drugs – we focus on providing highly skilled support and state-of-the-art manufacturing resources. We support our customers from the initial phases of clinical drug product development and filling to commercial manufacturing, device assembly and packaging, and lifecycle management. Over 80% of our active projects are biologics.

We are a reliable, responsive, and progressive partner

Our portfolio of services includes dedicated resources for clinical development and commercial manufacturing as well as assembly and packaging, and more. We provide tailored solutions to meet your product’s specific market needs.

Services

› Drug Product Development

Support in navigating key early decisions in your product’s evolution with scalability, quality and efficiency in mind.

› Aseptic Filling & Visual Inspection

Comprehensive expertise in manufacturing injectable drug products and related visual inspection systems.

› Device Assembly & Packaging

Strategic, technical and packaging support for patient-friendly combination products.

› Analytical Services

Robust, customizable testing methods for drug products including evaluation and quality verification.

› Regulatory Support

Support to achieve milestones related to compliance during clinical development, market authorization and beyond.

› Logistic Services

Cutting-edge solutions that maximize efficiency, transparency and precision of a vital supply chain.

Fast facts: Vetter-at-a-glance

› Headquartered in Ravensburg, Germany

› Dedicated clinical production facilities in Rankweil, Austria, and Chicago, USA

› Commercial production sites in Ravensburg and Langenargen, Germany

› Branch offices for Asia Pacific in Singapore, Japan, South Korea, and China

› More than 6,600 employees worldwide

› Global specialist in the aseptic production of prefilled drug delivery systems

› International expertise with regulatory authorities including FDA, EMA, PMDA (Japan), and RP (Germany)

› Service offerings for pharma and biotech firms of all sizes and locations

› Numerous patents including technologies for protection against tampering and counterfeiting

› Lyophilization (freeze-drying) and siliconization specialist

› CO 2 neutral at all corporate sites since 2021

For more information, please scan the QR code.

Name ›

Address/P.O. Box › Postal Code/City › State ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) ›

Areas of activity ›

Vivoryon Therapeutics N.V.

Weinbergweg 22 06120 Halle (Saale)

Saxony-Anhalt

Franz-Josef-Delonge-Strasse 5 81249 Munich Bavaria Anne Döring, CFA +49-345-555-99-00 info@vivoryon.com www.vivoryon.com I 14 1997 Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, cancer

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines.

About VIVORYON

We are focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases.

We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The mechanisms of action underlying our approach enables us to target a variety of disease areas with high medical need.

With historic roots in diabetes research and development as well as neurodegenerative disorders, Vivoryon’s focus is now on applying our approach to developing medicines in inflammatory and fibrotic disorders.

Lead candidate VAROGLUTAMSTAT

Vivoryon’s lead candidate, varoglutamstat (PQ912) is a proprietary, potent, nanomolar, oral and selective inhibitor of human glutaminyl cyclases QPCT and QPCTL with therapeutic potential in indications including inflammatory and fibrotic diseases, neurodegenerative diseases, cancer and others.

Initially advancing development aiming to treat Alzheimer’s disease (AD), varoglutamstat has been investigated in a number of different clinical studies, all of which have consistently demonstrated a favourable safety and tolerability profile both in healthy volunteers and patients with AD. Based on the most recent efficacy data in patients with early AD, which suggest no consistent effect of varoglutamstat at the doses tested, and highly encouraging efficacy data suggesting an improvement in kidney function in this elderly population, the Company is currently focusing on developing varoglutamstat in kidney disease.

Varoglutamstat has not yet been approved by any regulatory authority and the safety and efficacy have not yet been established.

Address/P.O.

WuXi Biologics Germany GmbH

Chempark Leverkusen, Building D501, Tor 11

51368 Leverkusen North Rhine-Westphalia

Martin Wans +49-214-357-62001

Info.germany@wuxibiologics.com www.wuxibiologics.com I 400+ 2020

Drug Substance Manufacturing; Drug Product Manufacturing; Analytical Services

Our company

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialisation – for the benefit of patients worldwide.

We operate over 20 state-of-the-art, premier quality cGMP drug substance and drug product facilities in China, Ireland, Germany and USA for the production of a wide array of biologics from both mammalian and microbial expression systems. This expansive manufacturing network provides our clients a global dual source option for clinical and commercial manufacturing. All of our manufacturing operations are overseen by our comprehensive global quality system that has been audited by multiple regulatory agencies including the U.S. FDA, EMA and NMPA.

State-of-the-art Drug Product & Drug Substance facilities in Germany

Since 2020, WuXi Biologics has significantly invested in the purchase of two state-of-the-art manufacturing facilities in Germany in order to globalize the manufacturing network.

Leverkusen Drug Product Fill Facility

Acquired in 2020 from Bayer, the WuXi Biologics Leverkusen facility is a fill and finish drug product manufacturing plant that offers over 13,000 sq. m. of commercial-scale drug product filling capabilities. The site achieved its GMP approval for Drug Product manufacturing in June 2020. The facility is located in the heart of the CHEMPARK Leverkusen which provides robust infrastructure. The sterile filling and freeze-drying plant provides an annual capacity of approximately ten million doses and is being expanded to include a second filling line for prefilled syringes (PFS). Name

Wuppertal Biologics Drug Substance Facility

The WuXi Biologics Wuppertal site is a state-of-the-art drug substance facility with flexible and open spaces for future expansion. Ideally located in Wuppertal, an important focal point of Germany’s Pharma industry. The facility offers more than 30,000 sq. m. operating space, including currently 12.000L bioreactor capacity from 6x2000L bioreactors, flexible downstream capacities, integrated laboratory space and warehouse withing the building. The expansion plan for the site foresees adding another 6x2000L bioreactor to achieve a maximum of 24.000L bioreactor capacity.

Wuppertal Aprath – Analytical Laboratory

In addition, WuXi Biologics operates an up-to-date analytical laboratory in Wuppertal-Aprath. It supports our own manufacturing facilities but also offers stand-alone analytical services for clients, e.g. material importation testing or batch release testing.

Jointly with our drug substance facility in Wuppertal and drug product facility in Leverkusen, WuXi Biologics Germany offers the entirety of the biologics manufacturing process and analytical services to our clients as an E2E provider.

Name ›

Address/P.O. Box › Postal Code/City

State

Contact Person

Telephone

Fax

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity › X-act Cologne Clinical Research GmbH

Rudi-Conin-Strasse 4 50829 Cologne North Rhine-Westphalia

Olivia F. Hoffmann, Sales & Marketing Manager Jasmin Atarodi, Managing Director

Andreas Fichtner, Head Biostatistical Services

Ilka Strehlau, Head Clinical Data Management +49-221-337716-0 +49-221-337716-33 business@x-act-cologne.com https://x-act-cologne.com I Q 35+ 1994

| Specialised service provider | Clinical data management | Biostatistical services

Passion for evidence since 1994!

We are an experienced partner to the life science industry, obtaining reliable study results for the development of safe and innovative therapies.

› Owner-managed CRO.

› Established 1994 and located in Cologne, Germany.

› Successful conduct of more than 450 interventional (Phase I to IV), non-interventional and medical device studies.

› 35 + seasoned and technophile team members contribute to the success of your project.

Biostatistical Services

› Statistical consulting, assuring that your scientific questions are answered.

› Delivering sample size determinations and statistical input to your study protocols.

› Development of a randomisation plan. Performing randomisation according to your study requirements.

› Developing Statistical Analysis Plans with a clear focus on the statistical programming of key results and analyses.

› SDTM and ADaM Mapping supporting the submisson of your study results.

› Biostatistical reporting as part of your clinical study / investigational report, publication or dossier.

Clinical Data Management

› Strategic consulting to find the best eClinical solution for your project.

› eCRF implementation according to CDSIC | CDASH supporting submission.

› Development of all essential DM documents for your successful project conduct.

› Implementing Good Clinical Data Management Practices throughout your project.

› The conduct of all DM activities is supported by the excellent procedures of our SOPs.

› Targeted data review and data cleaning in close collaboration with your CRA team.

› Benefit from expressive status reports providing transparency and overview to the study team.

Curious about our special services? Please contact: business@x-act-cologne.com

Address/P.O. Box

Postal Code/City

State

Telephone

Fax

Email

Social Media

Number of Employees

Founded (year)

YMC Europe GmbH

Schöttmannshof 19 46539 Dinslaken North Rhine-Westphalia

+49-2064-427-0

+49-2064-427-222

info@ymc.eu www.ymc.eu

50 (Europe) 485 (worldwide) 1993

| Glass Columns for Lab and Pilot Scale

| Prepacked Glass Columns | Laboratory Services

| Preparative Liquid Chromatography | Analytical Liquid Chromatography

Your resource for chromatography

As a research-driven chromatography specialist, YMC provides chromatographic solutions for compounds such as peptides and proteins, mAbs, and ADCs, as well as oligonucleotides from R&D scale through scale-up to production and final quality control in your lab. We supply innovative bio-chromatography resins and columns for preparative processes, as well as highly reproducible BioLC-(U)HPLC-columns for SEC, IEX, RP, & HIC.

Furthermore, YMC glass columns in laboratory as well as pilot scale are designed to meet bio-chromatographers’ demands. You can choose them empty as well as prepacked according to your requirements by YMC’s in-house packing service. In addition, you can make use of on-demand services for application support, screening, analytical, or preparative method development. Trainings on different chromatographic topics complement the products and services.

Innovations

The most recent and interesting developments include:

› The new standard for columns for bio purification suitable for self-packing: YMC PilotPLUS

› Next generation RP phase for peptide purification: YMC-Triart Prep Bio200 C8

› Innovative solutions for BioLC: YMC-Triart Bio (U)HPLC columns, also available in bioinert hardware

The broad and continuously growing portfolio of stationary phases especially designed for the separation of biomolecules provides high flexibility for the chromatographer and ensures successful lab results, day after day. Additionally, the availability of particle sizes from analytical to preparative scale guarantees smooth and easy scale-up processes. Name

Worldwide availability and support guaranteed

YMC products are available worldwide through a dedicated support network that guarantees qualified and meaningful practical assistance with regard to method development, method transfer, method validation, purification services, and custom column packing – locally, personally, and efficiently. It is not only product specifications that represent YMC quality, also but the positive energy and dynamics of our employees, who provide competent and consistent performance together with pronounced reliability even for the most difficult and demanding separations. The YMC network consists of highly focused product specialist teams to provide active support for chromatographers.

Regulatory Support

Since all YMC processes and working procedures are thoroughly monitored and documented, YMC resins and glass columns are fully compliant with requirements. Full technical documentation is available to show compliance with all applicable regulations.

Name ›

YUMAB GmbH

Science Campus Braunschweig-Süd

Address/P.O. Box › Postal Code/City › State ›

Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

Inhoffenstr. 7

38124 Braunschweig

Lower Saxony

Dr Inga Hochnadel +49-531-481170-0 info@yumab.com www.yumab.com I 30 2012 S1, S2

| Fully human antibody discovery & lead development | Antibody Libraries | Engineering & Humanization | R&D services (CRO) | Partnered innovation

Request for › Further Collaborations

YUMAB seeks clients & partners for human antibody development in the biopharma, biotech, & diagnostic industries.

Bridging the gap from target to lead

YUMAB is a contract developer of fully human antibodies for the global biotechnological and biopharmaceutical industry. Starting in 2012 with the goal to bridge the gap between innovative research and novel therapies, the company has since become a global player that advances medicine by accelerating the development of next-generation biotherapeutics.

Our advanced discovery platform provides access to challenging targets, enables new formats, and accelerates the development of human antibodies at a high success rate. From target discovery to fully characterised lead – our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner.

Jump start for translation

The YUMAB ® R&D platform delivers fully human antibodies, the closest to natural germline among those on the market, using fast and reliable in vitro discovery technologies. The company’s highly diverse, human antibody libraries contain 1011 natural antibody sequences and specificities to all types of antigens. Unlike animalderived, chimeric, humanised, or synthetic antibodies, each YUMAB® antibody sequence has been shaped in the human body, which maximises epitope diversity and overcomes restriction by in vivo immune responses while minimising immunogenicity and potential adverse effects in clinical development.

Our advanced in vitro selection technology is also efficient for rare and difficult target antigens and allows pre-design of epitope specificity, interspecies X-reactivity, affinity, stability, and other properties early in the discovery and development process. First antibody candidates are identified swiftly within a few weeks and are highly developable into all types of antibody drug formats such as full-length IgGs, Fabs, scFvs, bispecifics, CARs, fusion proteins, and ADCs.

Proven success

Our contract research and partnered development has been proven successful by more than 200 projects over the past decade with over 120 clients and partners worldwide.

Therapeutic antibody discovery & development

From Target to Lead

When the Corona pandemic hit in 2020, YUMAB collaborated with the University Braunschweig and other partners to develop antibodies against SARS-CoV-2, generating leads in only four months. The awarded fast track collaboration led in 2020 to the spin-out of CORAT Therapeutics GmbH, which is pursuing the clinical testing of the antibody drug candidate COR-101 (phase Ib/II) in hospitalised patients with moderate to severe COVID-19. COR-101 is designed not to induce elevated immune responses that contribute to lung damage, which enables treatment of patients with high viral loads.

Trusted partner

YUMAB provides tailored service and partnering concepts to jump-start translation from research innovation to drug development with affordable entry costs, flexible licensing options, and no additional third-party obligations. Our expert team values close communication with customers and partners, whom we consult and guide through the entire process of antibody development –from target to lead.

YUMAB at a glance

Human antibody discovery platform

› Natural fully human libraries for low immunogenicity

› Optimised in vitro selection to address difficult targets

› Rapid discovery within weeks

Direct link to lead development

› Advanced antibody lead development & optimisation

› All antibody formats, all disease areas

› Robust process, high success rates

YUMAB® platform

› Fully integrated discovery & development platform from target to optimised lead

› Customised project plans with flexible entry & exit points

› Smooth translation from bench to bedside

Flexible services, collaborations & partnering

› CRO: fee-for-service & flexible licensing options

› No technology access fees

› Collaborative development

The leading biotech magazine in German

Focus on Germany, Austria and Switzerland: |transkript reports on biotechnology and life sciences in German-speaking Europe – competent, networked, never boring. As a printed magazine or daily updated online at transkript.de

Economy. Technology. Life. 2024 in its 30

ISSN 1435-5272

Subscription: transkript.de

transkript.de

Profiles

of Service Providers

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Person › Telephone › Fax › Email › Website › Social Media ›

Number of Employees › Founded (year) › Areas of Activity ›

BIO.NRW The Home of Biotech

Merowingerplatz 1

40225 Dusseldorf North Rhine-Westphalia

Dr Nils Schrader

+49-211-385-469-9200

+49-211-385-469-9220 bio.nrw@bio.nrw.de www.bio.nrw.de

9 2008

| Technology transfer

| Effective Network for Scientists, Founders and Entrepreneurs

| Assisting Start-Ups and SMEs in Terms of Financing and Internationalisation

| National and international fairs, exhibitions and conferences

| Analysis of biotechnology in North Rhine-Westphalia for location data

| Central Platform for Life Science Topics

| Supporting Students and Young Talents

BIO.NRW – Business for

biotech

Since 2008, BIO.NRW is the official biotechnology network of the German federal state North Rhine-Westphalia (NRW). We catalyse the sustainable development of the state’s biotech sector by building on NRW’s strengths in industrial and pharmaceutical biotechnology, bioeconomy, and in enabling technologies. BIO. NRW is actively supporting the implementation of life science technologies, which are key to answering the most challenging tasks of our society.

Our services include:

Central Platform for Life Science Topics

We organise events, congresses, workshops, expert panels and roundtable discussions to promote the dialogue between business, research, investors and policymakers to activate cooperation.

Effective

Network for Scientists, Founders and Entrepreneurs

BIO.NRW compiles comprehensive and current online databases of academic institutions and companies active in the life sciences in NRW. Free to access and easy to use, these resources are valuable tools for identifying business partners. More information on www.bio.nrw.de

External › Collaborations

| Local to international companies, research institutions, financiers, and further biotech stakeholders

Assisting Start-Ups and SMEs in Terms of Financing and Internationalisation

Companies and academic institutions can generate awareness of their activities locally, nationally and internationally by being a part of the BIO.NRW shared booths at fairs, exhibitions and conferences.

Supporting Students and Young Talents

Tech transfer support is a key contribution from BIO.NRW. The network takes special interest in assisting young professionals in biotechnology. We offer a range of activities and events that are of specific interest for founders and start-ups. The BIO.NRW Business Angel Network for example helps financing and funding biotec start-ups.

A snapshot of NRW’s biotech sector

North Rhine-Westphalia is situated at Europe’s geographic and economic centre. NRW is the state with Germany’s highest gross domestic product (GDP), corresponding to 4.9% of the European GDP (EU-27). If classified as an independent nation, NRW would rank 20th in the world. In this vibrant industrial location the chemical and pharmaceutical industry traditionally plays an essential role. New companies and start-ups founded by young academics have been stimulating the corporate landscape in the life sciences sector for years.

NRW offers the most extensive network of academic institutions in Germany. Five of the ten largest universities (by number of students) in Germany are located in NRW. More than 20 Max Planck Institutes, Fraunhofer Institutes, Leibnitz Association facilities and Helmholtz research centers complement the academic research in the field of life sciences in NRW. This variety of academic institutions is a good basis for an agile start-up scene. Young, innovative companies such as Detechgene, BioThrust and PROSION, together with international global players such as Bayer, Qiagen, Miltenyi and a strong network of SMEs form the economic backbone of NRW.

Most of the NRW biotech companies are traditionally active in the pharmaceutical sector. For this reason, the thematic focus BIO.NRW.red was launched in 2010. It bundles the diverse competencies of academic institutions, companies, clinics, biomedical and technology centers in the field of red biotechnology. The interactive network addresses the most important topics in medicine, health, and the pharmaceutical industry in NRW.

Another strength of NRW’s biotech industry is industrial (‘white’) biotechnology, which benefits from the states strong chemical industry, e.g. Evonik, Henkel, Covestro, Lanxess. The sector is connected by the bioeconomy and circular-economy activities of BIO.NRW. Since 2021 these forward-looking activities are bundled in the thematic focus BIO.NRW.eco.

Name ›

BIOCOM Interrelations GmbH – a BIOCOM AG company

Address/P.O. Box › Postal Code/City › State

Contact Person

Telephone

Fax

Email

Website

Number of Employees

Founded (year)

Areas of Activity

Jacobsenweg 61 13509 Berlin Berlin

Andreas Mietzsch

+49-30-264921-0 +49-30-264921-11 service@biocom.de www.biocom.de 30 1986 | Consulting | Publishing | Events | Video production

Our mission

Information and communication for the biotechnology, content-driven and results-oriented - that has been BIOCOM’s self-formulated mission statement since it was founded 39 years ago. A lot has developed scientifically and technically in these four decades, but the core task is more topical than ever. In times of looming climate catastrophe and a rapidly ageing population in many countries, biotechnological solutions are the means of choice. Yet reliably informing all actors in the economic, political and social arena about this is a greater task than ever. At BIOCOM today, a dedicated team of young as well as more experienced staff is ready to take on this information task via many different channels.

Publishing

With our journals |transkript (German) and European Biotechnology Magazine (English), which are published both in print and online, we have the two leading B2B publications in Europe in our programme. Plus various books, such as this Guide to German Biotech Companies. BIOCOM’s media are useful for the reader and attractive for the companies. From advertisements to advertorials and online campaigns to corporate publishing, many things are possible.

Information platforms

Comprehensive information platforms on behalf of the public sector are a very successful business area for BIOCOM. An excellent example is biooekonomie.de: This is the information portal on the bioeconomy in Germany and worldwide. Here everyone can find news, portraits, interviews and reports, videos and podcasts, innovative multimedia stories as well as databases on funding programmes, researchers and research institutions. In addition, exhibitions, information stands and on-site events help to communicate the bioeconomy to a broad target group.

Events

BIOCOM organises large and small events, such as the INDUSTRIA BIOTEC. At this conference, industrial biotechnology solutions are discussed and presented to a wider public.

Consulting and studies

BIOCOM prepares market, financial and technologyspecific studies with the highest user value for its clients. It conducts qualitative and quantitative analyses, developed closely with customers and delivering focused, accurate data. The result is clear, informative dossiers with highest quality information to effectively support professionals in industry and politics.

Industry surveys

Consistent and internationally comparable statistics are a valuable tool for political decision makers. BIOCOM has long-standing experience in sector-specific surveys of both industry and academia. Based on global definitions such as the OECD’s biotechnology statistics framework, we have so far performed surveys in several European countries. Survey results are kept in proprietary databases of the European life science sector and are aggregated and processed for publication.

Horizon Europe and beyond

BIOCOM compiles targeted communication for projects such as the EU Framework Programme for Research and Innovation (e.g. RIBES, COMBINE, BIO2REG). Our communication expertise ranges from strategy development, digital and print communication, public relations, website development, film and animation, and social media. Besides network management and secretariat organisation (e.g. for the International Advisory Council on Global Bioeconomy), we create memorable experiences in the form of inspiring conferences, exhibitions, innovative workshops and dialogue formats. Beyond this, we draw on years of experience in policy analysis and evidence-based policy advice and capacity building.

Video production

BIOCOM offers the full range of services for the creation of audiovisual content: from consulting and conception, filming and post-production to strategies for the distribution in social media. The portfolio includes image and corporate films, recruiting videos, product and explainer videos, documentaries and portraits as well as animations in 2D and 3D.

Name ›

BioM Biotech Cluster Development GmbH

Address/P.O. Box › Postal Code/City › State

Contact Person

Telephone

Fax

Email

Website

Social Media

Number of Employees › Founded (year)

Areas of Activity ›

Am Klopferspitz 19a

82152 Martinsried, Munich

Bavaria

Prof. Dr Ralf Huss

+49-89-899679-0

+49-89-899679-79

info@bio-m.org

www.bio-m.org

 I  22 1997

| Supporting start-ups regarding foundation and financing with specialised coaching, training, and mentoring programmes

| Start-up Incubator MAxL (Munich Accelerator Life Sciences & Medicine)

| Supporting biotech and pharmaceutical companies with an extensive network

| Connecting Bavarian life sciences companies with national and international companies, investors, and relevant stakeholders

| National and international trade fairs, conferences and exhibitions

| Seminars and workshops

| Company database

| Online job market

| News, press releases, annual report „Biotech in Bavaria“

Bio M – Biotechnology Cluster Management for Munich and Bavaria

Since 1997, BioM has been the central network organisation for the biotechnology sector in Munich and Bavaria, commissioned by the Bavarian Ministry of Economic Affairs. As a non-profit organisation, BioM supports the biotech community in a variety of ways with its extensive network. The cluster management connects Bavarian life science companies with relevant national and international partners.

Bio M – central point of contact

› non-profit organisation funded by the Free State of Bavaria

› supporting start-ups and SMEs through specialised and customised business support services since 1997

› bringing together the key life sciences actors in Bavaria

› attracting international investors and industrial partners

› coaching founders and founders-to-be

› preparing the ground for a thriving and sustainable biotech economy in Bavaria

› connecting Bavarian biotechnology world-wide

Bavaria: the place for the medicine of the future

BioM recognises the challenges of the medicine of the future and promotes the innovation process by identifying and connecting matching partners from science, industry, medicine, and finance. By organising individual partnerings with global and local companies as well as scientific institutions, we help companies to find the right contacts and to cooperate with leading organisations. In addition, BioM offers a variety of workshops and training courses on industry-specific topics and advice on funding opportunities for small and medium-sized enterprises.

BioM - Biotechnology Cluster Management

Bio M for founders

Bio M supports Bavarian biotech companies at every stage of setting up their business. Therefore, BioM has developed a unique support programme tailor-made for aspiring start-ups and entrepreneurs in the life sciences sector. In total, BioM has supported more than 250 startup companies in over 25 years.

From idea to success:

› Start-up Coaching – get hands-on support

› Mentor Circle – inspired by experts

› Pitch Training – how to convince investors

› BioEntrepreneur Bootcamp – validate your business idea

› BioAngels Investors Network – find the right investor

› m4 Award – create the future of medicine

› MAxL – BioM start-up incubator

MAxL – Munich Accelerator Life Sciences & Medicine

MAxL is BioM’s unique start-up incubator and supports selected Bavarian pre-seed and early-stage start-up teams from the life sciences and healthtech sectors with well-targeted funding. On 900m2 MAxL offers exclusive high-end infrastructure and access to a vibrant start-up community and BioM’s extensive network.

News - Events - Jobs - CompaniesReport

In addition, Bio M offers comprehensive information on its website www.bio-m.org: current news, a company database, event information, a job exchange, and much more. Every year Bio M publishes the report “Biotech in Bavaria”, a compilation of current business figures and success stories of the Bavarian biotechnology and pharmaceutical industry with a comprehensive company list and detailed company profiles.

Name › Address/P.O. Box ›

Postal Code/City

State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

biomindz

Standortentwicklungsgesellschaft

Mainz mbH

Taunusstr. 59-61

55118 Mainz

Rhineland-Palatinate

Felix Wälder + 49-6131-126280

info@biomindz.com

https://www.biomindz.com

I  6 2023

Campus Development: | support for life sciences and biotechnology companies interested in setting up or growing at the Life Science Campus Mainz

Network Management: | enabling access to the biotechecosystem in Mainz | connecting start-ups and companies with international companies and start-ups, investors and other relevant stakeholders

| Organisation of regular networking events

International marketing: | advertising and communication activities

| presence at national and international fairs, exhibitions and conferences

The Life Science Hub Mainz –For People’s Benefit

Thanks to the success of BioNTech in particular, the science and biotechnology location of Mainz has moved into the worldwide focus of attention. The city of Mainz is making targeted use of this momentum and is to become an internationally visible and successful biotechnology location.

The goal is based on a socially relevant core: Life Science and biotechnology from Mainz improve the quality of life of people – everywhere.

biomindz - to support the biotech industry in Mainz

To enable startups and companies to successfully establish and grow in Mainz, the biomindz Standortentwicklungsgesellschaft Mainz mbH (biomindz) was founded as a municipally owned company.

The organisation’s primary task is to support the ongoing development and promotion of the life sciences and biotechnology sector in Mainz.

In doing so, biomindz will be closely coordinating its activities with departments within the city responsible for urban planning and development as well as sustainable mobility.

Our Services

The company’s activities are divided into four key areas:

› Development of the Life Science Campus close to the University, the University Medical Center and the University of Applied Sciences Campuses.

› Sustainability management to ensure sustainable and, as far as possible, net zero carbon development from the outset that is intended to serve as a showcase for subsequent projects.

› Networking management to connect various local partners and to support the creation of structures for a supra-regional and neutral cluster organisation in Rhineland-Platinate.

› Public relations and marketing activities to raise the international profile of and market the location as well as to provide regular updates to the public.

Our promise

In Mainz you can successfully research, found and grow sustainably – for people’s benefit!

More Information

On our website (www.biomindz.com), you will find information on the prospects, strengths, and potential for life science and biotechnology in Mainz. In addition, the website provides an overview of all life science and biotechnology companies as well as R&D organisations and science institutions. It offers direct contact to various persons who may help you if you have any interest in the life science hub Mainz.

Name › Address/P.O. Box › Postal Code/City › State › Email › Website › Social Media › Number of Members › Founded (year) › Areas of Activity ›

btS – Life Sciences

Studierendeninitiative e.V. btS e.V.

Jacobsenweg 61 13509 Berlin Berlin kooperationen@bts-ev.de https://bts-ev.de/ https://bts-sciecon.de/

F I I

More than 1,100 members 1996

On a nationwide level, we organise biannual career fairs, the “ScieCons”, and we are running an online tool called “ScieMatch” to match talents with companies based on the cultural fit. At the local level, we organise excursions, company presentations, workshops, and various other events.

External › Collaborations

The success of our commitment to life science students is enabled by the support of our various partners, such as Thermo Fisher Scientific Inc., jobvector GmbH, Sartorius AG, T5 Karriereportal, A.S.I. Wirtschaftsberatung AG, BIOCOM AG, BIO Deutschland e.V., Gesellschaft für Virologie e.V., VBIO e.V. and Verband deutscher Studierendeninitiativen e.V.

Request for › Further Collaborations

btS is always interested in new partners and collaborations. There is a wide variety of possible projects and events you can be part of. Please feel free to contact us if you are interested.

The btS – Life Sciences Studierendeninitiative e.V. is a Germany-based student initiative that is active in 23 cities all over Germany. With various activities, btS creates an interface between students, universities, research institutes and companies. For this purpose, we organise career fairs, excursions, networking events, lectures, workshops and scientific symposia.

With more than 1100 members, btS is the largest student initiative in the life science sector. In addition to the large network of students, we are supported by alumni and associate members from both university and industry backgrounds.

We offer students the chance to realise their creative ideas and gain valuable experience for their personal development. In addition to the acquisition of key competences in areas such as project management, communication, time management, leadership and teamwork, our members get insights into various fields of work early on during their studies since we work together with many different partners from academia and industry.

Opportunities for partnering up with btS

Would you like to get in touch with highly skilled life science students? In this case, btS is the perfect partner for you! We offer a wide range of events, contributions to our career blog and newsletters as well as other cooperation opportunities. In addition to bringing you to the university, we are also interested in organising an excursion to your company. Those local events offer unprecedented insights for the participating students.

Member of

Another great chance to meet many life science students face-to-face is our career fair ScieCon. The fair is specifically targeted to students, graduates and doctoral candidates in the field of life sciences and offers a perfect link between industry and academic education. The ScieCon attracts students from local universities and from all over Germany. It offers companies a platform for self-presentation and recruiting new employees.

One of our latest achievements targets the need of companies to find graduates that share their company values and philosophy. Therefore, we have launched ScieMatch, a digital career matching platform that was awarded the Stifterverband’s Hochschulperle of the year 2021. Through our unique matching algorithm, we can bring talents to your attention that match with your company based on a high cultural fit. Other parts of the ScieMatch platform include job profile matching as well as a digital research group catalogue for students.

Do you want to ensure the long-term success of your life science company? Get the attention of the most committed life science students with a nationwide partnership with btS. Even a completely new format of cooperation is feasible.

Feel free to contact us at any time!

Name ›

Address/P.O. Box › Postal Code/City › State

Contact Person

Telephone

Fax

Email

Website

Social Media

Number of Employees › Founded (year) › Areas of Activity

Dr. Ebeling & Assoc. GmbH

Isestrasse 5 20144 Hamburg Hamburg Cigdem Demircan

+49-40-548007-0 +49-40-548007-290 info@ebeling-assoc.com www.ebeling-assoc.com I 40 2005

Pharmacovigilance, Materiovigilance, Risk Management, Medical Science, Medical Affairs, Medical Writing, Medical Device Services, Regulatory Affairs, Audits, Quality Management, Good Clinical Practice, Drug Development, Biologics Development, Scientific Advice, PRIME, Breakthrough Program

External › Collaborations

| Pharma Deutschland e.V.

| Bundesverband der Pharmazeutischen Industrie e.V. (BPI)

| Medicines for Europe (MfE)

| Drug Information Association (DIA)

| Regulatory Affairs Professionals Society (RAPS)

Dr. Ebeling & Assoc. GmbH: Your reliable partner in Healthcare!

Dr. Ebeling & Assoc. GmbH (E&A) is an established service provider in the healthcare sector, specialising in the areas of drug and biologics safety/pharmacovigilance, medical science and medical devices. With over 30 experts in our team, we bring creative, synergistic, extensive and long-standing knowledge about the pharmaceutical and medical technology industry to our consulting services. Our expertise enables us to offer customised and effective solutions that meet your individual strategies.

Our comprehensive areas of expertise cover the entire lifecycle of drugs, biologics and medical devices, including all related regulatory, medical and safety aspects. We work closely with your teams to ensure that your drugs and/or medical devices not only comply with regulatory requirements but also maintain the highest quality standards.

Whether you are looking to outsource your entire PVsystem or just individual projects, E&A is here to help. Our services include:

› Consultancy services: Our experts provide guidance in Medical Affairs and Medical Science, addressing targeted regulatory requirements.

› Signal Management and Continuous-Benefit Risk Assessment (CoBRA®): We proactively manage risks for drugs and medical devices, ensuring safety and efficacy.

› EudraVigilance-based Signal Management (EViSiMa®): Our state-of-the-art-procedure uses the large dataset contained in EudraVigilance for signal detection and/ or further evaluation of any potential risks.

› Thorough safety assessments and risk management: Our meticulous approach safeguards patient wellbeing.

Member of

› Pharmaco-/Materio-Vigilance and reporting of ICSRs and SUSARs: We handle product safety reporting using various E2B-databases.

› Compliance checks and Audits: Our rigorous checks maintain compliance integrity and inspection readiness.

Our experts are constantly undergoing further training to meet the ever-increasing prerequisites. Through regular audits and discussions our systems are put to the test and constantly developed further. The processes are supported by comprehensive quality management and represents not only high quality, but also compliance with regulatory and time requirements.

Our success is based on strong partnerships with the industry. We have been working closely with leading pharmaceutical associations such as Pharma Deutschland and BPI for over 20 years. Thanks to these long-standing partnerships, we are always up to date with the latest regulation developments in the industry and can offer you synergetic solutions.

Our customer base is as diverse as the pharmaceutical industry itself. We support small family-run companies with just a few products as well as global brands with a diverse portfolio and highest standards. From the development of a risk minimisation plan and the reporting of individual cases to the development of a complete outsourced PV-system, we always offer cost-effective solutions that are tailored to your individual needs and requirements.

We would be happy to provide you with a personalised offer as we are here to support you!

Name ›

HealthCapital – Cluster Healthcare Industries Berlin-Brandenburg

The Berlin-Brandenburg BioRegion … … a Leading Hub for Life Sciences

Address/P.O. Box ›

Postal Code/City › State › Contact Person

Fasanenstr. 85

10623 Berlin Berlin

Telephone

Email

Website

Social Media

Areas of Activity

Dr Kai Bindseil, Clustermanager HealthCapital Berlin-Brandenburg +49-30-46302-463 info@healthcapital.de www.healthcapital.de I #HealthCapitalBB

l Technology transfer between science and industry

l Initiation and support of networks

l Support for technology-oriented start-ups

l Funding support for innovative project concepts

l Providing and presenting regional life sciences information

l Building and coordinating of scientific and interdisciplinary networks

l Establishing contacts between experts from all disciplines

l Organisation of events and seminars, Public Relations work for the life sciences region

External

Collaborations

l Member of the Council of European Bioregions (CEBR)

l Member and contact point in Berlin for Enterprise Europe Network (EEN)

l Collaborations with European Life Science clusters and SMEs in several European projects and other activities

l Bio Deutschland

l Global Health Hub

The Berlin-Brandenburg region is one of the leading, international locations for life sciences. The area concentrates on clinical research via a dense and compact healthcare network, and boasts a state-of-the-art IT infrastructure. It is no coincidence that the region is Germany’s ‘health capital’ as it is home to both the German government, as well as the centre for healthcare industries.

The region’s distinction is anchored in its unique research and clinical landscape, as well as its ability to closely link the key players in the life sciences and healthcare. Biotechnology, in particular, is a strong driving force within the Berlin-Brandenburg healthcare industries cluster – HealthCapital – generating innovation and growth there and beyond. Through networking the pharmaceutical, diagnostics and medical technology sectors completely new fields of business are created. More than 300 biotechnology and 35 pharmaceutical companies are located in the German capital region. They include market leaders like Bayer, BERLIN-CHEMIE (Menarini), Daiichi Sankyo, Pfizer, Bausch + Lomb, Sanofi, and Takeda. Along with the sectors many small and mid-sized companies, they benefit from close cooperation, both with science and with more than 150 hospitals – above all, one of Europe´s largest university hospitals: Charité – Universitätsmedizin Berlin. Customers from research and industry have access to patient cohorts of urban and rural populations of about 180 ethnicities, covering all medical indications. The many technology parks and networks in the various branches of modern biotechnology create the excellent infrastructure and technological support that characterize the BerlinBrandenburg life sciences area. Focus of biotech activity within the region are biomedicine and diagnostics, therapeutics and regenerative medicine as well as industrial biotechnology.

… connected to the European Hotspots

Active cooperation in the networks of Europe’s BioRegions has played a central role in the internationalisation efforts in the region. The region is a member of the Council of European Bioregions (CEBR).

… offering Service and Support for Life Sciences in the Capital Region

The central contact and coordination office for all issues concerning life sciences in the German Capital Region is HealthCapital. At the interface of business, science and clinics, the HealthCapital cluster management drives networking and the technology transfer and supports companies interested in relocating to the region. Berlin Partner for Business and Technology and the Economic Development Agency Brandenburg (WFBB) are responsible for managing the cluster.

Meet us 2025 at

› RegMed Forum | February 27, Berlin, Germany

› BIO Europe Spring | March 17-19, Milan, Italy

› BIONNALE | May 14-15, Berlin, Germany

› BIO International Convention | June 16-19, Boston, MA, USA

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Areas of Activity › External › Collaborations

HOX Life Science GmbH

Wilhelm-Leuschner-Straße 68 Frankfurt am Main Hesse

Dr Marta Lee

+49-698-700-664-21 marta.lee@hox.de www.hox.de I I 60+ 2019

Human Relations & Business

Consulting; Life-Science Career Companions & Academy

| btS - Life Sciences Studierendeninitiative e.V. | DKFZ Heidelberg

Just as HOX Genes play a crucial role in embryonic development, at HOX Life Science we would like to make a vital contribution to the life science community. Since we ourselves are scientists with “first-hand experience” in the life sciences industry, we understand the language, needs, and requirements of our business partners and clients. Our motto is: “Scientists supporting Scientists”.

HOX for Companies

Staffing, Recruiting & Employer Branding

Our holistic Human Relation Services Program is tailored to the life science industry.

To support and lighten the workload on internal HR, recruitment and staffing can be outsourced in full or in part, depending on actual needs. We will support you with customized solutions so that you can concentrate on your day-to-day operations even during peak times or staff shortages and still get in contact with many highly educated and experienced life-science-experts and -specialists.

Candidates go through multiple steps in the candidate journey before they decide to apply to your company. We support you to improve the candidate experience along all touchpoints with your company as one part of our individually tailored employer branding strategy to position your company as an outstanding employer. With customized job ads and recruiting videos for social media and your webpage we attract and retain suitable new employees for the long term.

Support in Marketing and Sales

We at HOX Life Science firmly believe that companies in the life science industry in particular need contentdriven marketing concepts. This means that even when implementing the marketing mix, the focus should always be on the scientific content. Because after all, these are products that require a high level of explanation. And, very often, special compliance rules also need to be observed when advertising and selling life science products and pharmaceuticals.

According to our motto “Scientists supporting Scientists”, we offer marketing concepts tailored to the life science industry along with the corresponding operational tools and measures. In joint sessions, together we will develop the marketing strategy that meets the technical and scientific specifics of your product and develop from these the target-oriented marketing measures. We use intelligence to attract clients, not showmanship.

HOX for Experts

Job offers

At HOX, you may be certain that your CV will be understood and that you will be treated as an individual. Since we are scientists ourselves, we discuss your expertise at a professional level. We understand your goals and wishes, but also your “where it hurts”. By combining our own professional experience in the life science sector with comprehensive HR know-how, we can be a competent and, above all, honest partner in helping you achieve your professional goals. Due to our life science background, we have a large network of business partners ranging from:

› Pharma to Biotech

› Food to Chemistry

› Laboratory Equipment to Research Products

› Diagnostics to Medical Technology.

HOX Academy

Join our Online Courses and be ready for the life science industry.

› Business Administration

Learn more about the value chain of drug development, the importance of marketing and sales, and all the possible positions for Scientists in the Pharma and Biotech sector.

› Project Management

Master the tools of project management, get acquainted with Microsoft Project and become skilled at planning and managing projects with real life examples from the Pharma and Biotech industry.

Name

Address/P.O. Box

Postal Code/City

State

Contact Person

Telephone

iQ spaces Management GmbH

Neuer Wall 30 20354 Hamburg Hamburg

Vincent Wege, Jörg Hoffmann

+49-40-33468-3120

contact@iq-spaces.com

vw@iq-spaces.com

jh@iq-spaces.com

www.iq-spaces.com

Social Media

Number of Employees

Founded (year)

Areas of Activity

I >10 2019

iQ Spaces specializes in developing and renting high-tech laboratory, office, and research spaces tailored for the life sciences sector.

iQ spaces –

driving

innovation with flexible spaces

At iQ spaces, we understand the specialised needs of biotech and life science companies, thus we develop and let flexible laboratory, research, and office spaces that form the foundation for scientific discovery and breakthrough innovations.

Our facilities combine state-of-the-art infrastructure with modular layouts, providing the ideal environment for both established industry leaders and growing biotech firms.

Laboratory solutions – tailored to your growing demands

We take pride in offering more than just spaces – we deliver highly specialised environments that cater to the technical and regulatory requirements of life sciences firms. From GMP-compliant labs to modular research and production facilities, we offer solutions that enable your teams to work efficiently and scale rapidly.

Each space is equipped with modular wet and dry labs, modern office setups, and scalable production zones, ensuring your operations are always supported with the right infrastructure.

Whether you’re in pharmaceutical R&D, medical diagnostics, or biomanufacturing, our laboratory solutions are fully customisable to your specifications.

Our spaces:

› iQ space Potsdam, located in the heart of the Potsdam Science Park, offers cutting-edge research and office spaces tailored for high-demand users – seamlessly integrating complex laboratory needs with modern New Work concepts. Flexible layouts support lab, office, and documentation areas, while advanced building systems enhance energy efficiency and streamline workflows.

› iQ space Munich North, situated in the Munich Airport Business Park, offers customisable spaces for pro -

duction, logistics, research, and offices. It features modern infrastructure, efficient warehousing, and sustainable energy solutions. With optimal transport connections and nearby leisure facilities, it provides an attractive workplace for forward-thinking businesses.

Strategic locations in leading science and biotech hubs

iQ spaces operates in life sciences clusters across Germany, offering facilities in proximity to academic institutions, industry peers, and innovation ecosystems. Our locations are chosen to promote synergies between research, commercialisation, and talent acquisition. We eliminate the need for significant upfront capital investments by offering flexible leasing options, allowing companies to focus on what matters most: advancing science.

iQ spaces – empowering science

› Life-Science Focused: Tailored to meet GMP, GLP, and other regulatory standards.

› Flexible leasing: Expandable spaces that grow with your company’s needs.

› State-of-the-Art infrastructure: Equipped with modular lab setups, advanced HVAC, and energy-efficient systems.

› Strategic locations: Proximity to top biotech clusters, academic institutions, and talent pools.

› Sustainability: Facilities designed to meet the highest environmental standards, crucial for future-proofing innovation.

More about our lab and research spaces:

Name ›

Fördergesellschaft IZB –Innovations- und Gründerzentrum Biotechnologie mbH

Address/P.O. Box › Postal Code/City › State › Contact Persons › Telephone › Fax › Email › Website ›

Number of Employees › Founded (year) › Type of Labaratory ›

Areas of Activity ›

Number of Firmes › External › Collaborations

Am Klopferspitz 19

82152 Planegg/Martinsried

Bavaria Christian Gnam

+49-89-5527948-0

+49-89-5527948-29 info@izb-online.de www.izb-online.de 36 1995 S1

l Biotechnology l Life Sciences over 40 start-ups

l Collaborations with the scientific faculties on the Campus Martinsried l Munich Life Science Pitch Day with the High-Tech Gründerfonds Management GmbH l IZBrunch - Science meets Sciencs l Law Lab - law for biotech businesses

Hotspot for Life Sciences

The Innovation and Start-up Center for Biotechnology (IZB) with sites in Planegg-Martinsried and FreisingWeihenstephan near Munich is one of the leading biotechnology centres in Europe. The company Fördergesellschaft IZB mbH, founded in 1995, operates the IZB. The IZB hosts over 40 biotech companies with more than 700 employees across a 26,000 m² area. At the main site in Planegg-Martinsried, spanning 23,000 m², resident start-ups primarily focus on medical biotechnology. The IZB in Freising provides ideal conditions for founders in the life sciences sector.

Outstanding infrastructure

The IZB offers young companies a superior environment and infrastructure for realising their product and service ideas. Crucial for successful growth are S1 laboratories and office spaces that flexibly adapt to the companies‘ needs. Additionally, the IZB provides excellent infrastructure. At the Martinsried location, start-ups have access to modern conference rooms, a design hotel, the restaurants „The Bowl“ and „Seven and More“, as well as the Bio Kids kindergarten.

A strong network

Another vital success factor for IZB start-ups is the close proximity of both locations to cutting-edge research. On the Weihenstephan Campus, you’ll find the TUM school of Life Sciences of the Technical University of Munich, as well as the University of Applied Sciences Weihenstephan-Triesdorf. Adjacent to the IZB on the Martinsried/ Großhadern campus, you’ll find, among others, two Max Planck Institutes, faculties, and facilities of LMU, as well as the University Hospital of Munich-Großhadern. The close proximity of the scientific institutes around the Martinsried campus provides an enormous competitive advantage. Young scientists can benefit from incorporating scientific and research expertise into their own companies; short distances promote interaction and cooperation between biotech companies - in the face of globalisation, both factors are essential for successfully entering world markets.

The IZB fosters and supports this strong network through various measures: The Faculty Club offers an exceptional venue for founders and scientists to exchange ideas and know-how. With an array of event formats like the IZBrunch and the Munich Life Science Pitch Day, the IZB has established itself as a key meeting point in the industry, extending far beyond Munich.

IZB – in brief

› 26,000 m2 laboratory and office space for start-ups and growing companies

› Home for nearly 40 start-ups

› Business development support

› In-house estate management

› Center of an impressive research campus

› Access to an international network

› Flexible lab and office structures

› Close contacts with investment partners

› Joint location marketing

› Attractive, modern conference rooms, also for external booking

› IZB Residence CAMPUS AT HOME (42 Rooms)

› Faculty Club G2B

› Restaurants: SEVEN AND MORE and THE BOWL Food Lounge

› 2 day care centres (Bio Kids & Bio Kids 2)

Visit us: Get our Newsletter:

Name ›

Address/P.O. Box › Postal Code/City › State ›

Address/P.O. Box › Postal Code/City › Contact Person ›

Telephone › Email › Website › Social Media ›

Number of Employees › Founded (year) › Areas of Activity ›

External › Collaborations

Life Science Nord Management GmbH

Falkenried 88 20251 Hamburg Hamburg

NEW as of 12/2024: Steinhöft 5-7 20459 Hamburg

Jan Phillip Denkers (PR & Communications Manager) +49-40-593-62-61-23 denkers@lifesciencenord.de www.lifesciencenord.de I 20 2004

Cluster Management

| BIO Deutschland e. V.

| Council of BioRegions in Germany (AK-BioRegio)

| Council of European Bioregions (CEBR)

| Program “go-cluster”

| TransferAllianz e.V.

| Nordic Mentor Network for Entrepreneurship (NOME)

| MedTech Cluster Alliance D-A-CH

Together for Innovative Medicine

The Life Science Nord cluster in the federal states of Hamburg and Schleswig-Holstein embraces over 600 biotechnology, pharmaceutical, medical technology and digital health companies, clinics, and research institutes. More than 55,000 employees work in the industrial health economy.

Particular features of the cluster are the broad business base and the complete value chains from basic and applied research to clinical studies and the marketable end product. The outstanding, close cooperation between researchers, clinicians, and industrial partners in many fields is reflected in innovative products, projects, and technologies.

More than 290 Members, One Common Goal

The cluster management organisation Life Science Nord was set up by the Northern German federal states of Schleswig-Holstein and Hamburg to develop the cluster into a leading international life science network. The cluster agency Life Science Nord Management GmbH and the association Life Science Nord e.V. work as one together to achieve that goal.

More than 290 regional companies and institutions from the healthcare sector are active members of Life Science Nord. All members benefit from numerous competitive services and activities to promote regional networking, exchange experience and know-how, and jointly represent the life science sector of the two northernmost German federal states on a national and international level.

2021 Life Science Nord was awarded the GOLD label “Excel in Cluster Excellence” by the European Secretariat for Cluster Analysis (ESCA) for the third time in a row.

What Life Science Nord Offers

› Comprehensive support in initiating innovative projects, arranging contacts to experts, and providing know-how

› Fast and uncomplicated access to regional, national and EU funding programmes

› Admitting members to the network and helping them position themselves within the Life Science Nord cluster

› Extensive opportunities for collaboration within an international industry network

› Participation in leading international and national industry trade shows

› Providing data on business and technological capabilities in medical technology, biotechnology, and pharma in Northern Germany

› Providing the latest information on developments in business and science

› Organizing and hosting working groups, collaborative events, and networking activities

› Access to platforms on which the cluster players can exchange information and which support the dissemination of new developments in the cluster. This includes the online newsletter and the Life Science and online magazine, which can be read completely free of charge via the LSN website, as well as promoting cluster related news via social media.

Name ›

Address/P.O. Box ›

Postal Code/City › State ›

Contact Person › Telephone › Email › Website › Social Media ›

Number of Employees › Founded (year) › Areas of Activity ›

Lumis International GmbH

Giesebrechtstrasse 15 10629 Berlin Berlin Heike Schön

+49-30-235911-599 info@lumisinternational.com www.lumisinternational.com I

1-10

2013/2020

| Clinical Outsourcing | Vendor Oversight Management

| Quality Management as a Service | Regulatory Consultancy for Medicines | Regulatory Consulting for Medical Devices

| Legal and Data Representation

Lumis International GmbH provides consulting services to small and mid-sized medical device and biopharmaceutical companies when outsourcing their clinical activities.

We offer services in the following areas:

› Regulatory support medicines: preparing, organising, and follow-up of scientific advice meetings with national authorities and EMA. Applying for orphan drug designation with EMA and supporting the application as Small Medium Enterprise (SME)

› Regulatory support for Medical Devices: CE marking, Technical File preparation, Conformity Assessment, Audit preparation, Notified Body Selection

› Oversight Project Management: vendor selection and management, clinical trial oversight management, Implementation of Project Management tools

› Quality management as service: analysis and establishment of complete quality management systems to enhance our client inspection readiness, Vendor and site audits

Jointly with our customers, we develop tailored solutions to optimise their clinical product development programs. We collaborate with a network of experienced subject matter experts, cooperation partners and consultants for the best services in the different areas. Small to midsize pharmaceutical and medical device companies often face the challenges of limited human resources. Thus, outsourcing clinical trials is the common way to proceed with clinical development. Moreover, the survival of such companies is frequently dependent on successful, timely completion of one or two critical clinical trials at limited budgets. Thus, high efficiency in managing clinical vendors is crucial, while the safety of patients and the quality of clinical data must not be compromised.

Especially during first clinical investigations, it is not easy for companies to decide which activities to outsource and which to perform in-house. Thus, each activity should be evaluated in advance:

› for its strategic importance

› for the main reasons to outsource, e.g. cost savings, access to clinical and/or regulatory experience

› for related risks and benefits, e.g. increased complexity of project and oversight management, access to opinion leaders

Lumis’ experts support the development and implementation of effective risk-based management systems for sponsors to ensure efficient and active monitoring and evaluation of vendor performance. We apply Key Performance Indicators to oversee the progress of clinical investigations. Moreover, the integration of a shared governance model is vital for success, by guaranteeing that the sponsor and vendor share one vision and have common goals. We optimise the interaction between sponsor, CROs and vendors by mastering different corporate cultures and expectations, so that your company will smoothly advance your drug development. Our experts have been creating successful partnerships between sponsors and CROs/vendors for over 20 years.

Name › Address/P.O. Box › Postal Code/City › State

Contact Persons

Telephone

Fax

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity ›

Meissner Bolte Patentanwälte

Rechtsanwälte

Partnerschaft mbB

Widenmayerstr. 47

80538 Munich

P.O. Box 860624, 81633 Munich

Bavaria

Dr Lukas Bischoff, Dr Felix Letzelter

+49-89-2121860

+49-89-21218670

mail@mb.de www.meissnerbolte.com

I Q I

350 1908

Fields:

| Organic and Inorganic Chemistry

| Polymers

| Pharma

| Biotech

| Food and Agriculture

| Plant varieties

| Bioinformatics

| Artificial Intelligence

| Computer Implemented Inventions

| Medical technology

Legal Areas:

| IP Prosecution

| IP Litigation

| Patents

| Utility Models

| Supplementary Protection Certificates

| Plan Variety Protection

| Trademarks

| Designs

| Employee Invention Law

| Inspection Proceedings

| UPC

Services:

| IP Portfolio Management

| IP Search

| Freedom to Operate analyses

Developing new chemical products and medications is often a lengthy process involving very high costs. In order to ensure that the high investments ultimately pay off, most chemical and pharmaceutical companies rely on the monopoly granted by patents on end products.

Main areas of practice

Our qualified team of Patent Attorneys, specialised in chemistry and pharmaceuticals, routinely support multinational and medium-sized companies, start-ups, and scientific institutions in protecting the results of their research and development.

We are ready and able to advise on obtaining, enforcing, and defending protective rights in the chemical and pharmaceutical field. Areas in which we have proven expertise include the fields of: detergents, cosmetics, food and dietary supplements, textiles, tyres, alternative fuels, paints and coatings, adhesives, nanotechnology, polymers, construction chemicals, paper, packaging, classical active pharmaceutical ingredients, as well as pharmaceutical formulations and antibody drugs.

As the modern field of life sciences merges increasingly with the field of computer science to provide bioinformatics tools or artificial intelligences for solving biological problems, we offer an interdisciplinary team of computer- and life-scientists in order to best advise in this rapidly developing field of technology. We are here to assist you in the preparation of patent applications and support and accompany you on the road to a patent grant and to further represent and support you in opposition, nullity, and infringement proceedings. Expert opinions, FTO analyses, and due diligence examinations in the chemical and pharmaceutical sector are also part of our daily business. In the pharmaceutical sector, we also handle applications for supplementary protection certificates (SPC).

Our Patent Attorneys specialising in chemical, in biotech and pharmaceutical patents look forward to your contact at any time!

Meissner Bolte

Meissner Bolte is a fully integrated IP law firm providing legal services in all areas of intellectual property. Filing more than 2,000 patent applications per year, Meissner Bolte is one of the largest specialised IP boutique firms in Germany.

Boasting eleven offices throughout Germany and one office in the UK, our professionals combine close contact to clients with short lead times. With more than 60 patent attorneys and a total of 350 employees, Meissner Bolte handles patent portfolios of all sizes.

Our strong team of attorneys at law works in close cooperation with our patent attorneys to resolve all IP disputes, making use of the full know-how and technical expertise available. Our attorneys are currently handling over 50 cases before all major patent courts, including the novel Unified Patent Court (UPC), with our clients benefitting from detailed knowledge of both the proceedings and judges at these courts.

We further have an in-depth knowledge of German inspection proceedings, having successfully concluded dozens of cases to date.

Well-known “Of Counsel” support at Meissner Bolte:

› Rainer Engels, presiding judge BPatG, retired

› Dr Hans-Peter Felgenhauer, Member of the Board of Appeal, EPO, retired

Native speaking experts, including of English, Chinese, Korean and Japanese, provide valuable support to many of our international clients.

Industrial strengths:

› Specialist Chemistry/Pharmaceutical/Biotech Department

› Special department for handling computerimplemented inventions

Name ›

Osborne Clarke Rechtsanwälte Steuerberater Partnerschaft mbB

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone

Email › Website › Social Media › Number of Employees ›

Founded (year) › Areas of Activity ›

Innere Kanalstraße 15

50823 Cologne North Rhine-Westphalia

Dr Andrea Schmoll/Anja Jähnel

+49 221 5108 4260

+49 221 5108 4416

andrea.schmoll@osborneclarke.com

anja.jaehnel@osborneclarke.com www.osborneclarke.com

I I

In Germany: 552, including 68 partners and 106 trainees

Worldwide: 2,200 2001

| Banking and finance

| Commercial

| Competition, antitrust and trade

| Corporate

| Dispute resolution

| Employment and pensions

| Energy

| ESG – Environmental, Social and Governance

| Infrastructure services

| Intellectual property

| IT and data

| Public law

| Real estate

| Regulatory and compliance

| Tax

Osborne Clarke is an international legal practice with over 340 partners and more than 1300 lawyers in 26 locations, including 250+ lawyers in Berlin, Cologne, Hamburg, and Munich.

We give legal advice that is greater than the sum of its parts, combining legal expertise with sector and client understanding alongside insight into the global issues driving transformation.

Encouraging diversity and investing in our people’s wellbeing is important to us as we want everyone to be the best they can be and enjoy what they do, so that everyone benefits, including our clients. We’re here to help you tackle the challenges of today and tomorrow.

Our Life Sciences Practice

The Life Sciences sector is a key focus for Osborne Clarke. Our unique service offering stems from the intersection of legal expertise, a focus on the life sciences and healthcare sector, and our advisory experience in addressing the challenges and opportunities of digital transformation.

Our integrated team of experts understands the technical and regulatory issues of the life sciences and healthcare sector. With our global reach and knowledge, we assist clients in pharmaceuticals, biotechnology, and medical devices throughout the product life cycle. Everything we do benefits patients.

Confidently navigate the regulatory landscape, mitigate risks, and achieve objectives in the life sciences and healthcare sector

We offer comprehensive solutions through multidisciplinary groups supported by experienced transactional lawyers and life sciences specialists in regulatory, IP, antitrust, distribution, employment, and IT law. Our expertise spans digital health, medical technology, AI, and blockchain. This enables clients to navigate the complexities of digital transformation in healthcare, ensuring they stay ahead of technological advancements and regulatory changes.

Our highly regarded team of data protection experts advises on international data transfers and processing, cyber attacks, GDPR compliance, cloud migration in healthcare, integration, and use of the German telematics infrastructure, and the (planned) European Health Data Space. Our team also provides guidance on AI in healthcare, particularly AI Act and medical device regulation.

The Osborne Clarke IP team aligns with our sector approach and protects the patents and know-how of our life sciences clients. It offers the full range of IP legal services for the international market, particularly in licensing and commercialisation in life sciences.

Enabling strong growth in a highly regulated environment, our Life Sciences and Healthcare practice covers crucial regulatory matters, including competition law issues, enforceability of restrictive agreements, legality of pricing strategies, parallel trade, abuses of dominance, and “pay for delay” settlement agreements. We also defend clients in competition or market investigations, handle merger control notifications, and advise on state aid issues.

We offer extensive and integrated transaction and industry expertise in the life sciences sector, focusing on M&A transactions, financing rounds, global licensing, strategic partnerships, and joint ventures.

Our specialist international lawyers advise on all employment-related issues, including the future of work, workforce solutions, health & safety, immigration, employee tax, and incentives.

Finally, we help clients get their products to customers efficiently, cost-effectively, and compliantly. We select the right sales channels to seize market opportunities and leverage traditional logistics and new industry trends.

Name

Address/P.O. Box

Postal Code/City › State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Areas of Activity

restracon GmbH & Co. KG

Schroefelhofstrasse 66 81375 Munich Bavaria

Dr Claudia Reusch

+49-89-78576867 info@restracon.com www.restracon.com F I Q 6 2005

Professional recruitment and talent acquisition through systematic research and direct approach of highly qualified candidates for the life sciences industry in the areas of: | Medical technology | Laboratory diagnostics | Biotechnology | Pharma | Industrial technology | Medical services providers and payors

Competence and continuity

restracon is a highly specialized owner-managed recruitment agency dedicated to the life sciences industry. Since 2005 restracon systematically investigates target companies, identifies and directly approaches the most suitable candidates for the specific staffing needs of its customers nationwide.

restracon‘s expertise covers the whole range of the life sciences from the core sectors biotechnology, medical devices, laboratory diagnostics, pharmaceuticals, clinical research, chemicals and also extends into the fields of the neighbouring disciplines, e.g. environmental sciences and medicine. Within the healthcare industry, restracon has a strong focus on expert positions in research and development, clinical and regulatory affairs, quality and risk management, biostatistics and data management as well as administrative and medical leadership positions for medical services providers and payors.

The smart way to find the best candidates

The restracon team has profound market and technology knowledge, proprietary research tools and an extensive international network in science and industry which enable us to provide excellent advice and service to our customers. Our approach to each search assignment is finding the ideal candidate for the specific position.

We are passionate about offering a smart, customised, lean and transparent recruitment process by combining technology-driven strategies with face-to-face interactions and establishing long-term relationships with our customers and candidates based on mutual trust.

Weekly updates will keep you in the loop of the recruitment efforts delivered by restracon. Our way of billing does not link the fee to the annual salary of the position to be filled. Therefore you can be sure that we are definitely looking for the best candidate and not the most expensive one.

Your reliable partner in talent acquisition

Benefit from our vast industry expertise and market insights to gain the talent you need! You can rely on us that we will fulfil your expectations: We are happy to go the extra mile and find the needle in the haystack for you.

It is our firm belief that close personal interactions create strong relationships which are one of our biggest assets. The restracon team members are known for their discreet, honest and reliable manner and high service orientation. Please contact us directly via phone (+49 89 78576867) or e-mail (info@restracon.com) for finding out more about our tailor-made solutions and follow us on LinkedIn, Xing and Facebook.

Name ›

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Number of Employees ›

Founded (year) › Type of Laboratory › Areas of Activity ›

Rock Capital Group

Nördliche Münchner Straße 28, 82031 Grünwald

Bavaria

Andreas Wißmeier

+49-15116150106 wissmeier@rock-capital.de www.rock-capital.de 70 2004

S1/S2

Developer of biotech and life science spaces and hubs in the Munich area in the south of Germany. Construction and letting of S1/S2 laboratory spaces, lab offices and ready-to-use laboratory spaces.

Owner of the SKYGATE biotech hub at the Munich Airport Business Park in Hallbergmoos near the Munich Airport with over 40,000 sqm of space.

Developer of the followup biotech project HYBRID ONE in the north of Munich with over 30,000 sqm of space.

The Rock Capital Group is one of Germany’s leading project development companies in the residential and commercial property sector, founded by managing partners Peter G. Neumann and Christian Lealahabumrung. Thanks to the Rock Capital Group’s extensive experience in the development of residential and commercial space as well as urban neighborhoods, it is very active in the creation of new living, office, commercial, hotel and retail space in existing structures through creative concepts and planning. The company is currently developing around 1,000,000 sqm of office, commercial, residential, retail and hotel space including over 6,000 new residential units with a total investment volume of over 8 billion euros in the Munich and Frankfurt area.

Built for the future, available today

Rock Capital Group is the founder of the biotech and life science cluster SKYGATE at the Munich Airport Business Park in Hallbergmoos.

The Rock Capital Group develops, constructs and lets at the SKYGATE Campus in Hallbergmoos first-class, ultra-modern S1/S2 approved laboratory spaces and lab offices. It has already configured and built almost 20,000 sqm of state-of-the-art laboratory spaces and associated office spaces based on its tenants needs.

ROCK CAPITAL GROUP

Discover your new lab

A special feature of the Rock Capital Group is the letting of ready-to-use labs and lab offices. Equipped with all the necessary facilities, these laboratory spaces can be occupied and used immediately by future tenants, as all relevant equipment such as technical gases, digestors, laboratory furniture, demineralised water, air conditioning and ventilation are already available and ready for use. The laboratories can also be customised at any time according to the tenant’s wishes. Of course, new-work office spaces are reflecting today’s high grade standards of the Post-Covid area and are also available and can be rented additionally.

SKYGATE the new biotech highlight in the north of Munich

SKYGATE not only scores points with its highly specialised laboratory spaces. The campus offers a holistic concept for modern working environments. Flexible open-space office areas and socialising spots promote creative exchange and social interaction, while fully equipped meeting rooms including state-of-the-art conference technology enable professional collaborations. An in-house catering service takes care of one’s physical well-being. An integrated Radisson hotel with 212 rooms offers accommodation directly on site. The proximity to Europes largest and truly unique surfpark O2 SURFTOWN MUC rounds off the overall package and highlights the attractiveness of SKYGATE, as one can truly combine work and leisure.

SaxoCell - Living drugs made in Saxony

Address/P.O. Box

Contact Person

Number of Employees

Type of Laboratory

Areas of Activity

Relevant R&D Budget

SaxoCell e.V. Fetscherstraße 105 01307 Dresden

Saxony

Dr. Maren Henneken (TUD), Ilka Henze (IZI), Dr. Stefanie Binder (UL) +49-351-458-82014 info@saxocell.de www.saxocell.de

I > 100 2021

Cluster of academic and industrial partners

Cell and Gene Therapy

> €15 million

SaxoCell - Saxony’s precision therapy cluster - has set itself the goal of providing effective, safe and affordable cell and gene therapies to patients suffering from serious, partially untreatable diseases. We combine excellent basic and applied research expertise within Saxony with industrial resources and the know-how of other national and international partners to build a strong network for cell and gene therapy. Our core partners are the TU Dresden, the University Leipzig and their respective university hospitals, the Fraunhofer Institute for Cell Therapy and Immunology and the Chemnitz Hospital. SaxoCell is a winner of the nationwide Clusters4Future initiative of the BMBF and is funded with 15 million euros for the first implementation phase (2021-2024) and the next implementation phase is currently ongoing until end of 2027.

With its 7 innovative research projects on topics such as CAR-T and (CAR-)NK cell therapies, gene therapies based on designer recombinases and regenerative approaches, SaxoCell is positioned in a broad spectrum of therapy forms that are precisely tailored to the needs of patients. These innovative cell and gene therapies are developed and optimized in Saxony and are to be brought into automated production and ultimately into application with the help of our expertise and industrial partners via preclinical and clinical studies. In this way, the entire value chain will be mapped in Saxony. In the long term, we want to reduce the costs of such forms of therapy for patients and health insurance companies and strengthen Saxony as a business location.

As an innovative cluster, we are always interested in expanding our network, entering into discussions with new partners and developing project ideas together. We are open to all technologies and see interdisciplinary approaches as a means of advancing cell and gene therapy developments from Saxony in a focused and rapid manner. We pay particular attention to partners in the fields of automation and artificial intelligence. It is also possible to become part of SaxoCell by becoming a member of the SaxoCell e.V. association.

In addition to actual research and development, we also see ourselves as a support platform in the areas of research transfer, IP and innovation management. The employees from the hub team - SaxoCell’s cluster management - with their many years of experience are very well positioned here and are happy to provide advice. We support start-ups with a focus on cell and gene therapy on their way to becoming spin-offs and try to get companies interested in setting up or opening a branch in Saxony. Regional value creation in particular is an important concern in the cluster.

External collaborations

› Bausch und Ströbel Werk Sachsen GmbH und Co. KG

› Biotechnological-Biomedical Center (BBZ)

› BioThrust GmbH

› Cancilico GmbH

› Cell.Copedia GmbH

› Cytiva Germany GmbH

› Deutsches Rotes Kreuz Blutspendedienst Baden-Württemberg-Hessen gGmbH

› DKMS Life Science Lab gGmbH

› DKMS Stem Cell Bank gGmbH

› ecSeq Bioinformatics GmbH

› Haema AG

› Helmholtz Rossendorf

› Insightformer UG

› KyooBe Tech GmbH

› Lonza Group AG

› MDTB Cells GmbH

› Miltenyi Biotec B.V. & Co. KG

› ProBioGen AG

› QuoData GmbH

› ScaleReady

› Seamless Therapeutics GmbH

› T-Curx GmbH

› Tcell Tolerance GmbH

› TheryCell GmbH

› Universitätsklinikum Würzburg

› Wacker Chemie AG

Name ›

Address/P.O. Box › Postal Code/City

State

Contact Person

Telephone

Email

Website

Social Media

Number of Employees

Founded (year)

Type of Laboratory

Areas of Activity

Request for › Further Collaborations

Technologiepark Weinberg Campus

Heinrich-Damerow-Straße 3

06120 Halle (Saale) Saxony-Anhalt

Dr Ulf-Marten Schmieder

+49 (0) 345 13 14 15-00 service@weinberg-campus.de weinberg-campus.de

27 1993 S1, S2, S3

Life Sciences, Materials Sciences, Green Economy, Bioeconomy, IT

Startups

The Weinberg Campus Technology Park is a leading hub for innovation in the biomedical, life sciences, and materials science sectors in the region. Covering 134 hectares, it is the largest technology park in Central Germany. Approximately 300 startups have thrived here, benefiting from excellent conditions, and over 100 companies and institutes, employing around 6,000 people, are based on the campus. Biochemists, biotechnologists, physicians, materials scientists, pharmacists, agronomists, and nutritionists from major non-university research institutions – including the Fraunhofer Institutes, Helmholtz Centre, Leibniz Institutes, Max Planck Institute, and Martin Luther University Halle-Wittenberg – work closely together. Scientific ideas are transformed into innovations, often leading to spin-off companies.

More space for startups and growth

Ongoing construction and investment projects are underway at the Weinberg Campus to provide even more labs and workspaces for startups and foster further growth. As part of its continuous expansion, in 2024, the campus became part of the Digital Hub Initiative launched by the Federal Ministry for Economic Affairs and Climate Action, making it Saxony-Anhalt’s first de:hub in Germany, with a special focus on Life Sciences and Bioeconomy.

The significance of the Weinberg Campus continues to grow, supported by these new investments and the continuous expansion of research and production facilities.

Startup elevator Saxony-Anhalt

The Startup Elevator Saxony-Anhalt is a distinctive support program by the Weinberg Campus Technology Park that is designed to elevate startups in the life sciences and bioeconomy sectors to the next level. Startups benefit from personalized support, guidance from the idea stage to market entry, and investment readiness. Through comprehensive analysis, startup coaches develop tailored plans to help participants succeed.

Halle and Magdeburg join forces

The Weinberg Campus collaborates with the STIMULATE Research Campus in Magdeburg to offer Startup Elevator participants valuable industry contacts and additional opportunities. Startups in the pre-seed or seed phase can apply for the 9-month Business Accelerator (September to May) and/or the 12-week Investment Bootcamp (February to April) offered by Startup Elevator. The program is funded by the state of Saxony-Anhalt and co-financed by the European Union.

Selection of resident biotech companies

› BioNTech Delivery Technologies GmbH

› BioSolutions Halle GmbH

› EastCyte Bioscience GmbH

› HMC – Heppe Medical Chitosan GmbH

› Icon Genetics GmbH

› IdentMe GmbH

› matrihealth GmbH

› Navigo Proteins GmbH

› NH DyeAGNOSTICS GmbH

› NOMAD Bioscience GmbH

› PerioTrap Pharmaceuticals GmbH

› Radius Biotech Holding GmbH

› RGCC Central Europe GmbH

› SerYmun GmbH

› Simris Biologics GmbH

› Wacker Biotech GmbH

Name ›

VON ROHR Patentanwälte Partnerschaft mbB

Address/P.O. Box › Postal Code/City › State › Contact Person

Telephone

Email

Website

Social Media

Number of Employees › Founded (year)

Areas of Activity

Rüttenscheider Str. 62

45130 Essen

North Rhine-Westphalia

Marike Rommeswinkel

+49-201-890 65 890 rommeswinkel@vonrohr.de www.vonrohr.de

I 45 2012 | IP Prosecution | IP Strategy | IP Searches | Litigation | Due Diligence | Portfolio Management | IP Enforcement | IP Defense

Turning technology into claims

If your company is developing an innovative product, think about the right IP strategy now! An appropriate IP strategy is the basis for maintaining the economic advantages of a technical innovation over competitors over a longer period of time. IP rights effectively protect against imitation by competitors. Start-ups often need their own intellectual property to enter the market as the capital injections from investors needed for market entry are only possible if the products and developments are protected from imitators. Regardless of your current status, it is always our passion to find an IP strategy that fits best for your company and to turn your technology into claims.

Our clients

As a mid-sized law firm with strong personal client support our clients are predominantly innovative mediumsized companies located in Germany and abroad. Nevertheless, we also advise international corporations, start-ups, universities and research organisations as well as individual inventors and further act as a partner of foreign law firms in patent prosecution and litigation. We attach great importance to providing our clients with personalised advice – tailored to their needs – in order to put their IP protection on a solid and sustainable basis.

Our technical expertise

Our life science and chemistry department is with six lawyers holding degrees in biology, biotechnology and chemistry at your disposal. Through our patent attorney and university careers, we provide expertise in the fields of pharmaceuticals, cosmetics and hygiene products, antibodies, organic and inorganic chemistry, gene therapy and cell biology, food technology, genetic engineering, industrial and grey biotechnology, process engineering, bioanalytical and bioorganic chemistry as well as biophysics. VON ROHR is a member of BIO Deutschland e.V. Furthermore, Dr. Ingo K. Strehlke is a member of the Committee for Biotechnology of the Chartered Institute of German Patent Attorneys.

If your innovation is interdisciplinary, we will work together with our colleagues from our mechanics, physics and electrical engineering departments. Furthermore, our law firm provides extensive knowledge in the protection of AI-based inventions.

Our interdisciplinary orientation makes us a strong partner for companies operating in all scientific and technical field.

Our legal support

Our comprehensive technical background enables us to gain a deep understanding of your developments. In our legal support, we focus on the development of a sustainable IP strategy, which includes the development of your own IP portfolio and freedom to operate as well as the monitoring of competitors’ IP activities. We also support in the enforcement and defence of IP rights. In course of this, we draft and prosecute patent, trademark and design applications before the EPO, the German Patent and Trademark Office and the EUIPO, conduct prior art and FTO searches and represent in opposition, nullity and cancellation proceedings before the respective authorities and courts. We also act in patent, trademark and design disputes before the ordinary courts of law. If you are facing an IP-related legal dispute, we have an extensive network of IP lawyers with whom we have worked successfully for many years.

Contact us

Please do not hesitate to contact us via phone or email for an initial consultation, which is of course free of charge.

Name

Address/P.O. Box ›

Postal Code/City

State

Contact Person

Telephone

Email

Social Media

Number of Employees

Founded (year)

Areas of Activity

Saxony Trade & Invest Corp.Wirtschaftsförderung Sachsen GmbH (WFS)

Bertolt-Brecht-Allee 22 01309 Dresden

Saxony

Andreas Lippert

+49-351-2138-0 info@wfs.saxony.de www.business-saxony.com

60 1991

| Support for life sciences companies, esp. SME and start-ups

| Support and guidance of domestic and foreign investors from the initial idea all the way to the implementation of their business setup or expansion project

| Support technology transfer between science, industry and networks

| Creation of cross-cluster-work between various branches

| Guidance of business start-ups through their founding process and even beyond

| Creation of networks between Saxon life sciences companies and national/ international companies, investors and relevant stakeholders

| Organisation of national and international fair/exhibition/ conference participation

| Organisation of entrepreneurial travel

| Analysis of life sciences in Saxony regarding location data and pooling information

| Provision of a company database

| Marketing & PR for the life sciences location of Saxony

Life Sciences „made in Saxony“

Saxony is one of the most exciting life sciences regions in Germany and offers companies the best location conditions. Here they encounter an ideal ecosystem for innovation and growth, which has been created with the support of the Free State’s Biotechnology Initiative and will celebrate 25 years of the biotechnology offensive next year. The tremendous dynamic in the numerous research centres, the high degree of networking between research and companies, the cross-sectoral cooperation in many industries and the custom-fit support provided by industry networks such as biosaxony have played a major role in shaping this positive development. Life sciences “made in Saxony” have become an international quality attribute.

With companies from the healthcare industry, biotechnology, medical technology, the pharmaceutical industry as well as pharmaceutical and medical logistics, Saxony unites a broad spectrum of high-performance players and covers the entire value chain: from research and development via production and marketing to logistics and service. The agile environment not only offers innovative start-ups and hidden champions optimal conditions. Many international companies also choose the location.

Advantages of cross-sectoral cooperation

In this context, many companies particularly appreciate the potential of interdisciplinary and cross-sectoral cooperation. Due to the traditionally proficient industry competence in the fields of micro- and nanoelectronics, automation and robotics, a growing competence for smart medical applications is developing in Saxony - be it in the field of telemedicine, point-of-care diagnostics or computer-assisted surgery. Saxony Trade & Invest Corp. provides targeted support with suitable crosscluster activities.

Saxony has also earned an excellent national and international reputation in research in the life sciences sector and is now a national centre of excellence in the fields of cell and gene therapy as well as regenerative medicine. The Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig and the Centre for Regenerative Therapies Dresden (CRTD), a unique cluster of excellence in Europe, are representative of this. In addition, the Dresden site of the National Centre for Tumour Diseases (NCT) is one of the main pillars of German cancer research.

The nukliD Radiopharmacy Cluster Dresden is developing into a leading radiopharmacy centre in Europe. The growth nucleus for this was the former GDR core research centre, now the Helmholtz-Zentrum DresdenRossendorf (HZDR), which met the demand for radiopharmaceutical preparations even before reunification. Numerous companies have now settled around the HZDR, such as Isotope Technologies Dresden GmbH, ROTOP Pharmaka GmbH, ABX advanced biochemical compounds GmbH and CUP-Laboratorien Dr. Freitag.

Our Services

› Support for domestic and foreign investors from the idea to the realisation of the settlement or expansion project

› Consulting for start-up companies in the founding process and beyond

› Contact to regional and supra-regional industry networks as well as research institutions and universities

› International marketing of the industry’s know-how

› Support and expansion of the export activities of Saxon entrepreneurs, e.g. within the framework of business trips and by organising trade fair participations (e.g. at Arab Health, Medica and PharmedHealthcare-Vietnam)

› Promotion and support of cross-sectoral cooperation and technology transfer (e.g. in project workshops and the annual Life Sciences Forum).

© SMWA/Kristin Schmidt

© SMWA/Kristin Schmidt

Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Areas of Activity ›

Wuesthoff & Wuesthoff Patentanwälte PartG mbB

Schweigerstrasse 2 81541 Munich

Bavaria

Dr Hendrik Wichmann +49-89-621-800-0 wichmann@wuesthoff.de www.wuesthoff.de I 120 1927 | Drafting IP rights | IP prosecution | Challenging IP rights | Defending IP rights | Litigation | IP strategy | Portfolio Management | Plant variety rights Name ›

You invent

Intellectual Property (IP), especially patents, trademarks, and designs, is usually the most valuable asset of companies in the biotechnology and pharmaceutical industry. For start-ups, IP rights are often the decisive factor in the next round of financing; for large companies, the IP-pipeline guarantees success in the longterm future; and for technology transfer centres, IP is the essential basis for the successful commercialisation of an innovation. Inventions in life sciences often have the potential to change the market or even open up a new market segment. At the same time, inventors may be confronted with challenges such as how to best protect early developments in a highly competitive field or particular exceptions from patentability.

We protect

Our Life Sciences team is committed to understanding your invention with all its implications and applications, transforming it into a solid platform for your business, and accompaning you throughout the entire commercialisation process. We support you against your competitors and fight for the best possible outcome with passion. The client’s success is our success.

Our background

Our team consists of scientists holding PhDs in the fields of biochemistry, chemistry, and biology. We are particularly happy that each of our patent attorneys completed his/her scientific training in a different life sciences specialisation, including antibody therapeutics, cell biology, DNA repair and organic/inorganic chemistry. In addition to our scientific expertise, we are legally certified as German and/or European Patent Attorneys with many years of experience. This allows us to offer you the best suited expert for your invention, or, if applicable, an efficient and goal-oriented team of experts for your case.

Our activities

Our activities range from evaluating invention reports, drafting, and prosecuting patent applications before the EPO and the German Patent and Trademark Office to nullity and infringement proceedings before German courts. Of course, we also provide support regarding FreedomTo-Operate Analyses (FTO) and Supplementary Protection Certificates (SPCs). Our clients include universities and highly recognised research institutes (tech transfer offices), start-ups, SMEs, and global players.

Contact us

We are happy to support you with our proven expertise and experience in all phases of the development of your products or services. Just reach out to us for a non-binding initial consultation with one of our experts.

German Biotech Companies

2cureX GmbH, Hamburg

300MICRONS GmbH, Karlsruhe

350 PPM Biotech GmbH, Hamburg

3a-diagnostics GmbH, Frickenhausen

3B Pharmaceuticals GmbH, Berlin

4 Animals AlsterScience GmbH, Hamburg

4base lab AG, Reutlingen

4HF Biotec GmbH, Freiburg

4SC AG, Martinsried

4TEEN4 Pharmaceuticals GmbH, Hennigsdorf

A

Aachen Proteineers GmbH, Baesweiler

Aamuthera Biotech GmbH, Würzburg

AATec Medical GmbH, Hohenbrunn

AaviGen GmbH, Heidelberg

AB Diagnostic Systems GmbH, Berlin

AB Enzymes GmbH, Darmstadt

Abalos Therapeutics GmbH, Düsseldorf

Abcalis GmbH, Braunschweig

ABclonal Germany GmbH, Düsseldorf

ABiTEP GmbH, Berlin

ACA CELL BIOTECH GmbH, Heidelberg

Acaryon GmbH, Berlin

acCELLerate GmbH, Hamburg

Acousia Therapeutics GmbH, Tübingen acphis GmbH & Co. KG, Halstenbek

Across Barriers GmbH, Saarbrücken

ActiTrexx GmbH, Mainz

Actome GmbH, Freiburg

Acus Laboratories GmbH, Düren adivo GmbH, Martinsried AdrenoMed AG, Hennigsdorf

advanceCOR GmbH, Martinsried

AdVita Lifescience GmbH, Gundelfingen

AESKU.DIAGNOSTICS, Wendelsheim

Aeterna Zentaris GmbH, Frankfurt a. Main Affimed GmbH, Mannheim

AGC Biologics GmbH, Heidelberg Agrobiogen GmbH, Hilgertshausen-Tandern AgroProtect GmbH, Geilenkirchen

AiCuris Anti-infective Cures AG, Wuppertal aidCURE AG, Frankfurt

Aignostics GmbH, Berlin aimed analytics, Bonn Alacris Theranostics GmbH, Berlin Albutec GmbH, Rostock Algenium GmbH, Bielefeld

Algiax Pharmaceuticals GmbH, Erkrath Allecra Therapeutics GmbH, Freiburg

Allogenetics GmbH, Hannover

Alpspitz Bioscience GmbH, Gattendorf altona Diagnostics GmbH, Hamburg

Alvotech Germany GmbH, Jülich

Alvotech Hannover GmbH, Hannover

alytas therapeutics GmbH, Jena

Ambiatec Biosolutions GmbH, Bönen

AMGEN GmbH, München

Amgen Research (Munich) GmbH, München

AMODIA Bioservice GmbH, Braunschweig

AmplexDiagnostics GmbH, Gars Bahnhof

AmpliVak Immunotherapy GmbH, Berlin

Amptec GmbH, Hamburg

AMSilk GmbH, Neuried

AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG, Potsdam

Anavo Therapeutics, Heidelberg

Anchor Diagnostics GmbH, Hamburg

ANiMOX GmbH, Berlin

Aokin AG, Berlin

Apogenix GmbH, Heidelberg

Aptamimetics GmbH, Stegen

Aptarion biotech AG, Berlin

Aquarray GmbH, Eggenstein-Leopoldshafen

Arcensus GmbH, Rostock

Ariceum Therapeutics GmbH, Berlin arrows biomedical Deutschland GmbH, Münster

ARTCLINE GmbH, Rostock

Artemiflow GmbH, Potsdam

ARTES Biotechnology GmbH, Langenfeld

ASA Spezialenzyme GmbH, Wolfenbüttel

ASC Oncology GmbH, Berllin

Ascend Gene and Cell Therapies GmbH, Planegg-Martinsried

Ascendis Pharma GmbH, Heidelberg

ASKA Biotech GmbH, Hennigsdorf

Assay.Works GmbH, Regensburg

Astaxa GmbH, Ritschenhausen

Astra Biotech GmbH, Berlin

ATG:biosynthetics GmbH, Merzhausen

Athenata GmbH, Wuppertal

ATLAS Biolabs GmbH, Berlin

Atriva Therapeutics GmbH, Tübingen

ATTO-LAB GmbH, Lübeck

Attomol GmbH, Bronkow, OT Lipten attyloid GmbH, Düsseldorf

Aucteq Biosystems GmbH, Mannheim

Auregen BioTherapeutics GmbH, Reutlingen

Auto Tissue Berlin GmbH, Berlin

Ava Lifescience GmbH, Denzlingen

AvenCell Europe GmbH, Dresden

AVENTRA Gesellschaft für biologische Diagnostik mbH, Osnabrück

Avocet Bio GmbH, Göttingen

Axolabs GmbH, Kulmbach axxelera UG, Karlsruhe

B

b.fab GmbH, Köln

B4 PharmaTech GmbH, Berlin

Badische Peptide & Proteine GmbH, Mannheim baseclick GmbH, Neuried

BASF Metabolome Solutions GmbH, Berlin

BAST GmbH, Heidelberg

Bavarian Nordic GmbH, Martinsried

BBT Biotech GmbH, Baesweiler

Belyntic GmbH, Berlin beniag GmbH, Jülich

Berlin Cures GmbH, Berlin betaSENSE GmbH, Münster beworm GbR, Garching

Bex-Biotec GmbH & Co. KG, Bönen

Biaffin GmbH & Co KG, Kassel

BianoGMP GmbH, 07546

BianoScience GmbH (seit 2024: XNApharma GmbH), Gera

BIBITEC GmbH & Co. KG, Bielefeld

Bicoll GmbH, Planegg/Martinsried

Bind-X GmbH, Martinsried

BINOMED GmbH, Ulm

Bio-Protect GmbH, Konstanz

bio.logis digital health GmbH, Frankfurt

BioAgilytix Europe GmbH, Hamburg

Bioanalytics Gatersleben UG, Gatersleben

BioCheck GmbH, Münster

BioControl Jena GmbH, Jena

BioCopy Analytix GmbH, Frankfurt am Main

BioCopy GmbH, Emmendingen

BIOCYC Gesellschaft für Biotechnologie und Recyclingverfahren

mbH & Co. Entwicklungs KG, Potsdam-Golm

BioDataAnalysis GmbH, München

BioEcho Life Sciences GmbH, Köln

bioeq GmbH, Holzkirchen

Biofidus AG, Bielefeld

Biofrontera AG, Leverkusen

BioGenes GmbH, Berlin

BioKryo GmbH, Saarbrücken

Biolog Life Science Institute GmbH & Co. KG, Bremen

BioMed X GmbH, Heidelberg

Biomedro – Biomedizinische Forschung & Entwicklung Rostock GmbH, Bad Doberan

BionFarming GmbH, Hennigsdorf

BioNTech Cell & Gene Therapies GmbH, Mainz

BioNTech Delivery Technologies GmbH, Halle

BioNTech Diagnostics GmbH, Mainz

BioNTech GmbH, Martinsried

BioNTech Innovative Manufacturing Services GmbH, Idar-Oberstein

BioNTech Manufacturing GmbH, Mainz

BioNTech Manufacturing Marburg GmbH, Marburg

Biontex Laboratories GmbH, München

BioNukleo GmbH, Berlin

BIOPHARM GmbH, Eppelheim

Biophotonics Diagnostics GmbH, Jena

BioPlanta GmbH, Grimma

BIOPRACT GmbH, Berlin

BioSolveIT GmbH, Sankt Augustin

BioSpring - Gesellschaft für Biotechnologie mbH, Frankfurt a. Main

Biosynth GmbH, Berlin

biotechrabbit GmbH, Berlin

BioTeSys GmbH, Esslingen

BioTeZ Berlin-Buch GmbH, Berlin

BioThrust GmbH, Aachen

biotx.ai GmbH, Potsdam

Biotype GmbH, Dresden

BioVariance GmbH, Tirschenreuth

BIOVOX, Darmstadt

Bioweg UG, Quakenbrück

Bioworx, Berlin bitop AG, Dortmund

Black Drop Biodrucker GmbH, Aachen

Blue Biolabs GmbH, Berlin

BlueBioTech GmbH, Büsum

BlueLab Wasseranalysesysteme GmbH, Tübingen

Bluu Seafood GmbH, Hamburg

Boehringer Ingelheim Therapeutics GmbH, Ochsenhausen

Bosque Foods GmbH, Berlin

botiss biomaterials GmbH, Zossen

BRAIN Biotech AG, Zwingenberg

BrainRepair UG, Bochum

Brandenburg Antiinfektiva GmbH , Borstel

Breakpoint Therapeutics GmbH, Hamburg

BromMarin GmbH, Freiberg

BSL BIOSERVICE Scientific Laboratories Munich GmbH, Planegg

BSV Bioscience GmbH, Baesweiler

Byonoy GmbH, Hamburg

C

c-LEcta GmbH, Leipzig

cAHRmeleon Bioscience GmbH, Heidelberg CalTIC GmbH, Dortmund

Cambrex IEP GmbH, Wiesbaden

Cambrium GmbH, Berlin Camm Solutions GmbH, Überlingen candidum GmbH, Stuttgart Captain T Cell GmbH, Schönefeld CarboCode Germany GmbH, Konstanz Cardior Pharmaceuticals GmbH, Hannover CARTemis Therapeutics GmbH, Berlin

CASCAT GmbH, Straubing

Catalent Düsseldorf GmbH, Langenfeld

CatalYm GmbH, Martinsried CCRP Therapeutics GmbH, Berlin CeCaVa GmbH, Tübingen

CeGaT GmbH, Tübingen

Cell.Copedia GmbH, Leipzig cellasys know-how UG, Kronburg Cellbricks GmbH, Berlin CellDEG GmbH, Berlin Cellendes GmbH, Reutlingen

Cellerna Bioscience GmbH, Baesweiler

CELLphenomics GmbH, Berlin

CellServe GmbH, Berlin Cellsystems GmbH, Troisdorf

Celltec Systems GmbH, Lübeck

CellTrend GmbH, Luckenwalde

Cellzome GmbH, Heidelberg

Celonic Deutschland GmbH & Co. KG, Heidelberg Cenata GmbH, Tübingen

Centogene AG, Rostock

Cevec Pharmaceuticals GmbH, Köln

Charles River Laboratories Germany GmbH, Erkrath CheckImmune GmbH, Berlin Chembiotech - DNA Technologies, Materials and Reagents, Münster Cherry Biolabs GmbH, Winterhausen Chimera Biotec GmbH, Dortmund Chr. Hansen HMO GmbH, Rheinbreitbach Chromatec GmbH, Greifswald ChromoTek GmbH, Martinsried Cilian AG, Münster Cinference GmbH, Berlin

CLS Cell Lines Service GmbH, Eppelheim CMR CureDiab Metabolic Research GmbH, Düsseldorf CO.DON GmbH, Leipzig CO2BioClean GmbH, Kronberg Colipi Biotech, Hamburg Complement Therapeutics GmbH, München Computomics GmbH, Tübingen Conaris Research Institute AG, Kiel CONGEN Biotechnologie GmbH, Berlin CORAT Therapeutics GmbH, Braunschweig corlife oHG, Hannover

CPTx GmbH, Martinsried Creative Therapeutics GmbH, Wuppertal Crelux GmbH, Martinsried CrystalsFirst GmbH, Marburg Cube Biotech GmbH, Monheim Cultimate Foods UG, Berlin

CureVac AG, Tübingen

Curexsys GmbH, Göttingen

Cygenia GmbH, Aachen

Cysal GmbH, Münster

Cytecs GmbH, Münster

cytena GmbH, Freiburg

Cytolytics GbR, Tübingen

CytoPharma GmbH, Darmstadt

Cytophorics GbR, München

D

Davids Biotechnologie GmbH, Regensburg

Deep LS GmbH, Limburg denovoMATRIX GmbH, Dresden Deoxy GmbH, München

Dermagnostix GmbH, Freiburg

Detechgene GmbH, Köln

Dewpoint Therapeutics GmbH, Dresden Diarect GmbH, Freiburg

Digital Diagnostics AG, Mainz

DISCO Pharmaceuticals GmbH, Köln

Discovery Life Sciences Biomarker GmbH, Kassel

Dispendix GmbH, Stuttgart

DMG Deutsche Malaria GmbH , Hamburg DNTOX GmbH, Düsseldorf

Doderm GmbH, Koblenz

Dr. Rölleke - Labor für Genetische Analytik GmbH, Potsdam

DyNAbind GmbH, Dresden

Dynamic Biosensors GmbH, München Dynamic42 GmbH, Jena Dynavax GmbH, Düsseldorf

Ee~nema GmbH, Schwentinental

EastCyte Biosciences GmbH, Halle ecolocked GmbH, Berlin

ecSeq Bioinformatics GmbH, Leipzig

Eisbach Bio GmbH, Martinsried Electrochaea GmbH, Planegg eleva GmbH, Freiburg

Ella Biotech – Gesellschaft für angewandte Biotechnologie mbH, Fürstenfeldbruck

ellennbe GmbH, Bad Heilbrunn

EMC microcollections GmbH, Tübingen EMP Genetech, Ingolstadt

EnFin GmbH, Heidelberg

Enzymaster Deutschland GmbH, Hilden Enzymicals AG, Greifswald

Epiblok Therapeutics GmbH, Berlin

Epigenomics AG, Berlin

EpiLogic GmbH, Agrarbiologische Forschung und Beratung, Freising

Epimune GmbH, Berlin

EPITOPIC GmbH, Leipzig

Esencia Foods UG, Berlin

Eternygen GmbH, Berlin ethris GmbH, Planegg

Eupheria Biotech GmbH, Dresden

Eurofins BioPharma Product Testing Munich GmbH, Planegg

Eurofins GeneScan GmbH, Freiburg

Eurofins Genomics Europe Pharma and Diagnostics

Products & Services Sanger/PCR GmbH, Konstanz

Eurofins Genomics Germany GmbH, Ebersberg

Eurofins LifeCodexx GmbH, Planegg

EVANIUM Healthcare GmbH, Regensburg eversyn, Magdeburg

Evotec, Köln

Evotec (München) GmbH, Neuried

Evotec International GmbH, Göttingen

Evotec SE, Hamburg

evoxx technologies GmbH, Monheim am Rhein

EW Biotech GmbH, Leuna

Exact Sciences Proteomics GmbH, Planegg

Exazyme GmbH, Berlin

Exciva GmbH, Heidelberg

Eximmium Biotechnologies GmbH, München

Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbH, Berlin

F

Feral GmbH, Berlin

Formo Bio GmbH, Berlin

Formycon AG, Martinsried

Formycon Project 203 GmbH, Martinsried

FRIZ Biochem GmbH, Neuried

FundaMental Pharma GmbH, Heidelberg

Fusix Biotech GmbH, München

FyoniBio GmbH, Berlin

G

GA Generic Assays GmbH, Dahlewitz

GALAB Technologies GmbH, Hamburg

Gen-H Genetic Engineering Heidelberg GmbH, Heidelberg

GEN-IAL GmbH, Troisdorf

GenArc (Genome Architecture) GmbH, Dresden

Genaxxon bioscience GmbH, Ulm

GenCC GmbH & Co. KG, Heidelberg

Genedata Bioinformatik GmbH, München

Generatio GmbH - Center for Animal Genetics, Tübingen

GeneSurge GmbH, München

Genetek Biopharma GmbH, Berlin

Genevention GmbH, Göttingen

GENEWIZ Germany GmbH, Leipzig

geneXplain GmbH, Wolfenbüttel

Genome Biologics, Frankfurt

Genovac GmbH, Freiburg

GenXPro GmbH, Frankfurt am Main

GFE Blut mbH, Frankfurt a. Main

Global Bioenergies GmbH, Leuna

Global Sustainable Transformation GST GmbH, Dachau

Glycotope GmbH, Berlin

GlycoUniverse GmbH & Co.KGaA, Potsdam

glyXera GmbH, Magdeburg

GOENOMICS GmbH, Göttingen

Gold Standard Diagnostics Kassel GmbH, Kassel GQ Bio Therapeutics GmbH, Hamburg

Green Elephant Biotech GmbH, Gießen

GVG Diagnostics GmbH, Leipzig

H

Hain Lifescience GmbH, Nehren

HD Therapeutics GmbH, Ketsch

Heidelberg Biolabs GmbH, Heidelberg

Heidelberg Epignostix GmbH, Heidelberg

Heidelberg ImmunoTherapeutics GmbH, Heidelberg

Heidelberg Pharma AG, Ladenburg

Heidelberg Pharma Research GmbH, Ladenburg

HepaRegeniX GmbH, Tübingen

Heppe Medical Chitosan GmbH, Halle

highQu GmbH, Kraichtal

HMNC Brain Health, München

HP Health Solutions Germany GmbH, Martinsried

HS Diagnomics GmbH, Berlin

Human Gesellschaft für Biochemica und Diagnostica mbH, Wiesbaden

Human Tissue and Cell Research-Services (HTCR) GmbH, Planegg/Martinsried humatrix AG, Pfungstadt

Hummingbird Diagnostics GmbH, Heidelberg Hygiena Diagnostics GmbH, Potsdam HYpharm GmbH, Bernried

IIBA Lifesciences GmbH, Göttingen

ibidi GmbH, Gräfelfing IBT GmbH, Ertingen IcanoMAB GmbH, Polling ICHORtec GmbH, Düren

Icon Genetics GmbH, Halle IdentXX GmbH, Stuttgart

Idorsia (Berlin) Pharmaceuticals GmbH, Berlin IFB Halle GmbH, Halle IFM Therapeutics GmbH, Bonn IGUANA BioTechnology GmbH, München

IIT - Institut für Innovationstransfer an der Universität Bielefeld GmbH, Bielefeld

IMD Natural Solutions GmbH, Dortmund IMGM Laboratories GmbH, Martinsried immatics NV, Tübingen

Immundiagnostik AG, Bensheim Immungenetics AG, Hamburg Immunic AG, Gräfelfing immunoGlobe Antikörpertechnik GmbH, Himmelstadt Immunologik GmbH, Berlin ImmunoQure AG, Düsseldorf Immunservice GmbH, Hamburg Immutep GmbH, Leipzig imusyn GmbH & Co. KG, Hannover in.vent DIAGNOSTICA GmbH, Hennigsdorf Independent Data Lab UG, München Indical Bioscience GmbH, Leipzig INDIVUMED GmbH, Hamburg Indivumed Services GmbH, Hamburg InfanDx AG, Köln Infinite Roots Mushlabs GmbH, Hamburg inflamed pharma GmbH, Jena InflaRx N.V., Jena iniuva GmbH, Hamburg Innocent Meat GmbH, Papendorf Innovative Molecules GmbH, München innoVitro GmbH, Jülich InSCREENeX GmbH, Braunschweig Insempra GmbH, Martinsried Institut Virion\Serion GmbH, Würzburg Intana Bioscience GmbH, Martinsried Intavis Peptide Services GmbH, Tübingen INVICOL GmbH, Berlin

INVIGATE GmbH, Jena Invitek Molecular GmbH, Berlin Invitris GmbH, Garching InVivo BioTech Services GmbH, Hennigsdorf iOmx Therapeutics AG, Martinsried Ionera Technologies GmbH, Freiburg Iris Biotech GmbH, Marktredwitz IRUBIS GmbH, München

ISAR Bioscience GmbH, Planegg Isarna Therapeutics GmbH, München

Isoloid GmbH, Düsseldorf

ITM Isotope Technologies Munich SE, Garching

IVD – Gesellschaft für Innovative Veterinärdiagnostik mbH, Seelze-Letter

Ix Therapeutics GmbH, Hamburg

J

Jena Bioscience GmbH, Jena JeNaCell - An Evonik company, Jena JPT Peptide Technologies GmbH, Berlin JunctuCell Biomed Manufacturing GmbH, Hohenbrunn

K

Katairo GmbH, Kusterdingen

KHR Biotech GmbH, Mainz

Koralo GmbH, Baldham

Kosmas Therapeutics GmbH, Nürnberg krauts & sprouts, Düsseldorf

KreLo GmbH, Ulm Kupando GmbH, Schönefeld

Kynda Biotech GmbH, Jelmstorf

Kyoobe Tech GmbH, Leinfelden-Echterdingen

L

Labor Dr. Merk & Kollegen, Ochsenhausen

LABOR FÜR DNA-ANALYTIK, Freiburg

Labvantage - Biomax GmbH, Martinsried Lallemand Biologicals GmbH, Wismar LAMPseq Diagnostics GmbH, Bonn Larova GmbH, Jena

Lead Discovery Center GmbH, Dortmund LenioBio GmbH, Düsseldorf

Leopard Biosciences GmbH, Gauting

LEUKOCARE AG, Martinsried LGC Genomics GmbH, Berlin Life & Brain GmbH, Bonn

LifeGlimmer GmbH, Berlin lifespin GmbH, Regensburg

Ligandis UG, Gülzow-Prüzen

Lignilabs GmbH, Wiesbaden Lignopure GmbH, Hamburg LIMAA Technologies GmbH, Berlin LINDIS Biotech GmbH, Puchheim Lindis Bloodcare GmbH, Hennigsdorf Lionex GmbH, Braunschweig Lipocyte BioMed GmbH, Bremen Lipotype GmbH, Dresden Lonza Cologne GmbH, Köln Lumatix Biotech GmbH, Garching Lumobiotics GmbH, Karlsruhe Lysando Innovations Lab GmbH, Regensburg Lysatpharma GmbH, Jena

MMainz Biomed NV, Mainz Mallia Therapeutics GmbH, Erlangen MalVa GmbH, Heidelberg Matricel GmbH, Herzogenrath MBBL Dr. Bartling GmbH, Bielefeld mbiomics GmbH, Neuried Medea Biopharma, Ludwigshafen Mediagnost GmbH, Reutlingen Medical Biomaterial GmbH, Neustadt-Glewe

Medigene AG, Planegg/Martinsried Medigene Immunotherapies GmbH, Planegg

MEDIPAN GMBH, Dahlewitz

Meidrix Biomedicals GmbH, Esslingen

MELEMA Pharma GmbH, Hamburg

Merlion Pharmaceuticals GmbH, Berlin

Mermaid Bio GmbH, München

metabion GmbH, Planegg

Metabolon GmbH, Hallbergmoos

Metaron Diagnostics GmbH i.G., Oberschleißheim

MetaSysX GmbH, Potsdam

Micro Pro GmbH, Magdeburg

Microbify GmbH, Straubing

Microcoat Biotechnologie GmbH, Bernried MicroDiscovery GmbH, Berlin MicroHarvest GmbH, Hamburg

Micromun Privates Institut für Mikrobiologische Forschung GmbH, Greifswald

Microsynth Seqlab GmbH, Göttingen

MiGenTra GmbH, Berlin Mikrogen GmbH, Neuried

Milenia Biotec GmbH, Gießen

Miltenyi Biomedicine GmbH, Bergisch Gladbach

Miltenyi Biotec B.V. Co.KG, Bergisch Gladbach

Miltenyi Biotec GmbH, Teterow

Mimi-Q GmbH, Potsdam

Minaris Regenerative Medicine GmbH, Ottobrunn

Minerva Analytix GmbH, Rangsdorf

Minerva Biolabs GmbH, Berlin

mir|detect GmbH, Bremerhaven

Mireca Medicines GmbH, Tübingen

mk2 Biotechnologies GmbH, Planegg

MLM Medical Labs GmbH, Mönchengladbach

MoBiTec GmbH, Göttingen

MODAG GmbH, Wendelsheim

Moderna Germany GmbH, München

molab.ai GmbH, München

Molecular Health GmbH, Heidelberg

MOLEQLAR Analytics GmbH, Martinsried moloX GmbH, Berlin

Molzym GmbH & Co.KG, Bremen

MorphoSys AG, Planegg

Mosaiques Diagnostics and Therapeutics AG, Hannover

MSAID GmbH, Garching

MucosaTec GmbH, Schiffweiler Mukocell GmbH, Dortmund multiBIND biotec GmbH, Köln multimmune GmbH, München Multiplexion GmbH, Friedrichshafen MyBiotech GmbH, Überherrn Mycolever GmbH, Rheinbach

Myelo Therapeutics GmbH, Berlin MyoPax GmbH, Berlin myotwin GmbH, Göttingen

myPOLS Biotec GmbH, Konstanz Myriad GmbH, München

Myriad International GmbH, Köln

MyriaMeat GmbH, München myriamed GmbH, Göttingen

N

nadicom Gesellschaft für angewandte Mikrobiologie mbH, Uhingen nandatec GmbH, Lübeck

Nanion Technologies GmbH, München

Nanogami GmbH, Leipzig

NanotecMARIN GmbH, Ingelheim am Rhein NanoTemper Technologies GmbH, München

nanoTOOLS Antikörpertechnik GmbH & Co. KG, Teningen

nanozoo GmbH, Jena Navigo Proteins GmbH, Halle

NEOsphere Biotechnologies GmbH, Martinsried Neovii Biotech GmbH, Gräfelfing Nephrolyx GmbH, Berlin

Neracare GmbH, Frankfurt

Neurevo GmbH, München

Neuron-D GmbH, Dresden

NeuroProfile GmbH, Regensburg new/era/mabs GmbH, Potsdam nextplant UG, Berlin NExtTec GmbH, Hilgertshausen

NGP Polymers GmbH, Jena NH DyeAGNOSTICS GmbH, Halle

Ningaloo Biosystems GmbH, Köln Nomad Bioscience GmbH, Halle

Norbitec GmbH, Uetersen Norden Vaccines GmbH, Braunschweig Noscendo GmbH, Duisburg

Nosh.bio GmbH, Berlin Nostos Genomics GmbH, Berlin

NOVA green GmbH, Vechta-Langförden

Novaliq GmbH, Heidelberg

NovaTec Immundiagnostica GmbH, Dietzenbach

Novis GmbH, Tübingen

Novozymes Berlin GmbH, Berlin

NUMAFERM GmbH, Düsseldorf numares AG, Regensburg

O

Ocean Pharma GmbH, Reinbek

oceanBASIS GmbH, Kiel

Octapharma Biopharmaceuticals GmbH, Heidelberg Okmed Biotech GmbH, Halle

OligoScience Biotechnology GmbH, Bönen

OMEICOS Therapeutics GmbH, Berlin

OmicScouts GmbH, Freising oncgnostics GmbH, Jena Oncimmune Germany GmbH, Dortmund OncoLead GmbH & Co. KG, Karlsfeld Oncoscience GmbH, Schenefeld one.five GmbH, Hamburg

OneWorld Diagnostics GmbH, Düsseldorf OntoChem GmbH, Halle OPSYON Therapeutics GmbH, München ORGENTEC Diagnostika GmbH, Mainz origenis GmbH, Martinsried ORYX GmbH & Co. KG, Baldham OxProtect GmbH, Münster

P

Pacifico Biolabs, Berlin PAIA Biotech GmbH, Köln

PAM Theragnostics GmbH, Hennigsdorf

PAN-Biotech GmbH, Aidenbach

PAN-Seratech GmbH, Aidenbach

Panosome GmbH, Heidelberg

Pantherna Therapeutics GmbH, Hennigsdorf

PELOBIOTECH GmbH, Martinsried Pentixapharm AG, Würzburg

PEPperPRINT GmbH, Heidelberg

Peptide Specialty Laboratories GmbH, Heidelberg peptides&elephants GmbH, Hennigsdorf

PerioTrap Pharmaceuticals GmbH, Halle

perora GmbH, Heidelberg

Phaeosynt GmbH, Hannover

PharmaInformatic, Emden Pharmbiotec GmbH, Schiffweiler Phenos GmbH, Hannover Phialogics GmbH, Frankfurt am Main Phyton Biotech GmbH, Ahrensburg Phytowelt GreenTechnologies GmbH, Nettetal Picea Biosolutions GmbH, Ohlsbach Pieris Pharmaceuticals GmbH, Hallbergmoos Pixelbiotech GmbH, Schriesheim PL BioScience GmbH, Aachen Planet A Foods GmbH, Plamegg PLANTegg GmbH, Kiel Planton GmbH, Kiel PlasmidFactory GmbH, Bielefeld Plectonic Biotech GmbH, Garching PLS-Design GmbH, Hamburg pluriSelect Life Science UG, Leipzig PolymerActive GmbH, Offenburg PolyQuant GmbH, Bad Abbach

PortaCellTec biosciences GmbH, Göttingen

PRAMOMOLECULAR GmbH, Berlin Precision for Medicine GmbH, Berlin PreOmics GmbH, Martinsried Priavoid GmbH, Düsseldorf

PRIMACYT Cell Culture Technology GmbH, Schwerin

Prime Vector Technologies GmbH, Tübingen ProBioGen AG, Berlin

PROGEN Biotechnik GmbH, Heidelberg Project Eaden GmbH, Berlin

ProJect Pharmaceutics GmbH, Martinsried Prolytic GmbH, Frankfurt am Main PromoCell GmbH, Heidelberg

PROSION GmbH, Köln

ProtaGene CGT GmbH, Heidelberg

ProtaGene GmbH, Heilbronn

ProteinDistillery GmbH, Ostfildern Proteome Factory AG, Berlin Proteome Sciences R&D GmbH & Co. KG, Frankfurt a. Main Proteros Biostructures GmbH, Martinsried PROVIREX Genome Editing Therapies GmbH, Hamburg provitro AG, Berlin PUEVIT GmbH, Dresden PXBioVisioN GmbH, Hannover

Q-bios GmbH, Edingen-Neckarhausen

QIAGEN, Hilden

QLi5 Therapeutics AG, Dortmund Quazy Foods GmbH, Berlin qubeto GmbH, Münster Quidel Germany GmbH, Kornwestheim

R

R-Biopharm AG, Darmstadt ravo Diagnostika GmbH, Freiburg Reaction Biology Europe GmbH, Freiburg

ReliaTech GmbH, Wolfenbüttel

Rentschler Biopharma SE, Laupheim

Repairon GmbH, Göttingen

Resolve BioSciences GmbH, Monheim

Revvity Gene Delivery GmbH, Grafelfing

RHEACELL GmbH, Heidelberg Ribocon GmbH, Bremen

Richter BioLogics GmbH & Co. KG, Hamburg

Ridom GmbH, Münster

RLP AgroScience GmbH, Neustadt

RNATICS GmbH, Martinsried

RNhale GmbH, München

Roboscreen GmbH, Leipzig

Roche mtm laboratories AG, Mannheim

ROSCUE Therapeutics GmbH, Wolfratshausen

S

Saaten-Union BIOTEC GmbH, Leopoldshöhe

Sartorius CellGenix GmbH, Freiburg

Sartorius Stedim Cellca GmbH, Ulm

Sartorius Xell GmbH, Schloß Holte-Stukenbrock

SCG Cell Therapy GmbH, Martinsried

ScheBo ® Biotech AG, Gießen

Scienion GmbH, Berlin

Scientific Research and Development GmbH, Oberursel

Sciomics GmbH, Neckargemünd

SciRhom GmbH, Martinsried

ScreenFect GmbH, Eggenstein-Leopoldshafen

ScreenSYS GmbH, Freburg

Seamless Therapeutics GmbH, Dresden

Secarna Pharmaceuticals GmbH & Co. KG, Martinsried

seedalive GmbH, Osnabrück

SeedForward GmbH, Osnabrück

selectION Therapeutics GmbH, Martinsried

Senara GmbH, Freiburg

Senova Gesellschaft für Biowissenschaft und Technik mbH, Weimar

SenseUp GmbH, Jülich

SensID GmbH, Rostock

Senzyme GmbH, Troisdorf

SEQ-IT GmbH & Co. KG, Kaiserslautern

Sequantrix GmbH, Aachen

SequentiX - Digital DNA Processing, Klein Raden

Seracell Pharma GmbH, Rostock

Seratec Gesellschaft für Biotechnologie mbH, Göttingen

Serengen GmbH, Dortmund

serYmun Yeast GmbH, Bernburg/Saale

SeSaM-Biotech GmbH, Aachen

Sidanis Pharma GmbH, Hamburg sifin diagnostics gmbh, Berlin Sigma-Aldrich Biochemie GmbH, Hamburg Signatope GmbH, Reutlingen

Signature Diagnostics GmbH, Potsdam SILANTES GmbH, München Silence Therapeutics GmbH, Berlin

Simris Biologics GmbH, Berlin

Singleron BioTechnologies GmbH, Köln

Sirana Pharma GmbH, Plannegg-Martinsried Sirius Fine Chemicals SiChem GmbH, Bremen siTOOLs Biotech GmbH, Martinsried Smartbax GmbH, München

Soluventis GmbH, Dortmund

SP Sourcon Padena GmbH, Tübingen

Sphingotec GmbH, Hennigsdorf Squarix GmbH, Marl

SRTD biotech GmbH, Jülich

Stabizym GmbH, Roßdorf

StarSEQ GmbH, Mainz

Steffens Biotechnische Analysen GmbH, Freiburg

StemVAC GmbH, Bernried

sterna biologicals GmbH, Marburg

SternEnzym GmbH & Co. KG, Ahrensburg

Subitec GmbH, Köngen

Sumaya Biotech GmbH & Co. KG, Heidelberg

Surflay Nanotec GmbH, Berlin SymBiosis GmbH, Eppelheim

Synaptic Systems Gesellschaft für neurobiologische Forschung, Entwicklung und Produktion mbH, Göttingen

Syntab Therapeutics GmbH, Würselen

Sysmex Inostics GmbH, Hamburg

Sysmex Partec GmbH, Görlitz

Systasy Bioscience GmbH, München

TT-CURX GmbH, Würzburg

T-knife GmbH, Berlin

Tacalyx GmbH, Berlin

Taconic Biosciences GmbH, Leverkusen targenomix GmbH, Potsdam

Telexos GmbH, Weiden

Tentamus Pharma & Med Deutschland GmbH, Karlsruhe

TETEC – Tissue Engineering Technologies AG, Reutlingen tgcBIOMICS GmbH, Bingen

The Cultivated B GmbH, Heidelberg

TherapySelect Dr. Frank Kischkel, Heidelberg

Therawis Diagnostics GmbH, München

Therawis Pharma GmbH, München

Thermo Fisher Scientific – B.R.A.H.M.S GmbH, Hennigsdorf

Thermo Fisher Scientific GENEART GmbH, Regensburg

Thermosome GmbH, Martinsried

Therycell GmbH, Berlin

tiakis Biotech AG, Kiel

Tib Molbiol Syntheselabor GmbH, Berlin tilibit nanosystems GmbH, München

TissUse GmbH, Berlin

TME Pharma NV, Berlin

TolerogenixX GmbH, Heidelberg

Topas Therapeutics GmbH, Hamburg traceless materials GmbH, Hamburg

Tranquil Immune GmbH, Bonn

Transimmune AG, Düsseldorf trenzyme GmbH, Konstanz

TRION Research, Puchheim

Trypto Therapeutics GmbH, Berlin Tubulis GmbH, Martinsried TunaTech GmbH, Düsseldorf

U

Ucaneo Biotech GmbH, Berlin UGA Biopharma GmbH, Hennigsdorf UGiSense AG, Dortmund upcyte technologies GmbH, Hamburg

V

Varicula Biotec GmbH, Wismar

VARUTA GmbH, Solingen

Vaximm GmbH, Mannheim

Vaxxinova Autogenous Vaccines GmbH, Cuxhaven

Vaxxinova Diagnostics GmbH, Leipzig Velvio GmbH, Regensburg

Veraxa Biotech GmbH, Heidelberg veriNOS pharmaceuticals GmbH, Würzburg vermicon AG, Hallbergmoos

VEROVACCiNES GmbH, Halle

Vibalogics GmbH, Cuxhaven

ViferaXS GmbH, Tübingen

ViGeneron GmbH, Martinsried

Vincerx Pharma GmbH, Monheim

Viramed Biotech AG, Planegg

VIROTECH Diagnostics GmbH, Dietzenbach

Vita 34 AG, Leipzig

Vitrofluidix, Köln

VivaCell Biotechnology GmbH, Denzlingen

vivo Science GmbH, Gronau

Vivoryon Therapeutics NV, Halle

WWacker Biotech GmbH, Jena

WeissBioTech GmbH, Ascheberg WMT AG, Heidelberg

XX-Zell Biotech GmbH, Lennestadt

XanTec bioanalytics GmbH, Düsseldorf

Xitra Therapeutics, Greifswald

XL-protein GmbH, Freising

Xvir Therapeutics GmbH, München

Y

Yokogawa Insilico Biotechnology GmbH, Stuttgart YUMAB GmbH, Braunschweig

Z

Zedira GmbH, Darmstadt

zell-kontakt GmbH, Nörten-Hardenberg

Zellkraftwerk GmbH, Leipzig

Zellwerk GmbH, Oberkrämer OT Eichstädt

ZytoVision GmbH, Bremerhaven

(All data is povided without guarantee.)

Become partner of the next guide edition!

Contact:

Andreas Macht Sales & Marketing

Tel. +49-30-264921-54

a.macht@biocom.de

SKYGATE LAB-OFFICES